Background  ||| S:24 E:43 ||| NN
The  ||| S:43 E:47 ||| DT
early  ||| S:47 E:53 ||| JJ
diagnosis  ||| S:53 E:63 ||| NN
of  ||| S:63 E:66 ||| IN
ovarian  ||| S:66 E:74 ||| JJ
cancer  ||| S:74 E:81 ||| NN
has  ||| S:81 E:85 ||| VBZ
the  ||| S:85 E:89 ||| DT
potential  ||| S:89 E:107 ||| JJ
to  ||| S:107 E:110 ||| TO
dramatically  ||| S:110 E:123 ||| RB
reduce  ||| S:123 E:130 ||| VB
the  ||| S:130 E:134 ||| DT
mortality  ||| S:134 E:144 ||| NN
associated  ||| S:144 E:155 ||| VBN
with  ||| S:155 E:160 ||| IN
this  ||| S:160 E:173 ||| DT
disease ||| S:173 E:180 ||| NN
.  ||| S:180 E:182 ||| .
Recently ||| S:182 E:190 ||| RB
,  ||| S:190 E:192 ||| ,
the  ||| S:192 E:196 ||| DT
use  ||| S:196 E:200 ||| NN
of  ||| S:200 E:203 ||| IN
surface-enhanced  ||| S:203 E:220 ||| FW
laser  ||| S:220 E:234 ||| FW
desorption ||| S:234 E:244 ||| FW
/ ||| S:244 E:245 ||| FW
ionization  ||| S:245 E:256 ||| FW
( ||| S:256 E:257 ||| -LRB-
SELDI ||| S:257 E:262 ||| NNP
)  ||| S:262 E:264 ||| -RRB-
time-of-flight  ||| S:264 E:279 ||| JJ
mass  ||| S:279 E:292 ||| NN
spectrometry  ||| S:292 E:305 ||| NN
profiling  ||| S:305 E:315 ||| NN
of  ||| S:315 E:318 ||| IN
patient  ||| S:318 E:326 ||| JJ
serum  ||| S:326 E:332 ||| JJ
proteins ||| S:332 E:340 ||| NNS
,  ||| S:340 E:342 ||| ,
combined  ||| S:342 E:359 ||| VBN
with  ||| S:359 E:364 ||| IN
advanced  ||| S:364 E:373 ||| JJ
data  ||| S:373 E:378 ||| NN
mining  ||| S:378 E:385 ||| NN
algorithms ||| S:385 E:395 ||| NN
,  ||| S:395 E:397 ||| ,
to  ||| S:397 E:400 ||| TO
detect  ||| S:400 E:407 ||| VB
protein  ||| S:407 E:423 ||| NN
patterns  ||| S:423 E:432 ||| NNS
associated  ||| S:432 E:443 ||| VBN
with  ||| S:443 E:448 ||| IN
malignancy ||| S:448 E:458 ||| NN
,  ||| S:458 E:460 ||| ,
has  ||| S:460 E:464 ||| VBZ
been  ||| S:464 E:469 ||| VBN
reported  ||| S:469 E:478 ||| VBN
as  ||| S:478 E:481 ||| IN
a  ||| S:481 E:491 ||| DT
promising  ||| S:491 E:501 ||| JJ
field  ||| S:501 E:507 ||| NN
of  ||| S:507 E:510 ||| IN
research  ||| S:510 E:519 ||| NN
to  ||| S:519 E:522 ||| TO
achieve  ||| S:522 E:530 ||| VB
the  ||| S:530 E:534 ||| DT
goal  ||| S:534 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
early  ||| S:542 E:556 ||| JJ
cancer  ||| S:556 E:563 ||| NN
detection  ||| S:563 E:573 ||| NNS
[  ||| S:573 E:575 ||| -LRB-
1  ||| S:575 E:577 ||| CD
2  ||| S:577 E:579 ||| CD
3  ||| S:579 E:581 ||| CD
4  ||| S:581 E:583 ||| CD
5  ||| S:583 E:585 ||| CD
]  ||| S:585 E:587 ||| -RRB-
.  ||| S:587 E:589 ||| .
Several  ||| S:589 E:597 ||| JJ
reports  ||| S:597 E:605 ||| NNS
have  ||| S:605 E:618 ||| VBP
detailed  ||| S:618 E:627 ||| VBN
the  ||| S:627 E:631 ||| DT
ability  ||| S:631 E:639 ||| NN
of  ||| S:639 E:642 ||| IN
this  ||| S:642 E:647 ||| DT
proteomic  ||| S:647 E:657 ||| JJ
method  ||| S:657 E:664 ||| NN
to  ||| S:664 E:667 ||| TO
diagnose  ||| S:667 E:684 ||| VB
the  ||| S:684 E:688 ||| DT
difference  ||| S:688 E:699 ||| NN
between  ||| S:699 E:707 ||| IN
ovarian  ||| S:707 E:715 ||| JJ
cancer  ||| S:715 E:722 ||| NN
[  ||| S:722 E:724 ||| -LRB-
6  ||| S:724 E:726 ||| CD
7  ||| S:726 E:728 ||| CD
8  ||| S:728 E:730 ||| CD
]  ||| S:730 E:732 ||| -RRB-
,  ||| S:732 E:734 ||| ,
prostate  ||| S:734 E:751 ||| JJ
cancer  ||| S:751 E:758 ||| NN
[  ||| S:758 E:760 ||| -LRB-
9  ||| S:760 E:762 ||| CD
10  ||| S:762 E:765 ||| CD
11  ||| S:765 E:768 ||| CD
12  ||| S:768 E:771 ||| CD
13  ||| S:771 E:774 ||| CD
]  ||| S:774 E:776 ||| -RRB-
,  ||| S:776 E:778 ||| ,
and  ||| S:778 E:782 ||| CC
bladder  ||| S:782 E:790 ||| JJ
cancer  ||| S:790 E:797 ||| NN
[  ||| S:797 E:799 ||| -LRB-
13  ||| S:799 E:802 ||| CD
14  ||| S:802 E:805 ||| CD
]  ||| S:805 E:807 ||| -RRB-
.  ||| S:807 E:817 ||| .
Much  ||| S:817 E:822 ||| RB
of  ||| S:822 E:825 ||| IN
the  ||| S:825 E:829 ||| DT
effort  ||| S:829 E:836 ||| NN
in  ||| S:836 E:839 ||| IN
these  ||| S:839 E:845 ||| DT
analyses  ||| S:845 E:854 ||| NN
has  ||| S:854 E:858 ||| VBZ
focused  ||| S:858 E:866 ||| VBN
on  ||| S:866 E:869 ||| IN
the  ||| S:869 E:873 ||| DT
use  ||| S:873 E:885 ||| NN
of  ||| S:885 E:888 ||| IN
a  ||| S:888 E:890 ||| DT
variety  ||| S:890 E:898 ||| NN
of  ||| S:898 E:901 ||| IN
data  ||| S:901 E:906 ||| NN
mining  ||| S:906 E:913 ||| NN
tools  ||| S:913 E:919 ||| NNS
such  ||| S:919 E:924 ||| JJ
as  ||| S:924 E:927 ||| IN
the  ||| S:927 E:931 ||| DT
evaluation  ||| S:931 E:942 ||| NN
of  ||| S:942 E:953 ||| IN
prostate  ||| S:953 E:962 ||| JJ
cancer  ||| S:962 E:969 ||| NN
using  ||| S:969 E:975 ||| VBG
peaks  ||| S:975 E:981 ||| NNS
in  ||| S:981 E:984 ||| IN
the  ||| S:984 E:988 ||| DT
mass  ||| S:988 E:993 ||| NN
to  ||| S:993 E:996 ||| TO
charge  ||| S:996 E:1003 ||| VB
( ||| S:1003 E:1004 ||| -LRB-
M ||| S:1004 E:1005 ||| NNP
/ ||| S:1005 E:1006 ||| NNP
Z ||| S:1006 E:1007 ||| NNP
)  ||| S:1007 E:1017 ||| -RRB-
region  ||| S:1017 E:1024 ||| NN
between  ||| S:1024 E:1032 ||| IN
2  ||| S:1032 E:1034 ||| CD
K  ||| S:1034 E:1036 ||| NNP
and  ||| S:1036 E:1040 ||| CC
40  ||| S:1040 E:1043 ||| CD
K  ||| S:1043 E:1045 ||| NN
combined  ||| S:1045 E:1054 ||| VBN
with  ||| S:1054 E:1059 ||| IN
boosted  ||| S:1059 E:1067 ||| JJ
decision  ||| S:1067 E:1084 ||| NN
tree  ||| S:1084 E:1089 ||| NN
analysis  ||| S:1089 E:1098 ||| NN
[  ||| S:1098 E:1100 ||| -LRB-
10  ||| S:1100 E:1103 ||| CD
]  ||| S:1103 E:1105 ||| -RRB-
to  ||| S:1105 E:1108 ||| TO
try  ||| S:1108 E:1112 ||| VB
to  ||| S:1112 E:1115 ||| TO
detect  ||| S:1115 E:1122 ||| VB
patterns  ||| S:1122 E:1131 ||| NNS
that  ||| S:1131 E:1136 ||| WDT
allow  ||| S:1136 E:1150 ||| VBP
the  ||| S:1150 E:1154 ||| DT
diagnosis  ||| S:1154 E:1164 ||| NN
of  ||| S:1164 E:1167 ||| IN
cancer  ||| S:1167 E:1174 ||| NN
versus  ||| S:1174 E:1181 ||| IN
non-cancer ||| S:1181 E:1191 ||| JJ
.  ||| S:1191 E:1193 ||| .
The  ||| S:1193 E:1197 ||| DT
use  ||| S:1197 E:1201 ||| NN
of  ||| S:1201 E:1212 ||| IN
similar  ||| S:1212 E:1220 ||| JJ
technology  ||| S:1220 E:1231 ||| NN
to  ||| S:1231 E:1234 ||| TO
evaluate  ||| S:1234 E:1243 ||| VB
bladder  ||| S:1243 E:1251 ||| JJ
cancer  ||| S:1251 E:1258 ||| NN
has  ||| S:1258 E:1262 ||| VBZ
also  ||| S:1262 E:1267 ||| RB
been  ||| S:1267 E:1280 ||| VBN
reported  ||| S:1280 E:1289 ||| VBN
[  ||| S:1289 E:1291 ||| -LRB-
13  ||| S:1291 E:1294 ||| CD
14  ||| S:1294 E:1297 ||| CD
]  ||| S:1297 E:1299 ||| -RRB-
.  ||| S:1299 E:1301 ||| .
Thus ||| S:1301 E:1305 ||| RB
,  ||| S:1305 E:1307 ||| ,
this  ||| S:1307 E:1312 ||| DT
field  ||| S:1312 E:1318 ||| NN
represents  ||| S:1318 E:1329 ||| VBZ
an  ||| S:1329 E:1332 ||| DT
active  ||| S:1332 E:1347 ||| JJ
area  ||| S:1347 E:1352 ||| NN
of  ||| S:1352 E:1355 ||| IN
current  ||| S:1355 E:1363 ||| JJ
research ||| S:1363 E:1371 ||| NN
.  ||| S:1371 E:1373 ||| .
For  ||| S:1373 E:1377 ||| IN
example ||| S:1377 E:1384 ||| NN
,  ||| S:1384 E:1386 ||| ,
a  ||| S:1386 E:1388 ||| DT
recent  ||| S:1388 E:1395 ||| JJ
report  ||| S:1395 E:1402 ||| NN
by  ||| S:1402 E:1413 ||| IN
the  ||| S:1413 E:1417 ||| DT
Clinical  ||| S:1417 E:1426 ||| NNP
Proteomics  ||| S:1426 E:1437 ||| NNP
Program  ||| S:1437 E:1445 ||| NNP
Databank  ||| S:1445 E:1454 ||| NNP
has  ||| S:1454 E:1458 ||| VBZ
demonstrated  ||| S:1458 E:1479 ||| VBN
that  ||| S:1479 E:1484 ||| IN
the  ||| S:1484 E:1488 ||| DT
use  ||| S:1488 E:1492 ||| NN
of  ||| S:1492 E:1495 ||| IN
genetic  ||| S:1495 E:1503 ||| JJ
algorithms  ||| S:1503 E:1514 ||| NNS
coupled  ||| S:1514 E:1522 ||| VBN
with  ||| S:1522 E:1527 ||| IN
clustering  ||| S:1527 E:1546 ||| JJ
analysis  ||| S:1546 E:1555 ||| NN
has  ||| S:1555 E:1559 ||| VBZ
resulted  ||| S:1559 E:1568 ||| VBN
in  ||| S:1568 E:1571 ||| IN
rule  ||| S:1571 E:1576 ||| NN
sets  ||| S:1576 E:1581 ||| NNS
that  ||| S:1581 E:1586 ||| WDT
can  ||| S:1586 E:1590 ||| MD
predict  ||| S:1590 E:1598 ||| VB
ovarian  ||| S:1598 E:1614 ||| JJ
cancers  ||| S:1614 E:1622 ||| NNS
( ||| S:1622 E:1623 ||| -LRB-
including  ||| S:1623 E:1633 ||| VBG
samples  ||| S:1633 E:1641 ||| NNS
from  ||| S:1641 E:1646 ||| IN
patients  ||| S:1646 E:1655 ||| NNS
with  ||| S:1655 E:1660 ||| IN
stage  ||| S:1660 E:1666 ||| NN
1  ||| S:1666 E:1676 ||| CD
disease ||| S:1676 E:1683 ||| NN
)  ||| S:1683 E:1685 ||| -RRB-
with  ||| S:1685 E:1690 ||| IN
100 ||| S:1690 E:1693 ||| CD
%  ||| S:1693 E:1695 ||| NN
sensitivity  ||| S:1695 E:1707 ||| NN
and  ||| S:1707 E:1711 ||| CC
96 ||| S:1711 E:1713 ||| CD
%  ||| S:1713 E:1715 ||| NN
specificity  ||| S:1715 E:1727 ||| NNS
[  ||| S:1727 E:1729 ||| -LRB-
6  ||| S:1729 E:1731 ||| CD
]  ||| S:1731 E:1733 ||| -RRB-
.  ||| S:1733 E:1743 ||| .
These  ||| S:1743 E:1749 ||| DT
results  ||| S:1749 E:1757 ||| NNS
have  ||| S:1757 E:1762 ||| VBP
been  ||| S:1762 E:1767 ||| VBN
extended  ||| S:1767 E:1776 ||| VBN
by  ||| S:1776 E:1779 ||| IN
the  ||| S:1779 E:1783 ||| DT
same  ||| S:1783 E:1788 ||| JJ
group  ||| S:1788 E:1794 ||| NN
to  ||| S:1794 E:1805 ||| TO
include  ||| S:1805 E:1813 ||| VB
a  ||| S:1813 E:1815 ||| DT
larger  ||| S:1815 E:1822 ||| JJR
series  ||| S:1822 E:1829 ||| NN
of  ||| S:1829 E:1832 ||| IN
ovarian  ||| S:1832 E:1840 ||| JJ
cancer  ||| S:1840 E:1847 ||| NN
patients  ||| S:1847 E:1856 ||| NNS
as  ||| S:1856 E:1859 ||| IN
well  ||| S:1859 E:1872 ||| RB
as  ||| S:1872 E:1875 ||| IN
prostate  ||| S:1875 E:1884 ||| JJ
cancer  ||| S:1884 E:1891 ||| NN
patients  ||| S:1891 E:1900 ||| NNS
[  ||| S:1900 E:1902 ||| -LRB-
7  ||| S:1902 E:1904 ||| CD
9  ||| S:1904 E:1906 ||| CD
]  ||| S:1906 E:1908 ||| -RRB-
.  ||| S:1908 E:1910 ||| .
The  ||| S:1910 E:1914 ||| DT
Clinical  ||| S:1914 E:1931 ||| NNP
Proteomics  ||| S:1931 E:1942 ||| NNP
Program  ||| S:1942 E:1950 ||| NNP
Databank  ||| S:1950 E:1959 ||| NNP
has  ||| S:1959 E:1963 ||| VBZ
provided  ||| S:1963 E:1972 ||| VBN
three  ||| S:1972 E:1978 ||| CD
sets  ||| S:1978 E:1983 ||| NNS
of  ||| S:1983 E:1994 ||| IN
ovarian  ||| S:1994 E:2002 ||| JJ
cancer  ||| S:2002 E:2009 ||| NN
data  ||| S:2009 E:2014 ||| NNS
to  ||| S:2014 E:2017 ||| TO
the  ||| S:2017 E:2021 ||| DT
scientific  ||| S:2021 E:2032 ||| JJ
community  ||| S:2032 E:2042 ||| NN
without  ||| S:2042 E:2058 ||| IN
restriction ||| S:2058 E:2069 ||| NN
.  ||| S:2069 E:2071 ||| .
These  ||| S:2071 E:2077 ||| DT
data  ||| S:2077 E:2082 ||| NN
sets  ||| S:2082 E:2087 ||| NNS
include  ||| S:2087 E:2095 ||| VBP
Lancet  ||| S:2095 E:2102 ||| NNP
Ovarian  ||| S:2102 E:2110 ||| NNP
Data  ||| S:2110 E:2123 ||| NNP
2-16-02  ||| S:2123 E:2131 ||| NNP
used  ||| S:2131 E:2136 ||| VBD
in  ||| S:2136 E:2139 ||| IN
the  ||| S:2139 E:2143 ||| DT
study  ||| S:2143 E:2149 ||| NN
noted  ||| S:2149 E:2155 ||| VBD
above  ||| S:2155 E:2161 ||| IN
[  ||| S:2161 E:2163 ||| -LRB-
6  ||| S:2163 E:2165 ||| CD
]  ||| S:2165 E:2167 ||| -RRB-
.  ||| S:2167 E:2169 ||| .
This  ||| S:2169 E:2174 ||| DT
study  ||| S:2174 E:2188 ||| NN
consisted  ||| S:2188 E:2198 ||| VBD
of  ||| S:2198 E:2201 ||| IN
a  ||| S:2201 E:2203 ||| DT
total  ||| S:2203 E:2209 ||| NN
of  ||| S:2209 E:2212 ||| IN
100  ||| S:2212 E:2216 ||| CD
control ||| S:2216 E:2223 ||| NN
,  ||| S:2223 E:2225 ||| ,
100  ||| S:2225 E:2229 ||| CD
cancer ||| S:2229 E:2235 ||| NN
,  ||| S:2235 E:2237 ||| ,
and  ||| S:2237 E:2241 ||| CC
16  ||| S:2241 E:2252 ||| CD
benign  ||| S:2252 E:2259 ||| JJ
disease  ||| S:2259 E:2267 ||| NN
samples  ||| S:2267 E:2275 ||| NNS
run  ||| S:2275 E:2279 ||| VBN
on  ||| S:2279 E:2282 ||| IN
a  ||| S:2282 E:2284 ||| DT
Ciphergen  ||| S:2284 E:2294 ||| NNP
H4  ||| S:2294 E:2297 ||| NNP
ProteinChip  ||| S:2297 E:2317 ||| JJ
array  ||| S:2317 E:2323 ||| NN
( ||| S:2323 E:2324 ||| -LRB-
since  ||| S:2324 E:2330 ||| IN
discontinued ||| S:2330 E:2342 ||| JJ
) ||| S:2342 E:2343 ||| -RRB-
.  ||| S:2343 E:2345 ||| .
The  ||| S:2345 E:2349 ||| DT
samples  ||| S:2349 E:2357 ||| NNS
were  ||| S:2357 E:2362 ||| VBD
manually  ||| S:2362 E:2379 ||| RB
processed ||| S:2379 E:2388 ||| VBN
.  ||| S:2388 E:2390 ||| .
The  ||| S:2390 E:2394 ||| DT
data  ||| S:2394 E:2399 ||| NNS
was  ||| S:2399 E:2403 ||| VBD
posted  ||| S:2403 E:2410 ||| VBN
after  ||| S:2410 E:2416 ||| IN
baseline  ||| S:2416 E:2425 ||| JJ
subtraction ||| S:2425 E:2436 ||| NN
.  ||| S:2436 E:2446 ||| .
The  ||| S:2446 E:2450 ||| DT
second  ||| S:2450 E:2457 ||| JJ
data  ||| S:2457 E:2462 ||| NNS
set ||| S:2462 E:2465 ||| VBN
,  ||| S:2465 E:2467 ||| ,
Ovarian  ||| S:2467 E:2475 ||| NNP
Dataset  ||| S:2475 E:2483 ||| NNP
4-3-02  ||| S:2483 E:2490 ||| NNP
consist  ||| S:2490 E:2498 ||| VBP
of  ||| S:2498 E:2501 ||| IN
the  ||| S:2501 E:2513 ||| DT
same  ||| S:2513 E:2518 ||| JJ
samples  ||| S:2518 E:2526 ||| NNS
as  ||| S:2526 E:2529 ||| IN
the  ||| S:2529 E:2533 ||| DT
first  ||| S:2533 E:2539 ||| JJ
but  ||| S:2539 E:2543 ||| CC
the  ||| S:2543 E:2547 ||| DT
samples  ||| S:2547 E:2555 ||| NNS
were  ||| S:2555 E:2560 ||| VBD
run  ||| S:2560 E:2564 ||| VBN
on  ||| S:2564 E:2567 ||| IN
a  ||| S:2567 E:2577 ||| DT
Ciphergen  ||| S:2577 E:2587 ||| NNP
WCX2  ||| S:2587 E:2592 ||| NNP
ProteinChip  ||| S:2592 E:2604 ||| JJ
array ||| S:2604 E:2609 ||| NN
.  ||| S:2609 E:2611 ||| .
The  ||| S:2611 E:2615 ||| DT
samples  ||| S:2615 E:2623 ||| NNS
were  ||| S:2623 E:2628 ||| VBD
manually  ||| S:2628 E:2645 ||| RB
prepared  ||| S:2645 E:2654 ||| VBN
and  ||| S:2654 E:2658 ||| CC
the  ||| S:2658 E:2662 ||| DT
data  ||| S:2662 E:2667 ||| NNS
was  ||| S:2667 E:2671 ||| VBD
posted  ||| S:2671 E:2678 ||| VBN
with  ||| S:2678 E:2683 ||| IN
baseline  ||| S:2683 E:2692 ||| JJ
subtraction ||| S:2692 E:2703 ||| NN
.  ||| S:2703 E:2713 ||| .
A  ||| S:2713 E:2715 ||| DT
model  ||| S:2715 E:2721 ||| NN
diagnostic  ||| S:2721 E:2732 ||| JJ
rule  ||| S:2732 E:2737 ||| NN
based  ||| S:2737 E:2743 ||| VBN
on  ||| S:2743 E:2746 ||| IN
this  ||| S:2746 E:2751 ||| DT
dataset  ||| S:2751 E:2759 ||| NN
is  ||| S:2759 E:2762 ||| VBZ
published  ||| S:2762 E:2780 ||| VBN
on  ||| S:2780 E:2783 ||| IN
the  ||| S:2783 E:2787 ||| DT
website ||| S:2787 E:2794 ||| NN
,  ||| S:2794 E:2796 ||| ,
but  ||| S:2796 E:2800 ||| CC
no  ||| S:2800 E:2803 ||| DT
data  ||| S:2803 E:2808 ||| NN
is  ||| S:2808 E:2811 ||| VBZ
given  ||| S:2811 E:2817 ||| VBN
regarding  ||| S:2817 E:2827 ||| VBG
the  ||| S:2827 E:2831 ||| DT
rules  ||| S:2831 E:2845 ||| NNS
sensitivity  ||| S:2845 E:2857 ||| NN
or  ||| S:2857 E:2860 ||| CC
specificity ||| S:2860 E:2871 ||| NN
.  ||| S:2871 E:2873 ||| .
In  ||| S:2873 E:2876 ||| IN
this  ||| S:2876 E:2881 ||| DT
report ||| S:2881 E:2887 ||| NN
,  ||| S:2887 E:2889 ||| ,
we  ||| S:2889 E:2892 ||| PRP
analyze  ||| S:2892 E:2900 ||| VBP
the  ||| S:2900 E:2912 ||| DT
third  ||| S:2912 E:2918 ||| JJ
Ovarian  ||| S:2918 E:2926 ||| NNP
Dataset  ||| S:2926 E:2934 ||| NNP
8-7-02  ||| S:2934 E:2941 ||| NNP
and  ||| S:2941 E:2945 ||| CC
corresponding  ||| S:2945 E:2959 ||| JJ
sample  ||| S:2959 E:2974 ||| NN
information  ||| S:2974 E:2986 ||| NN
downloaded  ||| S:2986 E:2997 ||| NN
from  ||| S:2997 E:3002 ||| IN
the  ||| S:3002 E:3006 ||| DT
Clinical  ||| S:3006 E:3015 ||| NNP
Proteomics  ||| S:3015 E:3026 ||| NNP
Program  ||| S:3026 E:3042 ||| NNP
Databank  ||| S:3042 E:3051 ||| NNP
website  ||| S:3051 E:3059 ||| NNS
[  ||| S:3059 E:3061 ||| -LRB-
7  ||| S:3061 E:3063 ||| CD
]  ||| S:3063 E:3065 ||| -RRB-
.  ||| S:3065 E:3067 ||| .
This  ||| S:3067 E:3072 ||| DT
set  ||| S:3072 E:3076 ||| NN
of  ||| S:3076 E:3079 ||| IN
data  ||| S:3079 E:3084 ||| NN
consists  ||| S:3084 E:3093 ||| VBZ
of  ||| S:3093 E:3096 ||| IN
serum  ||| S:3096 E:3110 ||| JJ
profiles  ||| S:3110 E:3119 ||| NNS
of  ||| S:3119 E:3122 ||| IN
162  ||| S:3122 E:3126 ||| CD
subjects  ||| S:3126 E:3135 ||| NNS
with  ||| S:3135 E:3140 ||| IN
ovarian  ||| S:3140 E:3148 ||| JJ
cancer  ||| S:3148 E:3155 ||| NN
and  ||| S:3155 E:3159 ||| CC
91  ||| S:3159 E:3170 ||| CD
non-cancer  ||| S:3170 E:3181 ||| JJ
control  ||| S:3181 E:3189 ||| NN
subjects ||| S:3189 E:3197 ||| NNS
.  ||| S:3197 E:3199 ||| .
The  ||| S:3199 E:3203 ||| DT
cancer  ||| S:3203 E:3210 ||| NN
group  ||| S:3210 E:3216 ||| NN
may  ||| S:3216 E:3220 ||| MD
be  ||| S:3220 E:3231 ||| VB
further  ||| S:3231 E:3239 ||| RB
divided  ||| S:3239 E:3247 ||| VBN
into  ||| S:3247 E:3252 ||| IN
28  ||| S:3252 E:3255 ||| CD
stage  ||| S:3255 E:3261 ||| NN
1  ||| S:3261 E:3263 ||| CD
patients ||| S:3263 E:3271 ||| NNS
,  ||| S:3271 E:3273 ||| ,
20  ||| S:3273 E:3276 ||| CD
stage  ||| S:3276 E:3282 ||| NN
2  ||| S:3282 E:3292 ||| CD
patients ||| S:3292 E:3300 ||| NNS
,  ||| S:3300 E:3302 ||| ,
99  ||| S:3302 E:3305 ||| CD
stage  ||| S:3305 E:3311 ||| NN
3  ||| S:3311 E:3313 ||| CD
patients ||| S:3313 E:3321 ||| NNS
,  ||| S:3321 E:3323 ||| ,
12  ||| S:3323 E:3326 ||| CD
stage  ||| S:3326 E:3332 ||| NN
4  ||| S:3332 E:3334 ||| CD
patients ||| S:3334 E:3342 ||| NNS
,  ||| S:3342 E:3344 ||| ,
and  ||| S:3344 E:3348 ||| CC
3  ||| S:3348 E:3358 ||| CD
no  ||| S:3358 E:3361 ||| DT
stage  ||| S:3361 E:3367 ||| NN
specified  ||| S:3367 E:3377 ||| VBN
patients ||| S:3377 E:3385 ||| NNS
.  ||| S:3385 E:3387 ||| .
For  ||| S:3387 E:3391 ||| IN
each  ||| S:3391 E:3396 ||| DT
subject  ||| S:3396 E:3404 ||| NN
a  ||| S:3404 E:3406 ||| DT
set  ||| S:3406 E:3410 ||| NN
of  ||| S:3410 E:3413 ||| IN
data  ||| S:3413 E:3426 ||| NNS
consisting  ||| S:3426 E:3437 ||| VBG
of  ||| S:3437 E:3440 ||| IN
intensities  ||| S:3440 E:3452 ||| NN
at  ||| S:3452 E:3455 ||| IN
15,154  ||| S:3455 E:3462 ||| CD
distinct  ||| S:3462 E:3471 ||| JJ
M ||| S:3471 E:3472 ||| NNP
/ ||| S:3472 E:3473 ||| NNP
Z  ||| S:3473 E:3475 ||| NNP
values  ||| S:3475 E:3490 ||| VBZ
ranging  ||| S:3490 E:3498 ||| VBG
from  ||| S:3498 E:3503 ||| IN
0.0000786  ||| S:3503 E:3513 ||| CD
to  ||| S:3513 E:3516 ||| TO
19995.513  ||| S:3516 E:3526 ||| NNP
was  ||| S:3526 E:3530 ||| VBD
available  ||| S:3530 E:3540 ||| JJ
for  ||| S:3540 E:3552 ||| IN
analysis ||| S:3552 E:3560 ||| NN
.  ||| S:3560 E:3562 ||| .
This  ||| S:3562 E:3567 ||| DT
dataset  ||| S:3567 E:3575 ||| NN
was  ||| S:3575 E:3579 ||| VBD
constructed  ||| S:3579 E:3591 ||| VBN
using  ||| S:3591 E:3597 ||| VBG
the  ||| S:3597 E:3601 ||| DT
Ciphergen  ||| S:3601 E:3619 ||| NNP
WCX2  ||| S:3619 E:3624 ||| NNP
ProteinChip  ||| S:3624 E:3636 ||| JJ
array ||| S:3636 E:3641 ||| NN
.  ||| S:3641 E:3643 ||| .
All  ||| S:3643 E:3647 ||| PDT
the  ||| S:3647 E:3651 ||| DT
steps  ||| S:3651 E:3657 ||| NNS
of  ||| S:3657 E:3660 ||| IN
preparing  ||| S:3660 E:3670 ||| VBG
the  ||| S:3670 E:3682 ||| DT
chips  ||| S:3682 E:3688 ||| NNS
for  ||| S:3688 E:3692 ||| IN
sample  ||| S:3692 E:3699 ||| NN
analysis  ||| S:3699 E:3708 ||| NN
were  ||| S:3708 E:3713 ||| VBD
preformed  ||| S:3713 E:3723 ||| JJ
robotically ||| S:3723 E:3734 ||| NN
,  ||| S:3734 E:3736 ||| ,
and  ||| S:3736 E:3748 ||| CC
the  ||| S:3748 E:3752 ||| DT
raw  ||| S:3752 E:3756 ||| JJ
data  ||| S:3756 E:3761 ||| NNS
without  ||| S:3761 E:3769 ||| IN
baseline  ||| S:3769 E:3778 ||| JJ
subtraction  ||| S:3778 E:3790 ||| NN
was  ||| S:3790 E:3794 ||| VBD
posted  ||| S:3794 E:3801 ||| VBN
for  ||| S:3801 E:3813 ||| IN
download ||| S:3813 E:3821 ||| NN
.  ||| S:3821 E:3823 ||| .
A  ||| S:3823 E:3825 ||| DT
model  ||| S:3825 E:3831 ||| NN
rule  ||| S:3831 E:3836 ||| NN
claiming  ||| S:3836 E:3845 ||| VBG
100 ||| S:3845 E:3848 ||| CD
%  ||| S:3848 E:3850 ||| NN
sensitivity  ||| S:3850 E:3862 ||| NN
and  ||| S:3862 E:3874 ||| CC
specificity  ||| S:3874 E:3886 ||| NN
is  ||| S:3886 E:3889 ||| VBZ
also  ||| S:3889 E:3894 ||| RB
given ||| S:3894 E:3899 ||| VBN
.  ||| S:3899 E:3901 ||| .
Additional  ||| S:3901 E:3912 ||| JJ
details  ||| S:3912 E:3920 ||| NNS
of  ||| S:3920 E:3931 ||| IN
experimental  ||| S:3931 E:3944 ||| JJ
data  ||| S:3944 E:3949 ||| NN
collection  ||| S:3949 E:3960 ||| NN
may  ||| S:3960 E:3964 ||| MD
be  ||| S:3964 E:3967 ||| VB
found  ||| S:3967 E:3973 ||| VBN
at  ||| S:3973 E:3976 ||| IN
the  ||| S:3976 E:3980 ||| DT
Clinical  ||| S:3980 E:3997 ||| NNP
Proteomics  ||| S:3997 E:4008 ||| NNP
Data  ||| S:4008 E:4013 ||| NNP
Bank  ||| S:4013 E:4018 ||| NNP
[  ||| S:4018 E:4020 ||| -LRB-
5  ||| S:4020 E:4022 ||| LS
]  ||| S:4022 E:4024 ||| -RRB-
.  ||| S:4024 E:4026 ||| .
In  ||| S:4026 E:4029 ||| IN
addition  ||| S:4029 E:4038 ||| NN
to  ||| S:4038 E:4041 ||| TO
the  ||| S:4041 E:4045 ||| DT
various  ||| S:4045 E:4061 ||| JJ
methods  ||| S:4061 E:4069 ||| NNS
of  ||| S:4069 E:4072 ||| IN
preparing  ||| S:4072 E:4082 ||| VBG
and  ||| S:4082 E:4086 ||| CC
running  ||| S:4086 E:4094 ||| VBG
the  ||| S:4094 E:4098 ||| DT
samples  ||| S:4098 E:4106 ||| NNS
on  ||| S:4106 E:4109 ||| IN
the  ||| S:4109 E:4113 ||| DT
mass  ||| S:4113 E:4126 ||| JJ
spectrometer ||| S:4126 E:4138 ||| NN
,  ||| S:4138 E:4140 ||| ,
the  ||| S:4140 E:4144 ||| DT
optimal  ||| S:4144 E:4152 ||| JJ
steps  ||| S:4152 E:4158 ||| NNS
in  ||| S:4158 E:4161 ||| IN
processing  ||| S:4161 E:4172 ||| VBG
the  ||| S:4172 E:4176 ||| DT
raw  ||| S:4176 E:4180 ||| JJ
data  ||| S:4180 E:4193 ||| NNS
from  ||| S:4193 E:4198 ||| IN
the  ||| S:4198 E:4202 ||| DT
mass  ||| S:4202 E:4207 ||| JJ
spectrometer  ||| S:4207 E:4220 ||| NN
for  ||| S:4220 E:4224 ||| IN
further  ||| S:4224 E:4232 ||| JJ
analysis  ||| S:4232 E:4241 ||| NN
have  ||| S:4241 E:4246 ||| VBP
not  ||| S:4246 E:4258 ||| RB
been  ||| S:4258 E:4263 ||| VBN
standardized  ||| S:4263 E:4276 ||| JJ
and  ||| S:4276 E:4280 ||| CC
remain  ||| S:4280 E:4287 ||| VB
a  ||| S:4287 E:4289 ||| DT
fertile  ||| S:4289 E:4297 ||| JJ
area  ||| S:4297 E:4302 ||| NN
for  ||| S:4302 E:4314 ||| IN
investigation  ||| S:4314 E:4328 ||| NN
[  ||| S:4328 E:4330 ||| -LRB-
15  ||| S:4330 E:4333 ||| CD
]  ||| S:4333 E:4335 ||| -RRB-
.  ||| S:4335 E:4337 ||| .
We  ||| S:4337 E:4340 ||| PRP
choose  ||| S:4340 E:4347 ||| VBP
the  ||| S:4347 E:4351 ||| DT
deliberately  ||| S:4351 E:4364 ||| RB
simple  ||| S:4364 E:4379 ||| JJ
strategy  ||| S:4379 E:4388 ||| NN
of  ||| S:4388 E:4391 ||| IN
using  ||| S:4391 E:4397 ||| VBG
Wilcoxon  ||| S:4397 E:4406 ||| JJ
test  ||| S:4406 E:4411 ||| NN
on  ||| S:4411 E:4414 ||| IN
the  ||| S:4414 E:4418 ||| DT
raw  ||| S:4418 E:4422 ||| JJ
data  ||| S:4422 E:4427 ||| NNS
to  ||| S:4427 E:4430 ||| TO
better  ||| S:4430 E:4445 ||| RB
understand  ||| S:4445 E:4456 ||| VB
the  ||| S:4456 E:4460 ||| DT
underlying  ||| S:4460 E:4471 ||| JJ
properties  ||| S:4471 E:4482 ||| NNS
of  ||| S:4482 E:4485 ||| IN
the  ||| S:4485 E:4489 ||| DT
data  ||| S:4489 E:4494 ||| NNS
set ||| S:4494 E:4497 ||| VBN
.  ||| S:4497 E:4499 ||| .
We  ||| S:4499 E:4510 ||| PRP
consider  ||| S:4510 E:4519 ||| VBP
this  ||| S:4519 E:4524 ||| DT
simple  ||| S:4524 E:4531 ||| JJ
approach  ||| S:4531 E:4540 ||| NN
a  ||| S:4540 E:4542 ||| DT
"benchmark  ||| S:4542 E:4553 ||| JJ
method ||| S:4553 E:4559 ||| NN
"  ||| S:4559 E:4561 ||| ''
to  ||| S:4561 E:4564 ||| TO
which  ||| S:4564 E:4578 ||| WDT
other  ||| S:4578 E:4584 ||| JJ
methods  ||| S:4584 E:4592 ||| NNS
can  ||| S:4592 E:4596 ||| MD
be  ||| S:4596 E:4599 ||| VB
compared ||| S:4599 E:4607 ||| VBN
.  ||| S:4607 E:4609 ||| .
Further ||| S:4609 E:4616 ||| RB
,  ||| S:4616 E:4618 ||| ,
we  ||| S:4618 E:4621 ||| PRP
use  ||| S:4621 E:4625 ||| VBP
Wilcoxon  ||| S:4625 E:4642 ||| JJ
test  ||| S:4642 E:4647 ||| NN
and  ||| S:4647 E:4651 ||| CC
stepwise  ||| S:4651 E:4660 ||| JJ
discriminant  ||| S:4660 E:4673 ||| JJ
analysis  ||| S:4673 E:4682 ||| NN
on  ||| S:4682 E:4685 ||| IN
a  ||| S:4685 E:4687 ||| DT
training  ||| S:4687 E:4704 ||| NN
subset  ||| S:4704 E:4711 ||| VBZ
consisting  ||| S:4711 E:4722 ||| VBG
of  ||| S:4722 E:4725 ||| IN
80  ||| S:4725 E:4728 ||| CD
cancer  ||| S:4728 E:4735 ||| NN
patients  ||| S:4735 E:4744 ||| NNS
and  ||| S:4744 E:4748 ||| CC
45  ||| S:4748 E:4751 ||| CD
controls ||| S:4751 E:4759 ||| NNS
,  ||| S:4759 E:4769 ||| ,
randomly  ||| S:4769 E:4778 ||| RB
chosen  ||| S:4778 E:4785 ||| VBN
from  ||| S:4785 E:4790 ||| IN
the  ||| S:4790 E:4794 ||| DT
original  ||| S:4794 E:4803 ||| JJ
data  ||| S:4803 E:4808 ||| NNS
set ||| S:4808 E:4811 ||| VBN
,  ||| S:4811 E:4813 ||| ,
to  ||| S:4813 E:4816 ||| TO
develop  ||| S:4816 E:4832 ||| VB
rules  ||| S:4832 E:4838 ||| NNS
to  ||| S:4838 E:4841 ||| TO
classify  ||| S:4841 E:4850 ||| VB
a  ||| S:4850 E:4852 ||| DT
test  ||| S:4852 E:4857 ||| NN
set  ||| S:4857 E:4861 ||| VBD
consisting  ||| S:4861 E:4872 ||| VBG
of  ||| S:4872 E:4875 ||| IN
the  ||| S:4875 E:4879 ||| DT
remaining  ||| S:4879 E:4897 ||| JJ
cancer  ||| S:4897 E:4904 ||| NN
and  ||| S:4904 E:4908 ||| CC
control  ||| S:4908 E:4916 ||| NN
subjects ||| S:4916 E:4924 ||| NNS
.  ||| S:4924 E:4926 ||| .
Disease  ||| S:4926 E:4934 ||| NN
classifiers  ||| S:4934 E:4946 ||| NN
of  ||| S:4946 E:4949 ||| IN
great  ||| S:4949 E:4963 ||| JJ
sensitivity  ||| S:4963 E:4975 ||| NN
and  ||| S:4975 E:4979 ||| CC
specificity  ||| S:4979 E:4991 ||| NN
could  ||| S:4991 E:4997 ||| MD
be  ||| S:4997 E:5000 ||| VB
readily  ||| S:5000 E:5008 ||| RB
constructed  ||| S:5008 E:5020 ||| VBN
by  ||| S:5020 E:5031 ||| IN
visual  ||| S:5031 E:5038 ||| JJ
inspection  ||| S:5038 E:5049 ||| NN
and  ||| S:5049 E:5053 ||| CC
manual  ||| S:5053 E:5060 ||| JJ
binning  ||| S:5060 E:5068 ||| NN
of  ||| S:5068 E:5071 ||| IN
M ||| S:5071 E:5072 ||| NNP
/ ||| S:5072 E:5073 ||| NNP
Z  ||| S:5073 E:5075 ||| NNP
values  ||| S:5075 E:5082 ||| VBZ
based  ||| S:5082 E:5088 ||| VBN
on  ||| S:5088 E:5099 ||| IN
the  ||| S:5099 E:5103 ||| DT
p-values  ||| S:5103 E:5112 ||| JJ
of  ||| S:5112 E:5115 ||| IN
the  ||| S:5115 E:5119 ||| DT
Wilcoxon  ||| S:5119 E:5128 ||| JJ
test  ||| S:5128 E:5133 ||| NN
combined  ||| S:5133 E:5142 ||| VBN
with  ||| S:5142 E:5147 ||| IN
classical  ||| S:5147 E:5165 ||| JJ
stepwise  ||| S:5165 E:5174 ||| JJ
discriminant  ||| S:5174 E:5187 ||| JJ
analysis ||| S:5187 E:5195 ||| NN
.  ||| S:5195 E:5197 ||| .
The  ||| S:5197 E:5201 ||| DT
ability  ||| S:5201 E:5209 ||| NN
of  ||| S:5209 E:5212 ||| IN
these  ||| S:5212 E:5218 ||| DT
rules  ||| S:5218 E:5232 ||| NNS
to  ||| S:5232 E:5235 ||| TO
classify  ||| S:5235 E:5244 ||| VB
disease  ||| S:5244 E:5252 ||| NN
and  ||| S:5252 E:5256 ||| CC
normal  ||| S:5256 E:5263 ||| JJ
samples  ||| S:5263 E:5271 ||| NNS
were  ||| S:5271 E:5276 ||| VBD
comparable  ||| S:5276 E:5287 ||| JJ
to  ||| S:5287 E:5298 ||| TO
the  ||| S:5298 E:5302 ||| DT
model  ||| S:5302 E:5308 ||| NN
rule  ||| S:5308 E:5313 ||| NN
published  ||| S:5313 E:5323 ||| VBN
on  ||| S:5323 E:5326 ||| IN
this  ||| S:5326 E:5331 ||| DT
dataset  ||| S:5331 E:5339 ||| NN
at  ||| S:5339 E:5342 ||| IN
the  ||| S:5342 E:5346 ||| DT
Clinical  ||| S:5346 E:5363 ||| NNP
Proteomics  ||| S:5363 E:5374 ||| NNP
Program  ||| S:5374 E:5382 ||| NNP
Databank  ||| S:5382 E:5391 ||| NNP
website  ||| S:5391 E:5399 ||| NN
which  ||| S:5399 E:5405 ||| WDT
was  ||| S:5405 E:5409 ||| VBD
developed  ||| S:5409 E:5427 ||| VBN
using  ||| S:5427 E:5433 ||| VBG
a  ||| S:5433 E:5435 ||| DT
proprietary  ||| S:5435 E:5447 ||| JJ
genetic  ||| S:5447 E:5455 ||| JJ
algorithm ||| S:5455 E:5464 ||| NN
.  ||| S:5464 E:5466 ||| .
Further ||| S:5466 E:5473 ||| RB
,  ||| S:5473 E:5475 ||| ,
in  ||| S:5475 E:5486 ||| IN
examining  ||| S:5486 E:5496 ||| VBG
all  ||| S:5496 E:5500 ||| DT
M ||| S:5500 E:5501 ||| NNP
/ ||| S:5501 E:5502 ||| NNP
Z  ||| S:5502 E:5504 ||| NNP
values ||| S:5504 E:5510 ||| NNS
,  ||| S:5510 E:5512 ||| ,
the  ||| S:5512 E:5516 ||| DT
M ||| S:5516 E:5517 ||| NNP
/ ||| S:5517 E:5518 ||| NNP
Z  ||| S:5518 E:5520 ||| NNP
values  ||| S:5520 E:5527 ||| NNS
that  ||| S:5527 E:5532 ||| WDT
discriminated  ||| S:5532 E:5554 ||| VBP
best  ||| S:5554 E:5559 ||| RB
between  ||| S:5559 E:5567 ||| IN
ovarian  ||| S:5567 E:5575 ||| JJ
cancer  ||| S:5575 E:5582 ||| NN
and  ||| S:5582 E:5586 ||| CC
control  ||| S:5586 E:5594 ||| NN
were  ||| S:5594 E:5599 ||| VBD
all  ||| S:5599 E:5603 ||| DT
found  ||| S:5603 E:5609 ||| VBN
to  ||| S:5609 E:5620 ||| TO
be  ||| S:5620 E:5623 ||| VB
less  ||| S:5623 E:5628 ||| JJR
than  ||| S:5628 E:5633 ||| IN
500 ||| S:5633 E:5636 ||| CD
,  ||| S:5636 E:5638 ||| ,
an  ||| S:5638 E:5641 ||| DT
area  ||| S:5641 E:5646 ||| NN
of  ||| S:5646 E:5649 ||| IN
the  ||| S:5649 E:5653 ||| DT
spectrum  ||| S:5653 E:5662 ||| NN
often  ||| S:5662 E:5668 ||| RB
discarded  ||| S:5668 E:5686 ||| VBN
as  ||| S:5686 E:5689 ||| IN
noise  ||| S:5689 E:5695 ||| NN
[  ||| S:5695 E:5697 ||| -LRB-
10  ||| S:5697 E:5700 ||| CD
]  ||| S:5700 E:5702 ||| -RRB-
.  ||| S:5702 E:5704 ||| .
These  ||| S:5704 E:5710 ||| DT
findings  ||| S:5710 E:5719 ||| NNS
are  ||| S:5719 E:5723 ||| VBP
useful  ||| S:5723 E:5730 ||| JJ
for  ||| S:5730 E:5734 ||| IN
several  ||| S:5734 E:5750 ||| JJ
reasons ||| S:5750 E:5757 ||| NNS
.  ||| S:5757 E:5759 ||| .
First ||| S:5759 E:5764 ||| NNP
,  ||| S:5764 E:5766 ||| ,
the  ||| S:5766 E:5770 ||| DT
statistical  ||| S:5770 E:5782 ||| JJ
methods  ||| S:5782 E:5790 ||| NNS
used  ||| S:5790 E:5795 ||| VBN
in  ||| S:5795 E:5798 ||| IN
this  ||| S:5798 E:5803 ||| DT
study  ||| S:5803 E:5817 ||| NN
are  ||| S:5817 E:5821 ||| VBP
readily  ||| S:5821 E:5829 ||| RB
available ||| S:5829 E:5838 ||| JJ
,  ||| S:5838 E:5840 ||| ,
widely  ||| S:5840 E:5847 ||| RB
understood ||| S:5847 E:5857 ||| VBN
,  ||| S:5857 E:5859 ||| ,
and  ||| S:5859 E:5863 ||| CC
can  ||| S:5863 E:5867 ||| MD
be  ||| S:5867 E:5878 ||| VB
cheaply  ||| S:5878 E:5886 ||| RB
implemented ||| S:5886 E:5897 ||| VBN
.  ||| S:5897 E:5899 ||| .
Secondly ||| S:5899 E:5907 ||| RB
,  ||| S:5907 E:5909 ||| ,
a  ||| S:5909 E:5911 ||| DT
vast  ||| S:5911 E:5916 ||| JJ
amount  ||| S:5916 E:5923 ||| NN
of  ||| S:5923 E:5934 ||| IN
mathematical  ||| S:5934 E:5947 ||| JJ
research  ||| S:5947 E:5956 ||| NN
and  ||| S:5956 E:5960 ||| CC
practical  ||| S:5960 E:5970 ||| JJ
experience  ||| S:5970 E:5981 ||| NN
underlies  ||| S:5981 E:5999 ||| VBD
their  ||| S:5999 E:6005 ||| PRP$
interpretation ||| S:6005 E:6019 ||| NN
.  ||| S:6019 E:6021 ||| .
Finally ||| S:6021 E:6028 ||| RB
,  ||| S:6028 E:6030 ||| ,
they  ||| S:6030 E:6035 ||| PRP
can  ||| S:6035 E:6039 ||| MD
be  ||| S:6039 E:6042 ||| VB
used  ||| S:6042 E:6047 ||| VBN
to  ||| S:6047 E:6050 ||| TO
discover  ||| S:6050 E:6067 ||| VB
unexpected  ||| S:6067 E:6078 ||| JJ
patterns  ||| S:6078 E:6087 ||| NNS
present  ||| S:6087 E:6095 ||| JJ
in  ||| S:6095 E:6098 ||| IN
the  ||| S:6098 E:6102 ||| DT
data  ||| S:6102 E:6107 ||| NNS
set ||| S:6107 E:6110 ||| VBN
.  ||| S:6110 E:6112 ||| .
These  ||| S:6112 E:6118 ||| DT
patterns  ||| S:6118 E:6135 ||| NNS
may  ||| S:6135 E:6139 ||| MD
be  ||| S:6139 E:6142 ||| VB
missed  ||| S:6142 E:6149 ||| VBN
by  ||| S:6149 E:6152 ||| IN
machine  ||| S:6152 E:6160 ||| NN
learning  ||| S:6160 E:6169 ||| VBG
methods  ||| S:6169 E:6177 ||| NNS
that  ||| S:6177 E:6182 ||| WDT
are  ||| S:6182 E:6186 ||| VBP
narrowly  ||| S:6186 E:6203 ||| RB
focused  ||| S:6203 E:6211 ||| VBN
on  ||| S:6211 E:6214 ||| IN
diagnostic  ||| S:6214 E:6225 ||| JJ
classification ||| S:6225 E:6239 ||| NN
,  ||| S:6239 E:6241 ||| ,
and  ||| S:6241 E:6245 ||| CC
do  ||| S:6245 E:6248 ||| VBP
not  ||| S:6248 E:6252 ||| RB
present  ||| S:6252 E:6268 ||| VB
the  ||| S:6268 E:6272 ||| DT
researcher  ||| S:6272 E:6283 ||| NN
with  ||| S:6283 E:6288 ||| IN
a  ||| S:6288 E:6290 ||| DT
broad  ||| S:6290 E:6296 ||| JJ
overview  ||| S:6296 E:6305 ||| NN
of  ||| S:6305 E:6308 ||| IN
the  ||| S:6308 E:6312 ||| DT
data ||| S:6312 E:6316 ||| NNS
.  ||| S:6316 E:6318 ||| .
As  ||| S:6318 E:6321 ||| IN
a  ||| S:6321 E:6331 ||| DT
result  ||| S:6331 E:6338 ||| NN
of  ||| S:6338 E:6341 ||| IN
these  ||| S:6341 E:6347 ||| DT
traditional  ||| S:6347 E:6359 ||| JJ
studies ||| S:6359 E:6366 ||| NNS
,  ||| S:6366 E:6368 ||| ,
a  ||| S:6368 E:6370 ||| DT
better  ||| S:6370 E:6377 ||| JJR
understanding  ||| S:6377 E:6399 ||| NN
of  ||| S:6399 E:6402 ||| IN
the  ||| S:6402 E:6406 ||| DT
weaknesses  ||| S:6406 E:6417 ||| NNS
and  ||| S:6417 E:6421 ||| CC
possible  ||| S:6421 E:6430 ||| JJ
strengths  ||| S:6430 E:6440 ||| NNS
of  ||| S:6440 E:6443 ||| IN
serum  ||| S:6443 E:6449 ||| JJ
proteomic  ||| S:6449 E:6467 ||| JJ
profiling  ||| S:6467 E:6477 ||| NN
becomes  ||| S:6477 E:6485 ||| VBZ
apparent ||| S:6485 E:6493 ||| JJ
.  ||| S:6493 E:6517 ||| .
Results  ||| S:6517 E:6525 ||| NNS
and  ||| S:6525 E:6529 ||| CC
Discussion  ||| S:6529 E:6548 ||| NNP
Based  ||| S:6548 E:6554 ||| NNP
on  ||| S:6554 E:6557 ||| IN
the  ||| S:6557 E:6561 ||| DT
initial  ||| S:6561 E:6569 ||| JJ
training  ||| S:6569 E:6578 ||| NN
set ||| S:6578 E:6581 ||| NN
,  ||| S:6581 E:6583 ||| ,
the  ||| S:6583 E:6587 ||| DT
intensity  ||| S:6587 E:6597 ||| NN
at  ||| S:6597 E:6600 ||| IN
each  ||| S:6600 E:6613 ||| DT
of  ||| S:6613 E:6616 ||| IN
the  ||| S:6616 E:6620 ||| DT
consecutive  ||| S:6620 E:6632 ||| JJ
15,154  ||| S:6632 E:6639 ||| NNP
M ||| S:6639 E:6640 ||| NNP
/ ||| S:6640 E:6641 ||| NNP
Z  ||| S:6641 E:6643 ||| NNP
values  ||| S:6643 E:6650 ||| NNS
was  ||| S:6650 E:6654 ||| VBD
first  ||| S:6654 E:6660 ||| RB
compared  ||| S:6660 E:6677 ||| VBN
using  ||| S:6677 E:6683 ||| VBG
a  ||| S:6683 E:6685 ||| DT
two-sided  ||| S:6685 E:6695 ||| JJ
Wilcoxon  ||| S:6695 E:6704 ||| JJ
test  ||| S:6704 E:6709 ||| NN
( ||| S:6709 E:6710 ||| -LRB-
see  ||| S:6710 E:6714 ||| VB
methods ||| S:6714 E:6721 ||| NNS
)  ||| S:6721 E:6723 ||| -RRB-
Figure  ||| S:6723 E:6730 ||| NN
1shows  ||| S:6730 E:6745 ||| VBZ
the  ||| S:6745 E:6749 ||| DT
pattern  ||| S:6749 E:6757 ||| NN
of  ||| S:6757 E:6760 ||| IN
the  ||| S:6760 E:6764 ||| DT
resulting  ||| S:6764 E:6774 ||| VBG
two-sided  ||| S:6774 E:6784 ||| JJ
Wilcoxon  ||| S:6784 E:6793 ||| JJ
test  ||| S:6793 E:6806 ||| NN
p-values  ||| S:6806 E:6815 ||| NN
generated  ||| S:6815 E:6825 ||| VBD
on  ||| S:6825 E:6828 ||| IN
a  ||| S:6828 E:6830 ||| DT
training  ||| S:6830 E:6839 ||| NN
set  ||| S:6839 E:6843 ||| VBD
consisting  ||| S:6843 E:6854 ||| VBG
of  ||| S:6854 E:6857 ||| IN
80  ||| S:6857 E:6868 ||| CD
cancer  ||| S:6868 E:6875 ||| NN
patients  ||| S:6875 E:6884 ||| NNS
and  ||| S:6884 E:6888 ||| CC
45  ||| S:6888 E:6891 ||| CD
controls  ||| S:6891 E:6900 ||| NNS
randomly  ||| S:6900 E:6909 ||| RB
chosen  ||| S:6909 E:6916 ||| VBN
from  ||| S:6916 E:6921 ||| IN
the  ||| S:6921 E:6933 ||| DT
larger  ||| S:6933 E:6940 ||| JJR
data  ||| S:6940 E:6945 ||| NNS
set ||| S:6945 E:6948 ||| VBN
,  ||| S:6948 E:6950 ||| ,
with  ||| S:6950 E:6955 ||| IN
the  ||| S:6955 E:6959 ||| DT
M ||| S:6959 E:6960 ||| NNP
/ ||| S:6960 E:6961 ||| NNP
Z  ||| S:6961 E:6963 ||| NNP
values  ||| S:6963 E:6970 ||| NNS
on  ||| S:6970 E:6973 ||| IN
the  ||| S:6973 E:6977 ||| DT
x-axis  ||| S:6977 E:6984 ||| JJ
and  ||| S:6984 E:6988 ||| CC
the  ||| S:6988 E:7000 ||| DT
negative  ||| S:7000 E:7009 ||| JJ
logarithm  ||| S:7009 E:7019 ||| NNS
( ||| S:7019 E:7020 ||| -LRB-
base  ||| S:7020 E:7025 ||| NN
10 ||| S:7025 E:7027 ||| CD
)  ||| S:7027 E:7029 ||| -RRB-
of  ||| S:7029 E:7032 ||| IN
the  ||| S:7032 E:7036 ||| DT
Wilcoxon  ||| S:7036 E:7045 ||| JJ
test  ||| S:7045 E:7050 ||| NN
p-values  ||| S:7050 E:7067 ||| NN
on  ||| S:7067 E:7070 ||| IN
the  ||| S:7070 E:7074 ||| DT
y-axis ||| S:7074 E:7080 ||| JJ
.  ||| S:7080 E:7082 ||| .
There  ||| S:7082 E:7088 ||| EX
are  ||| S:7088 E:7092 ||| VBP
a  ||| S:7092 E:7094 ||| DT
total  ||| S:7094 E:7100 ||| NN
of  ||| S:7100 E:7103 ||| IN
685  ||| S:7103 E:7107 ||| CD
distinct  ||| S:7107 E:7116 ||| JJ
M ||| S:7116 E:7117 ||| NNP
/ ||| S:7117 E:7118 ||| NNP
Z  ||| S:7118 E:7120 ||| NNP
values  ||| S:7120 E:7135 ||| VBZ
differing  ||| S:7135 E:7145 ||| VBG
between  ||| S:7145 E:7153 ||| IN
the  ||| S:7153 E:7157 ||| DT
cancer  ||| S:7157 E:7164 ||| NN
and  ||| S:7164 E:7168 ||| CC
control  ||| S:7168 E:7176 ||| NN
populations  ||| S:7176 E:7188 ||| NNS
with  ||| S:7188 E:7193 ||| IN
a  ||| S:7193 E:7203 ||| DT
p-value  ||| S:7203 E:7211 ||| JJ
of  ||| S:7211 E:7214 ||| IN
less  ||| S:7214 E:7219 ||| JJR
than  ||| S:7219 E:7224 ||| IN
10  ||| S:7224 E:7227 ||| CD
-6 ||| S:7227 E:7229 ||| CD
.  ||| S:7229 E:7231 ||| .
Also  ||| S:7231 E:7236 ||| RB
of  ||| S:7236 E:7239 ||| IN
note  ||| S:7239 E:7244 ||| NN
in  ||| S:7244 E:7247 ||| IN
this  ||| S:7247 E:7260 ||| DT
distribution  ||| S:7260 E:7273 ||| NN
is  ||| S:7273 E:7276 ||| VBZ
that  ||| S:7276 E:7281 ||| IN
all  ||| S:7281 E:7285 ||| DT
M ||| S:7285 E:7286 ||| NNP
/ ||| S:7286 E:7287 ||| NNP
Z  ||| S:7287 E:7289 ||| NNP
values  ||| S:7289 E:7296 ||| NNS
with  ||| S:7296 E:7301 ||| IN
a  ||| S:7301 E:7303 ||| DT
Wilcoxon  ||| S:7303 E:7312 ||| NNP
p-value  ||| S:7312 E:7328 ||| NNP
less  ||| S:7328 E:7333 ||| RBR
than  ||| S:7333 E:7338 ||| IN
10  ||| S:7338 E:7341 ||| CD
-12are  ||| S:7341 E:7348 ||| CD
found  ||| S:7348 E:7354 ||| VBN
at  ||| S:7354 E:7357 ||| IN
M ||| S:7357 E:7358 ||| NNP
/ ||| S:7358 E:7359 ||| NNP
Z  ||| S:7359 E:7361 ||| NNP
values  ||| S:7361 E:7368 ||| NNS
of  ||| S:7368 E:7371 ||| IN
less  ||| S:7371 E:7376 ||| JJR
than  ||| S:7376 E:7381 ||| IN
500 ||| S:7381 E:7384 ||| CD
.  ||| S:7384 E:7394 ||| .
The  ||| S:7394 E:7398 ||| DT
significance  ||| S:7398 E:7411 ||| NN
of  ||| S:7411 E:7414 ||| IN
this  ||| S:7414 E:7419 ||| DT
finding  ||| S:7419 E:7427 ||| NN
will  ||| S:7427 E:7432 ||| MD
be  ||| S:7432 E:7435 ||| VB
discussed  ||| S:7435 E:7445 ||| VBN
further  ||| S:7445 E:7461 ||| RBR
below ||| S:7461 E:7466 ||| RB
.  ||| S:7466 E:7476 ||| .
In  ||| S:7476 E:7479 ||| IN
order  ||| S:7479 E:7485 ||| NN
to  ||| S:7485 E:7488 ||| TO
determine  ||| S:7488 E:7498 ||| VB
if  ||| S:7498 E:7501 ||| IN
these  ||| S:7501 E:7507 ||| DT
data  ||| S:7507 E:7512 ||| NNS
could  ||| S:7512 E:7518 ||| MD
be  ||| S:7518 E:7521 ||| VB
used  ||| S:7521 E:7526 ||| VBN
to  ||| S:7526 E:7537 ||| TO
separate  ||| S:7537 E:7546 ||| VB
normal  ||| S:7546 E:7553 ||| JJ
from  ||| S:7553 E:7558 ||| IN
cancer ||| S:7558 E:7564 ||| NN
,  ||| S:7564 E:7566 ||| ,
we  ||| S:7566 E:7569 ||| PRP
used  ||| S:7569 E:7574 ||| VBD
three  ||| S:7574 E:7580 ||| CD
strategies  ||| S:7580 E:7591 ||| NNS
to  ||| S:7591 E:7602 ||| TO
develop  ||| S:7602 E:7610 ||| VB
rules  ||| S:7610 E:7616 ||| NNS
for  ||| S:7616 E:7620 ||| IN
diagnostic  ||| S:7620 E:7631 ||| JJ
classification ||| S:7631 E:7645 ||| NN
.  ||| S:7645 E:7647 ||| .
First ||| S:7647 E:7652 ||| NNP
,  ||| S:7652 E:7654 ||| ,
all  ||| S:7654 E:7666 ||| DT
data  ||| S:7666 E:7671 ||| NN
points  ||| S:7671 E:7678 ||| NNS
regardless  ||| S:7678 E:7689 ||| RB
of  ||| S:7689 E:7692 ||| IN
M ||| S:7692 E:7693 ||| NNP
/ ||| S:7693 E:7694 ||| NNP
Z  ||| S:7694 E:7696 ||| NNP
value  ||| S:7696 E:7702 ||| NN
were  ||| S:7702 E:7707 ||| VBD
sorted  ||| S:7707 E:7714 ||| VBN
from  ||| S:7714 E:7719 ||| IN
most  ||| S:7719 E:7732 ||| JJS
to  ||| S:7732 E:7735 ||| TO
least  ||| S:7735 E:7741 ||| JJS
significant  ||| S:7741 E:7753 ||| JJ
( ||| S:7753 E:7754 ||| -LRB-
according  ||| S:7754 E:7764 ||| VBG
to  ||| S:7764 E:7767 ||| TO
the  ||| S:7767 E:7771 ||| DT
two-sided  ||| S:7771 E:7781 ||| JJ
Wilcoxon  ||| S:7781 E:7798 ||| JJ
test  ||| S:7798 E:7803 ||| NN
p-values ||| S:7803 E:7811 ||| NN
)  ||| S:7811 E:7813 ||| -RRB-
and  ||| S:7813 E:7817 ||| CC
the  ||| S:7817 E:7821 ||| DT
100  ||| S:7821 E:7825 ||| CD
M ||| S:7825 E:7826 ||| NNP
/ ||| S:7826 E:7827 ||| NNP
Z  ||| S:7827 E:7829 ||| NNP
values  ||| S:7829 E:7836 ||| NNS
with  ||| S:7836 E:7841 ||| IN
the  ||| S:7841 E:7845 ||| DT
lowest  ||| S:7845 E:7860 ||| JJS
p-values  ||| S:7860 E:7869 ||| NN
were  ||| S:7869 E:7874 ||| VBD
chosen ||| S:7874 E:7880 ||| VBN
.  ||| S:7880 E:7882 ||| .
These  ||| S:7882 E:7888 ||| DT
100  ||| S:7888 E:7892 ||| CD
M ||| S:7892 E:7893 ||| NNP
/ ||| S:7893 E:7894 ||| NNP
Z  ||| S:7894 E:7896 ||| NNP
values  ||| S:7896 E:7903 ||| NNS
were  ||| S:7903 E:7908 ||| VBD
then  ||| S:7908 E:7921 ||| RB
separated  ||| S:7921 E:7931 ||| VBN
into  ||| S:7931 E:7936 ||| IN
distinct  ||| S:7936 E:7945 ||| JJ
bins  ||| S:7945 E:7950 ||| NN
by  ||| S:7950 E:7953 ||| IN
sorting  ||| S:7953 E:7961 ||| VBG
on  ||| S:7961 E:7964 ||| IN
consecutive  ||| S:7964 E:7976 ||| JJ
M ||| S:7976 E:7977 ||| NNP
/ ||| S:7977 E:7978 ||| NNP
Z  ||| S:7978 E:7988 ||| NNP
and  ||| S:7988 E:7992 ||| CC
requiring  ||| S:7992 E:8002 ||| VBG
a  ||| S:8002 E:8004 ||| DT
separation  ||| S:8004 E:8015 ||| NN
of  ||| S:8015 E:8018 ||| IN
at  ||| S:8018 E:8021 ||| IN
least  ||| S:8021 E:8027 ||| JJS
1  ||| S:8027 E:8029 ||| CD
M ||| S:8029 E:8030 ||| NNP
/ ||| S:8030 E:8031 ||| NNP
Z  ||| S:8031 E:8033 ||| NNP
value  ||| S:8033 E:8039 ||| NN
to  ||| S:8039 E:8042 ||| TO
start  ||| S:8042 E:8056 ||| VB
the  ||| S:8056 E:8060 ||| DT
next  ||| S:8060 E:8065 ||| JJ
bin  ||| S:8065 E:8069 ||| NNS
( ||| S:8069 E:8070 ||| -LRB-
12  ||| S:8070 E:8073 ||| CD
bins  ||| S:8073 E:8078 ||| NNS
were  ||| S:8078 E:8083 ||| VBD
detected  ||| S:8083 E:8092 ||| VBN
in  ||| S:8092 E:8095 ||| IN
this  ||| S:8095 E:8100 ||| DT
process ||| S:8100 E:8107 ||| NN
) ||| S:8107 E:8108 ||| -RRB-
.  ||| S:8108 E:8110 ||| .
The  ||| S:8110 E:8122 ||| DT
M ||| S:8122 E:8123 ||| NNP
/ ||| S:8123 E:8124 ||| NNP
Z  ||| S:8124 E:8126 ||| NNP
value  ||| S:8126 E:8132 ||| NN
with  ||| S:8132 E:8137 ||| IN
the  ||| S:8137 E:8141 ||| DT
smallest  ||| S:8141 E:8150 ||| JJS
p-value  ||| S:8150 E:8158 ||| JJ
in  ||| S:8158 E:8161 ||| IN
each  ||| S:8161 E:8166 ||| DT
bin  ||| S:8166 E:8170 ||| NN
was  ||| S:8170 E:8182 ||| VBD
selected ||| S:8182 E:8190 ||| VBN
.  ||| S:8190 E:8192 ||| .
The  ||| S:8192 E:8196 ||| DT
results  ||| S:8196 E:8204 ||| NNS
are  ||| S:8204 E:8208 ||| VBP
shown  ||| S:8208 E:8214 ||| VBN
in  ||| S:8214 E:8217 ||| IN
Table  ||| S:8217 E:8223 ||| NNP
1 ||| S:8223 E:8224 ||| CD
.  ||| S:8224 E:8226 ||| .
Next ||| S:8226 E:8230 ||| JJ
,  ||| S:8230 E:8232 ||| ,
stepwise  ||| S:8232 E:8249 ||| JJ
discriminate  ||| S:8249 E:8262 ||| JJ
analysis  ||| S:8262 E:8271 ||| NN
was  ||| S:8271 E:8275 ||| VBD
performed ||| S:8275 E:8284 ||| VBN
,  ||| S:8284 E:8286 ||| ,
and  ||| S:8286 E:8290 ||| CC
7  ||| S:8290 E:8292 ||| CD
M ||| S:8292 E:8293 ||| NNP
/ ||| S:8293 E:8294 ||| NNP
Z  ||| S:8294 E:8296 ||| NNP
values  ||| S:8296 E:8303 ||| NNS
were  ||| S:8303 E:8316 ||| VBD
selected  ||| S:8316 E:8325 ||| VBN
for  ||| S:8325 E:8329 ||| IN
Rule  ||| S:8329 E:8334 ||| NNP
1  ||| S:8334 E:8336 ||| CD
( ||| S:8336 E:8337 ||| -LRB-
of  ||| S:8337 E:8340 ||| IN
note ||| S:8340 E:8344 ||| NN
,  ||| S:8344 E:8346 ||| ,
all  ||| S:8346 E:8350 ||| DT
but  ||| S:8350 E:8354 ||| CC
one  ||| S:8354 E:8358 ||| CD
M ||| S:8358 E:8359 ||| NNP
/ ||| S:8359 E:8360 ||| NNP
Z  ||| S:8360 E:8362 ||| NNP
value  ||| S:8362 E:8368 ||| NN
was  ||| S:8368 E:8380 ||| VBD
below  ||| S:8380 E:8386 ||| IN
500 ||| S:8386 E:8389 ||| CD
) ||| S:8389 E:8390 ||| -RRB-
.  ||| S:8390 E:8392 ||| .
When  ||| S:8392 E:8397 ||| WRB
this  ||| S:8397 E:8402 ||| DT
rule  ||| S:8402 E:8407 ||| NN
was  ||| S:8407 E:8411 ||| VBD
applied  ||| S:8411 E:8419 ||| VBN
to  ||| S:8419 E:8422 ||| TO
the  ||| S:8422 E:8426 ||| DT
entire  ||| S:8426 E:8433 ||| JJ
data  ||| S:8433 E:8446 ||| NNS
set ||| S:8446 E:8449 ||| VBN
,  ||| S:8449 E:8451 ||| ,
test  ||| S:8451 E:8456 ||| NN
and  ||| S:8456 E:8460 ||| CC
training  ||| S:8460 E:8469 ||| NN
inclusive ||| S:8469 E:8478 ||| NN
,  ||| S:8478 E:8480 ||| ,
all  ||| S:8480 E:8484 ||| DT
162  ||| S:8484 E:8488 ||| CD
cancer  ||| S:8488 E:8495 ||| NN
and  ||| S:8495 E:8499 ||| CC
91  ||| S:8499 E:8510 ||| CD
controls  ||| S:8510 E:8519 ||| NNS
were  ||| S:8519 E:8524 ||| VBD
appropriately  ||| S:8524 E:8538 ||| RB
classified  ||| S:8538 E:8549 ||| VBN
without  ||| S:8549 E:8557 ||| IN
error  ||| S:8557 E:8563 ||| NN
for  ||| S:8563 E:8575 ||| IN
100 ||| S:8575 E:8578 ||| CD
%  ||| S:8578 E:8580 ||| NN
sensitivity  ||| S:8580 E:8592 ||| NN
and  ||| S:8592 E:8596 ||| CC
specificity ||| S:8596 E:8607 ||| NN
.  ||| S:8607 E:8609 ||| .
Given  ||| S:8609 E:8615 ||| VBN
that  ||| S:8615 E:8620 ||| IN
the  ||| S:8620 E:8632 ||| DT
interpretation  ||| S:8632 E:8647 ||| NN
of  ||| S:8647 E:8650 ||| IN
low  ||| S:8650 E:8654 ||| JJ
M ||| S:8654 E:8655 ||| NNP
/ ||| S:8655 E:8656 ||| NNP
Z  ||| S:8656 E:8658 ||| NNP
values  ||| S:8658 E:8665 ||| VBZ
maybe  ||| S:8665 E:8671 ||| RB
problematic ||| S:8671 E:8682 ||| JJ
,  ||| S:8682 E:8684 ||| ,
we  ||| S:8684 E:8687 ||| PRP
next  ||| S:8687 E:8700 ||| RB
focused  ||| S:8700 E:8708 ||| VBN
attention  ||| S:8708 E:8718 ||| NN
on  ||| S:8718 E:8721 ||| IN
a  ||| S:8721 E:8723 ||| DT
set  ||| S:8723 E:8727 ||| NN
of  ||| S:8727 E:8730 ||| IN
rules  ||| S:8730 E:8736 ||| NNS
which  ||| S:8736 E:8742 ||| WDT
met  ||| S:8742 E:8746 ||| VBD
the  ||| S:8746 E:8750 ||| DT
following  ||| S:8750 E:8768 ||| JJ
requirements ||| S:8768 E:8780 ||| NNS
.  ||| S:8780 E:8782 ||| .
First ||| S:8782 E:8787 ||| NNP
,  ||| S:8787 E:8789 ||| ,
the  ||| S:8789 E:8793 ||| DT
M ||| S:8793 E:8794 ||| NNP
/ ||| S:8794 E:8795 ||| NNP
Z  ||| S:8795 E:8797 ||| NNP
value  ||| S:8797 E:8803 ||| NN
had  ||| S:8803 E:8807 ||| VBD
to  ||| S:8807 E:8810 ||| TO
exceed  ||| S:8810 E:8817 ||| VB
2000 ||| S:8817 E:8821 ||| CD
,  ||| S:8821 E:8823 ||| ,
and  ||| S:8823 E:8835 ||| CC
the  ||| S:8835 E:8839 ||| DT
Wilcoxon  ||| S:8839 E:8848 ||| JJ
test  ||| S:8848 E:8853 ||| NN
P-value  ||| S:8853 E:8861 ||| NN
had  ||| S:8861 E:8865 ||| VBD
to  ||| S:8865 E:8868 ||| TO
be  ||| S:8868 E:8871 ||| VB
less  ||| S:8871 E:8876 ||| JJR
than  ||| S:8876 E:8881 ||| IN
10  ||| S:8881 E:8884 ||| CD
-6 ||| S:8884 E:8886 ||| CD
.  ||| S:8886 E:8888 ||| .
A  ||| S:8888 E:8898 ||| DT
total  ||| S:8898 E:8904 ||| NN
of  ||| S:8904 E:8907 ||| IN
462  ||| S:8907 E:8911 ||| CD
M ||| S:8911 E:8912 ||| NNP
/ ||| S:8912 E:8913 ||| NNP
Z  ||| S:8913 E:8915 ||| NNP
values  ||| S:8915 E:8922 ||| NNS
from  ||| S:8922 E:8927 ||| IN
the  ||| S:8927 E:8931 ||| DT
training  ||| S:8931 E:8940 ||| NN
set  ||| S:8940 E:8944 ||| VBD
met  ||| S:8944 E:8948 ||| VBN
these  ||| S:8948 E:8962 ||| DT
criteria ||| S:8962 E:8970 ||| NNS
.  ||| S:8970 E:8972 ||| .
As  ||| S:8972 E:8975 ||| RB
shown  ||| S:8975 E:8981 ||| VBN
in  ||| S:8981 E:8984 ||| IN
Table  ||| S:8984 E:8990 ||| NNP
2 ||| S:8990 E:8991 ||| CD
,  ||| S:8991 E:8993 ||| ,
a  ||| S:8993 E:8995 ||| DT
total  ||| S:8995 E:9001 ||| NN
of  ||| S:9001 E:9004 ||| IN
30  ||| S:9004 E:9007 ||| CD
bins  ||| S:9007 E:9012 ||| NNS
were  ||| S:9012 E:9025 ||| VBD
detected  ||| S:9025 E:9034 ||| VBN
by  ||| S:9034 E:9037 ||| IN
sorting  ||| S:9037 E:9045 ||| VBG
on  ||| S:9045 E:9048 ||| IN
consecutive  ||| S:9048 E:9060 ||| JJ
M ||| S:9060 E:9061 ||| NNP
/ ||| S:9061 E:9062 ||| NNP
Z  ||| S:9062 E:9064 ||| NNP
values  ||| S:9064 E:9071 ||| VBZ
as  ||| S:9071 E:9074 ||| RB
above ||| S:9074 E:9079 ||| RB
,  ||| S:9079 E:9081 ||| ,
and  ||| S:9081 E:9093 ||| CC
the  ||| S:9093 E:9097 ||| DT
most  ||| S:9097 E:9102 ||| RBS
significant  ||| S:9102 E:9114 ||| JJ
p-value  ||| S:9114 E:9122 ||| NN
from  ||| S:9122 E:9127 ||| IN
each  ||| S:9127 E:9132 ||| DT
bin  ||| S:9132 E:9136 ||| NN
was  ||| S:9136 E:9140 ||| VBD
selected  ||| S:9140 E:9149 ||| VBN
for  ||| S:9149 E:9161 ||| IN
stepwise  ||| S:9161 E:9170 ||| JJ
discriminant  ||| S:9170 E:9183 ||| JJ
analysis ||| S:9183 E:9191 ||| NN
.  ||| S:9191 E:9193 ||| .
Thirteen  ||| S:9193 E:9202 ||| NNP
M ||| S:9202 E:9203 ||| NNP
/ ||| S:9203 E:9204 ||| NNP
Z  ||| S:9204 E:9206 ||| NNP
values  ||| S:9206 E:9213 ||| NNS
were  ||| S:9213 E:9226 ||| VBD
retained  ||| S:9226 E:9235 ||| VBN
in  ||| S:9235 E:9238 ||| IN
Rule  ||| S:9238 E:9243 ||| NNP
2 ||| S:9243 E:9244 ||| CD
.  ||| S:9244 E:9246 ||| .
In  ||| S:9246 E:9249 ||| IN
the  ||| S:9249 E:9253 ||| DT
training  ||| S:9253 E:9262 ||| NN
set ||| S:9262 E:9265 ||| NN
,  ||| S:9265 E:9267 ||| ,
one  ||| S:9267 E:9271 ||| CD
subject  ||| S:9271 E:9279 ||| NN
in  ||| S:9279 E:9282 ||| IN
the  ||| S:9282 E:9294 ||| DT
cancer  ||| S:9294 E:9301 ||| NN
group  ||| S:9301 E:9307 ||| NN
was  ||| S:9307 E:9311 ||| VBD
misclassified  ||| S:9311 E:9325 ||| VBN
as  ||| S:9325 E:9328 ||| IN
normal  ||| S:9328 E:9335 ||| JJ
and  ||| S:9335 E:9339 ||| CC
one  ||| S:9339 E:9343 ||| CD
in  ||| S:9343 E:9346 ||| IN
the  ||| S:9346 E:9358 ||| DT
control  ||| S:9358 E:9366 ||| NN
group  ||| S:9366 E:9372 ||| NN
was  ||| S:9372 E:9376 ||| VBD
misclassified  ||| S:9376 E:9390 ||| VBN
as  ||| S:9390 E:9393 ||| IN
cancer ||| S:9393 E:9399 ||| NN
.  ||| S:9399 E:9401 ||| .
In  ||| S:9401 E:9404 ||| IN
the  ||| S:9404 E:9408 ||| DT
test  ||| S:9408 E:9413 ||| NN
set ||| S:9413 E:9416 ||| NN
,  ||| S:9416 E:9426 ||| ,
two  ||| S:9426 E:9430 ||| CD
subjects  ||| S:9430 E:9439 ||| NNS
from  ||| S:9439 E:9444 ||| IN
the  ||| S:9444 E:9448 ||| DT
control  ||| S:9448 E:9456 ||| NN
group  ||| S:9456 E:9462 ||| NN
were  ||| S:9462 E:9467 ||| VBD
misclassified  ||| S:9467 E:9481 ||| VBN
as  ||| S:9481 E:9492 ||| IN
cancer ||| S:9492 E:9498 ||| NN
.  ||| S:9498 E:9500 ||| .
Therefore  ||| S:9500 E:9510 ||| RB
for  ||| S:9510 E:9514 ||| IN
the  ||| S:9514 E:9518 ||| DT
test  ||| S:9518 E:9523 ||| NN
set ||| S:9523 E:9526 ||| NN
,  ||| S:9526 E:9528 ||| ,
the  ||| S:9528 E:9532 ||| DT
sensitivity  ||| S:9532 E:9544 ||| NN
was  ||| S:9544 E:9556 ||| VBD
82 ||| S:9556 E:9558 ||| CD
/ ||| S:9558 E:9559 ||| CD
82  ||| S:9559 E:9562 ||| CD
or  ||| S:9562 E:9565 ||| CC
100 ||| S:9565 E:9568 ||| CD
%  ||| S:9568 E:9570 ||| NN
and  ||| S:9570 E:9574 ||| CC
the  ||| S:9574 E:9578 ||| DT
specificity  ||| S:9578 E:9590 ||| NN
was  ||| S:9590 E:9594 ||| VBD
43 ||| S:9594 E:9596 ||| CD
/ ||| S:9596 E:9597 ||| CD
45  ||| S:9597 E:9600 ||| CD
or  ||| S:9600 E:9603 ||| CC
95.7 ||| S:9603 E:9607 ||| CD
% ||| S:9607 E:9608 ||| NN
.  ||| S:9608 E:9610 ||| .
For  ||| S:9610 E:9622 ||| IN
the  ||| S:9622 E:9626 ||| DT
test  ||| S:9626 E:9631 ||| NN
and  ||| S:9631 E:9635 ||| CC
training  ||| S:9635 E:9644 ||| NN
set  ||| S:9644 E:9648 ||| VBD
combined ||| S:9648 E:9656 ||| VBN
,  ||| S:9656 E:9658 ||| ,
one  ||| S:9658 E:9662 ||| CD
subject  ||| S:9662 E:9670 ||| NN
was  ||| S:9670 E:9682 ||| VBD
misclassified  ||| S:9682 E:9696 ||| VBN
in  ||| S:9696 E:9699 ||| IN
the  ||| S:9699 E:9703 ||| DT
cancer  ||| S:9703 E:9710 ||| NN
group  ||| S:9710 E:9716 ||| NN
as  ||| S:9716 E:9719 ||| IN
normal  ||| S:9719 E:9726 ||| JJ
and  ||| S:9726 E:9730 ||| CC
three  ||| S:9730 E:9744 ||| CD
subjects  ||| S:9744 E:9753 ||| NNS
were  ||| S:9753 E:9758 ||| VBD
misclassified  ||| S:9758 E:9772 ||| VBN
in  ||| S:9772 E:9775 ||| IN
the  ||| S:9775 E:9779 ||| DT
control  ||| S:9779 E:9787 ||| NN
group  ||| S:9787 E:9793 ||| NN
as  ||| S:9793 E:9796 ||| IN
cancer ||| S:9796 E:9802 ||| NN
.  ||| S:9802 E:9812 ||| .
Thus  ||| S:9812 E:9817 ||| RB
for  ||| S:9817 E:9821 ||| IN
this  ||| S:9821 E:9826 ||| DT
rule  ||| S:9826 E:9831 ||| NN
the  ||| S:9831 E:9835 ||| DT
overall  ||| S:9835 E:9843 ||| JJ
sensitivity  ||| S:9843 E:9855 ||| NN
was  ||| S:9855 E:9859 ||| VBD
161 ||| S:9859 E:9862 ||| CD
/ ||| S:9862 E:9863 ||| CD
162  ||| S:9863 E:9867 ||| CD
or  ||| S:9867 E:9878 ||| CC
99.4  ||| S:9878 E:9883 ||| CD
%  ||| S:9883 E:9885 ||| NN
and  ||| S:9885 E:9889 ||| CC
its  ||| S:9889 E:9893 ||| PRP$
overall  ||| S:9893 E:9901 ||| JJ
specificity  ||| S:9901 E:9913 ||| NN
was  ||| S:9913 E:9917 ||| VBD
88 ||| S:9917 E:9919 ||| CD
/ ||| S:9919 E:9920 ||| CD
91  ||| S:9920 E:9923 ||| CD
or  ||| S:9923 E:9926 ||| CC
96.7  ||| S:9926 E:9931 ||| CD
% ||| S:9931 E:9932 ||| NN
.  ||| S:9932 E:9942 ||| .
Finally ||| S:9942 E:9949 ||| RB
,  ||| S:9949 E:9951 ||| ,
Rule  ||| S:9951 E:9956 ||| NNP
3  ||| S:9956 E:9958 ||| CD
was  ||| S:9958 E:9962 ||| VBD
constructed  ||| S:9962 E:9974 ||| VBN
using  ||| S:9974 E:9980 ||| VBG
the  ||| S:9980 E:9984 ||| DT
30  ||| S:9984 E:9987 ||| CD
M ||| S:9987 E:9988 ||| NNP
/ ||| S:9988 E:9989 ||| NNP
Z  ||| S:9989 E:9991 ||| NNP
values  ||| S:9991 E:9998 ||| NNS
in  ||| S:9998 E:10009 ||| IN
Rule  ||| S:10009 E:10014 ||| NNP
2  ||| S:10014 E:10016 ||| CD
combined  ||| S:10016 E:10025 ||| VBN
with  ||| S:10025 E:10030 ||| IN
four  ||| S:10030 E:10035 ||| CD
M ||| S:10035 E:10036 ||| NNP
/ ||| S:10036 E:10037 ||| NNP
Z  ||| S:10037 E:10039 ||| NNP
values  ||| S:10039 E:10046 ||| VBZ
409.75936 ||| S:10046 E:10055 ||| NNP
,  ||| S:10055 E:10057 ||| ,
418.11364 ||| S:10057 E:10066 ||| NNP
,  ||| S:10066 E:10076 ||| ,
435.0751 ||| S:10076 E:10084 ||| NNP
,  ||| S:10084 E:10086 ||| ,
and  ||| S:10086 E:10090 ||| CC
464.3617  ||| S:10090 E:10099 ||| NNP
( ||| S:10099 E:10100 ||| -LRB-
all  ||| S:10100 E:10104 ||| DT
also  ||| S:10104 E:10109 ||| RB
used  ||| S:10109 E:10114 ||| VBN
in  ||| S:10114 E:10117 ||| IN
Rule  ||| S:10117 E:10122 ||| NNP
1 ||| S:10122 E:10123 ||| CD
) ||| S:10123 E:10124 ||| -RRB-
.  ||| S:10124 E:10126 ||| .
This  ||| S:10126 E:10131 ||| DT
was  ||| S:10131 E:10143 ||| VBD
done  ||| S:10143 E:10148 ||| VBN
because  ||| S:10148 E:10156 ||| IN
prior  ||| S:10156 E:10162 ||| JJ
studies  ||| S:10162 E:10170 ||| NNS
have  ||| S:10170 E:10175 ||| VBP
indicated  ||| S:10175 E:10185 ||| VBN
the  ||| S:10185 E:10189 ||| DT
possible  ||| S:10189 E:10206 ||| JJ
presence  ||| S:10206 E:10215 ||| NN
of  ||| S:10215 E:10218 ||| IN
low  ||| S:10218 E:10222 ||| JJ
molecular  ||| S:10222 E:10232 ||| JJ
weight  ||| S:10232 E:10239 ||| NN
biomarkers  ||| S:10239 E:10250 ||| NN
in  ||| S:10250 E:10253 ||| IN
ovarian  ||| S:10253 E:10269 ||| JJ
cancer  ||| S:10269 E:10276 ||| NN
( ||| S:10276 E:10277 ||| -LRB-
see  ||| S:10277 E:10281 ||| VB
below ||| S:10281 E:10286 ||| IN
) ||| S:10286 E:10287 ||| -RRB-
.  ||| S:10287 E:10289 ||| .
When  ||| S:10289 E:10294 ||| WRB
this  ||| S:10294 E:10299 ||| DT
set  ||| S:10299 E:10303 ||| NN
of  ||| S:10303 E:10306 ||| IN
M ||| S:10306 E:10307 ||| NNP
/ ||| S:10307 E:10308 ||| NNP
Z  ||| S:10308 E:10310 ||| NNP
values  ||| S:10310 E:10317 ||| NNS
was  ||| S:10317 E:10329 ||| VBD
subjected  ||| S:10329 E:10339 ||| VBN
to  ||| S:10339 E:10342 ||| TO
stepwise  ||| S:10342 E:10351 ||| VB
discriminant  ||| S:10351 E:10364 ||| JJ
analysis ||| S:10364 E:10372 ||| NN
,  ||| S:10372 E:10374 ||| ,
seven  ||| S:10374 E:10388 ||| CD
variables  ||| S:10388 E:10398 ||| NNS
at  ||| S:10398 E:10401 ||| IN
M ||| S:10401 E:10402 ||| NNP
/ ||| S:10402 E:10403 ||| NNP
Z  ||| S:10403 E:10405 ||| NNP
values  ||| S:10405 E:10412 ||| NNS
of  ||| S:10412 E:10415 ||| IN
418.1136 ||| S:10415 E:10423 ||| NNP
,  ||| S:10423 E:10425 ||| ,
435.0751 ||| S:10425 E:10433 ||| NNP
,  ||| S:10433 E:10435 ||| ,
464.3617 ||| S:10435 E:10443 ||| NNP
,  ||| S:10443 E:10453 ||| ,
4003.645 ||| S:10453 E:10461 ||| NNP
,  ||| S:10461 E:10463 ||| ,
4906.962 ||| S:10463 E:10471 ||| NNP
,  ||| S:10471 E:10473 ||| ,
6599.8232 ||| S:10473 E:10482 ||| NNP
,  ||| S:10482 E:10484 ||| ,
and  ||| S:10484 E:10488 ||| CC
6801.495  ||| S:10488 E:10497 ||| NNP
were  ||| S:10497 E:10502 ||| VBD
retained ||| S:10502 E:10510 ||| VBN
.  ||| S:10510 E:10520 ||| .
When  ||| S:10520 E:10525 ||| WRB
Rule  ||| S:10525 E:10530 ||| NNP
3  ||| S:10530 E:10532 ||| CD
was  ||| S:10532 E:10536 ||| VBD
applied  ||| S:10536 E:10544 ||| VBN
to  ||| S:10544 E:10547 ||| TO
the  ||| S:10547 E:10551 ||| DT
entire  ||| S:10551 E:10558 ||| JJ
data  ||| S:10558 E:10563 ||| NNS
set ||| S:10563 E:10566 ||| VBN
,  ||| S:10566 E:10568 ||| ,
test  ||| S:10568 E:10573 ||| NN
and  ||| S:10573 E:10585 ||| CC
training  ||| S:10585 E:10594 ||| NN
inclusive ||| S:10594 E:10603 ||| NN
,  ||| S:10603 E:10605 ||| ,
all  ||| S:10605 E:10609 ||| DT
162  ||| S:10609 E:10613 ||| CD
cancer  ||| S:10613 E:10620 ||| NN
and  ||| S:10620 E:10624 ||| CC
91  ||| S:10624 E:10627 ||| CD
controls  ||| S:10627 E:10636 ||| NNS
were  ||| S:10636 E:10649 ||| VBD
appropriately  ||| S:10649 E:10663 ||| RB
categorized  ||| S:10663 E:10675 ||| VBN
without  ||| S:10675 E:10683 ||| IN
error  ||| S:10683 E:10689 ||| NN
for  ||| S:10689 E:10693 ||| IN
100 ||| S:10693 E:10696 ||| CD
%  ||| S:10696 E:10706 ||| NN
sensitivity  ||| S:10706 E:10718 ||| NN
and  ||| S:10718 E:10722 ||| CC
specificity ||| S:10722 E:10733 ||| NN
.  ||| S:10733 E:10735 ||| .
The  ||| S:10735 E:10739 ||| DT
actual  ||| S:10739 E:10746 ||| JJ
classification  ||| S:10746 E:10769 ||| JJ
schema  ||| S:10769 E:10776 ||| NN
for  ||| S:10776 E:10780 ||| IN
all  ||| S:10780 E:10784 ||| DT
three  ||| S:10784 E:10790 ||| CD
rules  ||| S:10790 E:10796 ||| NNS
is  ||| S:10796 E:10799 ||| VBZ
shown  ||| S:10799 E:10805 ||| VBN
in  ||| S:10805 E:10808 ||| IN
Table  ||| S:10808 E:10814 ||| NNP
3 ||| S:10814 E:10815 ||| CD
.  ||| S:10815 E:10817 ||| .
The  ||| S:10817 E:10821 ||| DT
results  ||| S:10821 E:10837 ||| NNS
presented  ||| S:10837 E:10847 ||| VBN
with  ||| S:10847 E:10852 ||| IN
these  ||| S:10852 E:10858 ||| DT
three  ||| S:10858 E:10864 ||| CD
rules  ||| S:10864 E:10870 ||| NNS
were  ||| S:10870 E:10875 ||| VBD
all  ||| S:10875 E:10879 ||| DT
achieved  ||| S:10879 E:10888 ||| VBN
in  ||| S:10888 E:10891 ||| IN
the  ||| S:10891 E:10903 ||| DT
first  ||| S:10903 E:10909 ||| JJ
attempt ||| S:10909 E:10916 ||| NN
.  ||| S:10916 E:10918 ||| .
No  ||| S:10918 E:10921 ||| DT
effort  ||| S:10921 E:10928 ||| NN
was  ||| S:10928 E:10932 ||| VBD
made  ||| S:10932 E:10937 ||| VBN
to  ||| S:10937 E:10940 ||| TO
further  ||| S:10940 E:10948 ||| VB
optimize  ||| S:10948 E:10957 ||| VBN
these  ||| S:10957 E:10971 ||| DT
rules ||| S:10971 E:10976 ||| NNS
.  ||| S:10976 E:10978 ||| .
We  ||| S:10978 E:10981 ||| PRP
next  ||| S:10981 E:10986 ||| IN
interchanged  ||| S:10986 E:10999 ||| VBG
the  ||| S:10999 E:11003 ||| DT
test  ||| S:11003 E:11008 ||| NN
and  ||| S:11008 E:11012 ||| CC
training  ||| S:11012 E:11021 ||| NN
sets  ||| S:11021 E:11026 ||| NNS
and  ||| S:11026 E:11038 ||| CC
used  ||| S:11038 E:11043 ||| VBD
the  ||| S:11043 E:11047 ||| DT
same  ||| S:11047 E:11052 ||| JJ
three  ||| S:11052 E:11058 ||| CD
rule  ||| S:11058 E:11063 ||| NN
development  ||| S:11063 E:11075 ||| NN
strategies ||| S:11075 E:11085 ||| NNS
.  ||| S:11085 E:11087 ||| .
This  ||| S:11087 E:11100 ||| DT
resulted  ||| S:11100 E:11109 ||| VBN
in ||| S:11109 E:11111 ||| IN
:  ||| S:11111 E:11121 ||| :
1 ||| S:11121 E:11122 ||| LS
)  ||| S:11122 E:11124 ||| -RRB-
Rule  ||| S:11124 E:11129 ||| NNP
1  ||| S:11129 E:11131 ||| CD
with  ||| S:11131 E:11136 ||| IN
M ||| S:11136 E:11137 ||| NNP
/ ||| S:11137 E:11138 ||| NNP
Z  ||| S:11138 E:11140 ||| NNP
values  ||| S:11140 E:11147 ||| NNS
of  ||| S:11147 E:11150 ||| IN
2.8234234 ||| S:11150 E:11159 ||| NNP
,  ||| S:11159 E:11161 ||| ,
222.41828 ||| S:11161 E:11170 ||| NNP
,  ||| S:11170 E:11180 ||| ,
410.13727 ||| S:11180 E:11189 ||| NNP
,  ||| S:11189 E:11191 ||| ,
417.73207 ||| S:11191 E:11200 ||| NNP
,  ||| S:11200 E:11202 ||| ,
435.07512 ||| S:11202 E:11211 ||| NNP
,  ||| S:11211 E:11213 ||| ,
4027.2999 ||| S:11213 E:11222 ||| NNP
,  ||| S:11222 E:11224 ||| ,
and  ||| S:11224 E:11228 ||| CC
8035.0581 ||| S:11228 E:11237 ||| NNP
,  ||| S:11237 E:11247 ||| ,
achieved  ||| S:11247 E:11256 ||| VBD
100 ||| S:11256 E:11259 ||| CD
%  ||| S:11259 E:11261 ||| NN
sensitivity  ||| S:11261 E:11273 ||| NN
and  ||| S:11273 E:11277 ||| CC
specificity  ||| S:11277 E:11289 ||| NN
on  ||| S:11289 E:11292 ||| IN
both  ||| S:11292 E:11297 ||| PDT
the  ||| S:11297 E:11301 ||| DT
test  ||| S:11301 E:11314 ||| NN
and  ||| S:11314 E:11318 ||| CC
training  ||| S:11318 E:11327 ||| NN
sets.  ||| S:11327 E:11341 ||| CD
2 ||| S:11341 E:11342 ||| CD
)  ||| S:11342 E:11344 ||| -RRB-
Rule  ||| S:11344 E:11349 ||| NNP
2  ||| S:11349 E:11351 ||| CD
with  ||| S:11351 E:11356 ||| IN
M ||| S:11356 E:11357 ||| NNP
/ ||| S:11357 E:11358 ||| NNP
Z  ||| S:11358 E:11360 ||| NNP
values  ||| S:11360 E:11367 ||| NNS
of  ||| S:11367 E:11370 ||| IN
3676.3951 ||| S:11370 E:11379 ||| NNP
,  ||| S:11379 E:11381 ||| ,
3937.7816 ||| S:11381 E:11390 ||| NNP
,  ||| S:11390 E:11400 ||| ,
4003.6449 ||| S:11400 E:11409 ||| NNP
,  ||| S:11409 E:11411 ||| ,
4440.095 ||| S:11411 E:11419 ||| NNP
,  ||| S:11419 E:11421 ||| ,
5269.0367 ||| S:11421 E:11430 ||| NNP
,  ||| S:11430 E:11432 ||| ,
10511.699 ||| S:11432 E:11441 ||| NNP
,  ||| S:11441 E:11443 ||| ,
14182.82 ||| S:11443 E:11451 ||| NNP
,  ||| S:11451 E:11453 ||| ,
and  ||| S:11453 E:11465 ||| CC
17019.433 ||| S:11465 E:11474 ||| NNP
.  ||| S:11474 E:11476 ||| .
This  ||| S:11476 E:11481 ||| DT
rule  ||| S:11481 E:11486 ||| NN
achieved  ||| S:11486 E:11495 ||| VBD
100 ||| S:11495 E:11498 ||| CD
%  ||| S:11498 E:11500 ||| NN
sensitivity  ||| S:11500 E:11512 ||| NN
and  ||| S:11512 E:11524 ||| CC
specificity  ||| S:11524 E:11536 ||| NN
on  ||| S:11536 E:11539 ||| IN
the  ||| S:11539 E:11543 ||| DT
training  ||| S:11543 E:11552 ||| NN
set ||| S:11552 E:11555 ||| NN
.  ||| S:11555 E:11557 ||| .
However  ||| S:11557 E:11565 ||| RB
sensitivity  ||| S:11565 E:11577 ||| JJ
and  ||| S:11577 E:11589 ||| CC
specificity  ||| S:11589 E:11601 ||| NN
fell  ||| S:11601 E:11606 ||| VBD
on  ||| S:11606 E:11609 ||| IN
the  ||| S:11609 E:11613 ||| DT
test  ||| S:11613 E:11618 ||| NN
set  ||| S:11618 E:11622 ||| VBN
to  ||| S:11622 E:11625 ||| TO
96.25 ||| S:11625 E:11630 ||| CD
%  ||| S:11630 E:11632 ||| NN
and  ||| S:11632 E:11636 ||| CC
91.11 ||| S:11636 E:11641 ||| CD
%  ||| S:11641 E:11651 ||| NN
respectively.  ||| S:11651 E:11673 ||| CD
3 ||| S:11673 E:11674 ||| CD
)  ||| S:11674 E:11676 ||| -RRB-
Rule  ||| S:11676 E:11681 ||| NNP
3  ||| S:11681 E:11683 ||| CD
with  ||| S:11683 E:11688 ||| IN
M ||| S:11688 E:11689 ||| NNP
/ ||| S:11689 E:11690 ||| NNP
Z  ||| S:11690 E:11692 ||| NNP
values  ||| S:11692 E:11699 ||| NNS
of  ||| S:11699 E:11702 ||| IN
417.73207 ||| S:11702 E:11711 ||| NNP
,  ||| S:11711 E:11713 ||| ,
435.07512 ||| S:11713 E:11722 ||| NNP
,  ||| S:11722 E:11732 ||| ,
2666.361 ||| S:11732 E:11740 ||| NNP
,  ||| S:11740 E:11742 ||| ,
2674.0769 ||| S:11742 E:11751 ||| NNP
,  ||| S:11751 E:11753 ||| ,
3937.7816 ||| S:11753 E:11762 ||| NNP
,  ||| S:11762 E:11764 ||| ,
3991.8435 ||| S:11764 E:11773 ||| NNP
,  ||| S:11773 E:11775 ||| ,
4821.0481 ||| S:11775 E:11784 ||| NNP
,  ||| S:11784 E:11794 ||| ,
4839.2088 ||| S:11794 E:11803 ||| NNP
,  ||| S:11803 E:11805 ||| ,
5269.0367 ||| S:11805 E:11814 ||| NNP
,  ||| S:11814 E:11816 ||| ,
7627.1183 ||| S:11816 E:11825 ||| NNP
,  ||| S:11825 E:11827 ||| ,
14182.82 ||| S:11827 E:11835 ||| NNP
,  ||| S:11835 E:11837 ||| ,
and  ||| S:11837 E:11841 ||| CC
17019.433 ||| S:11841 E:11850 ||| NNP
.  ||| S:11850 E:11860 ||| .
This  ||| S:11860 E:11865 ||| DT
rule  ||| S:11865 E:11870 ||| NN
achieved  ||| S:11870 E:11879 ||| VBD
100 ||| S:11879 E:11882 ||| CD
%  ||| S:11882 E:11884 ||| NN
sensitivity  ||| S:11884 E:11896 ||| NN
and  ||| S:11896 E:11900 ||| CC
specificity  ||| S:11900 E:11912 ||| NN
on  ||| S:11912 E:11915 ||| IN
the  ||| S:11915 E:11927 ||| DT
training  ||| S:11927 E:11936 ||| NN
set ||| S:11936 E:11939 ||| NN
.  ||| S:11939 E:11941 ||| .
On  ||| S:11941 E:11944 ||| IN
the  ||| S:11944 E:11948 ||| DT
test  ||| S:11948 E:11953 ||| NN
set  ||| S:11953 E:11957 ||| VBD
it  ||| S:11957 E:11960 ||| PRP
achieved  ||| S:11960 E:11969 ||| VBD
a  ||| S:11969 E:11971 ||| DT
sensitivity  ||| S:11971 E:11983 ||| NN
of  ||| S:11983 E:11994 ||| IN
100 ||| S:11994 E:11997 ||| CD
%  ||| S:11997 E:11999 ||| NN
and  ||| S:11999 E:12003 ||| CC
a  ||| S:12003 E:12005 ||| DT
specificity  ||| S:12005 E:12017 ||| NN
of  ||| S:12017 E:12020 ||| IN
97.8 ||| S:12020 E:12024 ||| CD
% ||| S:12024 E:12025 ||| NN
.  ||| S:12025 E:12027 ||| .
We  ||| S:12027 E:12030 ||| PRP
have  ||| S:12030 E:12035 ||| VBP
used  ||| S:12035 E:12040 ||| VBN
a  ||| S:12040 E:12042 ||| DT
strategy  ||| S:12042 E:12059 ||| NN
identical  ||| S:12059 E:12069 ||| NN
to  ||| S:12069 E:12072 ||| TO
that  ||| S:12072 E:12077 ||| DT
used  ||| S:12077 E:12082 ||| VBN
in  ||| S:12082 E:12085 ||| IN
Rule  ||| S:12085 E:12090 ||| NNP
1  ||| S:12090 E:12092 ||| CD
to  ||| S:12092 E:12095 ||| TO
further  ||| S:12095 E:12103 ||| RB
analyze  ||| S:12103 E:12111 ||| VB
this  ||| S:12111 E:12124 ||| DT
data ||| S:12124 E:12128 ||| NNS
.  ||| S:12128 E:12130 ||| .
First ||| S:12130 E:12135 ||| NNP
,  ||| S:12135 E:12137 ||| ,
a  ||| S:12137 E:12139 ||| DT
randomly  ||| S:12139 E:12148 ||| RB
ordered  ||| S:12148 E:12156 ||| VBN
list  ||| S:12156 E:12161 ||| NN
of  ||| S:12161 E:12164 ||| IN
cancer  ||| S:12164 E:12171 ||| NN
spectra  ||| S:12171 E:12179 ||| NNS
and  ||| S:12179 E:12191 ||| CC
a  ||| S:12191 E:12193 ||| DT
randomly  ||| S:12193 E:12202 ||| RB
ordered  ||| S:12202 E:12210 ||| VBN
list  ||| S:12210 E:12215 ||| NN
of  ||| S:12215 E:12218 ||| IN
control  ||| S:12218 E:12226 ||| NN
spectra  ||| S:12226 E:12234 ||| NNS
were  ||| S:12234 E:12239 ||| VBD
prepared ||| S:12239 E:12247 ||| VBN
.  ||| S:12247 E:12257 ||| .
Next ||| S:12257 E:12261 ||| JJ
,  ||| S:12261 E:12263 ||| ,
we  ||| S:12263 E:12266 ||| PRP
assigned  ||| S:12266 E:12275 ||| VBD
the  ||| S:12275 E:12279 ||| DT
first  ||| S:12279 E:12285 ||| JJ
20 ||| S:12285 E:12287 ||| CD
%  ||| S:12287 E:12289 ||| NN
of  ||| S:12289 E:12292 ||| IN
each  ||| S:12292 E:12297 ||| DT
list  ||| S:12297 E:12302 ||| NN
to  ||| S:12302 E:12305 ||| TO
a  ||| S:12305 E:12307 ||| DT
test  ||| S:12307 E:12312 ||| NN
set  ||| S:12312 E:12324 ||| NN
and  ||| S:12324 E:12328 ||| CC
the  ||| S:12328 E:12332 ||| DT
remaining  ||| S:12332 E:12342 ||| JJ
80 ||| S:12342 E:12344 ||| CD
%  ||| S:12344 E:12346 ||| NN
to  ||| S:12346 E:12349 ||| TO
a  ||| S:12349 E:12351 ||| DT
training  ||| S:12351 E:12360 ||| NN
set ||| S:12360 E:12363 ||| NN
.  ||| S:12363 E:12365 ||| .
The  ||| S:12365 E:12369 ||| DT
process  ||| S:12369 E:12377 ||| NN
was  ||| S:12377 E:12389 ||| VBD
repeated  ||| S:12389 E:12398 ||| VBN
five  ||| S:12398 E:12403 ||| CD
times  ||| S:12403 E:12409 ||| NNS
assigning  ||| S:12409 E:12419 ||| VBP
the  ||| S:12419 E:12423 ||| DT
next  ||| S:12423 E:12428 ||| JJ
consecutive  ||| S:12428 E:12440 ||| JJ
20 ||| S:12440 E:12442 ||| CD
%  ||| S:12442 E:12444 ||| NN
of  ||| S:12444 E:12455 ||| IN
each  ||| S:12455 E:12460 ||| DT
list  ||| S:12460 E:12465 ||| NN
for  ||| S:12465 E:12469 ||| IN
the  ||| S:12469 E:12473 ||| DT
test  ||| S:12473 E:12478 ||| NN
set  ||| S:12478 E:12482 ||| VBN
on  ||| S:12482 E:12485 ||| IN
each  ||| S:12485 E:12490 ||| DT
occasion ||| S:12490 E:12498 ||| NN
.  ||| S:12498 E:12500 ||| .
The  ||| S:12500 E:12504 ||| DT
results  ||| S:12504 E:12520 ||| NNS
were  ||| S:12520 E:12525 ||| VBD
very  ||| S:12525 E:12530 ||| RB
similar  ||| S:12530 E:12538 ||| JJ
to  ||| S:12538 E:12541 ||| TO
those  ||| S:12541 E:12547 ||| DT
above  ||| S:12547 E:12553 ||| JJ
with  ||| S:12553 E:12558 ||| IN
all  ||| S:12558 E:12562 ||| DT
five  ||| S:12562 E:12567 ||| CD
rules  ||| S:12567 E:12581 ||| NNS
achieving  ||| S:12581 E:12591 ||| VBG
100 ||| S:12591 E:12594 ||| CD
%  ||| S:12594 E:12596 ||| NN
sensitivity  ||| S:12596 E:12608 ||| NN
and  ||| S:12608 E:12612 ||| CC
specificity ||| S:12612 E:12623 ||| NN
.  ||| S:12623 E:12625 ||| .
This  ||| S:12625 E:12630 ||| DT
data  ||| S:12630 E:12635 ||| NN
is  ||| S:12635 E:12646 ||| VBZ
posted  ||| S:12646 E:12653 ||| VBN
as  ||| S:12653 E:12656 ||| IN
additional  ||| S:12656 E:12667 ||| JJ
data  ||| S:12667 E:12672 ||| NNS
file  ||| S:12672 E:12677 ||| VBP
Supplement1.xls ||| S:12677 E:12692 ||| CD
.  ||| S:12692 E:12702 ||| .
Additional  ||| S:12702 E:12713 ||| JJ
File  ||| S:12713 E:12718 ||| NNP
1  ||| S:12718 E:12728 ||| CD
This  ||| S:12728 E:12733 ||| DT
Excel  ||| S:12733 E:12739 ||| NNP
file  ||| S:12739 E:12744 ||| NN
contains  ||| S:12744 E:12753 ||| VBZ
5  ||| S:12753 E:12755 ||| CD
work  ||| S:12755 E:12760 ||| NN
sheets ||| S:12760 E:12766 ||| NNS
.  ||| S:12766 E:12768 ||| .
Each  ||| S:12768 E:12773 ||| DT
sheet  ||| S:12773 E:12787 ||| NN
contains  ||| S:12787 E:12796 ||| VBZ
the  ||| S:12796 E:12800 ||| DT
most  ||| S:12800 E:12805 ||| RBS
significant  ||| S:12805 E:12817 ||| JJ
100  ||| S:12817 E:12821 ||| CD
MZ  ||| S:12821 E:12824 ||| NN
values  ||| S:12824 E:12831 ||| NNS
from  ||| S:12831 E:12836 ||| IN
a  ||| S:12836 E:12838 ||| DT
training  ||| S:12838 E:12855 ||| NN
set  ||| S:12855 E:12859 ||| VBD
consisting  ||| S:12859 E:12870 ||| VBG
of  ||| S:12870 E:12873 ||| IN
a  ||| S:12873 E:12875 ||| DT
different  ||| S:12875 E:12885 ||| JJ
80 ||| S:12885 E:12887 ||| CD
%  ||| S:12887 E:12889 ||| NN
subset  ||| S:12889 E:12896 ||| NN
of  ||| S:12896 E:12899 ||| IN
the  ||| S:12899 E:12903 ||| DT
data ||| S:12903 E:12907 ||| NNS
.  ||| S:12907 E:12909 ||| .
The  ||| S:12909 E:12921 ||| DT
MZ  ||| S:12921 E:12924 ||| NNP
values  ||| S:12924 E:12931 ||| NNS
have  ||| S:12931 E:12936 ||| VBP
been  ||| S:12936 E:12941 ||| VBN
sorted  ||| S:12941 E:12948 ||| VBN
into  ||| S:12948 E:12953 ||| IN
bins  ||| S:12953 E:12958 ||| NN
and  ||| S:12958 E:12962 ||| CC
the  ||| S:12962 E:12966 ||| DT
most  ||| S:12966 E:12979 ||| RBS
significant  ||| S:12979 E:12991 ||| JJ
MZ  ||| S:12991 E:12994 ||| NNP
value  ||| S:12994 E:13000 ||| NN
from  ||| S:13000 E:13005 ||| IN
each  ||| S:13005 E:13010 ||| DT
bin  ||| S:13010 E:13014 ||| NN
( ||| S:13014 E:13015 ||| -LRB-
marked  ||| S:13015 E:13022 ||| VBN
with  ||| S:13022 E:13027 ||| IN
a  ||| S:13027 E:13029 ||| DT
"I ||| S:13029 E:13031 ||| NN
"  ||| S:13031 E:13033 ||| ''
in  ||| S:13033 E:13044 ||| IN
column  ||| S:13044 E:13051 ||| NN
E ||| S:13051 E:13052 ||| NN
)  ||| S:13052 E:13054 ||| -RRB-
was  ||| S:13054 E:13058 ||| VBD
used  ||| S:13058 E:13063 ||| VBN
in  ||| S:13063 E:13066 ||| IN
stepwise  ||| S:13066 E:13075 ||| JJ
dicriminant  ||| S:13075 E:13087 ||| JJ
analysis ||| S:13087 E:13095 ||| NN
.  ||| S:13095 E:13097 ||| .
MZ  ||| S:13097 E:13108 ||| NNP
values  ||| S:13108 E:13115 ||| VBZ
retained  ||| S:13115 E:13124 ||| VBN
in  ||| S:13124 E:13127 ||| IN
the  ||| S:13127 E:13131 ||| DT
final  ||| S:13131 E:13137 ||| JJ
rule  ||| S:13137 E:13142 ||| NN
are  ||| S:13142 E:13146 ||| VBP
indicated  ||| S:13146 E:13156 ||| VBN
with  ||| S:13156 E:13161 ||| IN
an  ||| S:13161 E:13164 ||| DT
"s ||| S:13164 E:13166 ||| NN
"  ||| S:13166 E:13176 ||| ''
in  ||| S:13176 E:13179 ||| IN
column  ||| S:13179 E:13186 ||| NN
F.  ||| S:13186 E:13197 ||| NNP
Click  ||| S:13197 E:13203 ||| NNP
here  ||| S:13203 E:13208 ||| RB
for  ||| S:13208 E:13212 ||| IN
file  ||| S:13212 E:13225 ||| VB
The  ||| S:13225 E:13229 ||| DT
presence  ||| S:13229 E:13238 ||| NN
of  ||| S:13238 E:13241 ||| IN
statistically  ||| S:13241 E:13255 ||| JJ
significant  ||| S:13255 E:13267 ||| JJ
signals  ||| S:13267 E:13275 ||| NNS
at  ||| S:13275 E:13278 ||| IN
M ||| S:13278 E:13279 ||| NNP
/ ||| S:13279 E:13280 ||| NNP
Z  ||| S:13280 E:13290 ||| NNP
values  ||| S:13290 E:13297 ||| VBZ
less  ||| S:13297 E:13302 ||| JJR
than  ||| S:13302 E:13307 ||| IN
500  ||| S:13307 E:13311 ||| CD
was  ||| S:13311 E:13315 ||| VBD
unexpected  ||| S:13315 E:13326 ||| JJ
as  ||| S:13326 E:13329 ||| IN
some  ||| S:13329 E:13334 ||| DT
investigators ||| S:13334 E:13347 ||| NNS
,  ||| S:13347 E:13357 ||| ,
in  ||| S:13357 E:13360 ||| IN
their  ||| S:13360 E:13366 ||| PRP$
systems ||| S:13366 E:13373 ||| NNS
,  ||| S:13373 E:13375 ||| ,
conservatively  ||| S:13375 E:13390 ||| RB
disregard  ||| S:13390 E:13400 ||| JJ
data  ||| S:13400 E:13405 ||| NNS
beneath  ||| S:13405 E:13413 ||| IN
M ||| S:13413 E:13414 ||| NNP
/ ||| S:13414 E:13415 ||| NNP
Z  ||| S:13415 E:13425 ||| NNP
values  ||| S:13425 E:13432 ||| NNS
of  ||| S:13432 E:13435 ||| IN
2000  ||| S:13435 E:13440 ||| CD
as  ||| S:13440 E:13443 ||| IN
possible  ||| S:13443 E:13452 ||| JJ
noise  ||| S:13452 E:13458 ||| NN
[  ||| S:13458 E:13460 ||| -LRB-
12  ||| S:13460 E:13463 ||| CD
]  ||| S:13463 E:13465 ||| -RRB-
.  ||| S:13465 E:13467 ||| .
To  ||| S:13467 E:13470 ||| TO
further  ||| S:13470 E:13486 ||| RB
investigate  ||| S:13486 E:13498 ||| VB
this ||| S:13498 E:13502 ||| DT
,  ||| S:13502 E:13504 ||| ,
we  ||| S:13504 E:13507 ||| PRP
first  ||| S:13507 E:13513 ||| RB
repeated  ||| S:13513 E:13522 ||| VBN
the  ||| S:13522 E:13526 ||| DT
calculation  ||| S:13526 E:13538 ||| NN
of  ||| S:13538 E:13549 ||| IN
2-sided  ||| S:13549 E:13557 ||| NNP
Wilcoxon  ||| S:13557 E:13566 ||| NNP
test  ||| S:13566 E:13571 ||| NN
p-values  ||| S:13571 E:13580 ||| NN
at  ||| S:13580 E:13583 ||| IN
each  ||| S:13583 E:13588 ||| DT
of  ||| S:13588 E:13591 ||| IN
the  ||| S:13591 E:13595 ||| DT
15,154  ||| S:13595 E:13602 ||| NNP
M ||| S:13602 E:13603 ||| NNP
/ ||| S:13603 E:13604 ||| NNP
Z  ||| S:13604 E:13614 ||| NNP
values  ||| S:13614 E:13621 ||| VBZ
using  ||| S:13621 E:13627 ||| VBG
the  ||| S:13627 E:13631 ||| DT
entire  ||| S:13631 E:13638 ||| JJ
data  ||| S:13638 E:13643 ||| NNS
set  ||| S:13643 E:13647 ||| VBN
( ||| S:13647 E:13648 ||| -LRB-
see  ||| S:13648 E:13652 ||| VB
Figure  ||| S:13652 E:13659 ||| NNP
2 ||| S:13659 E:13660 ||| CD
) ||| S:13660 E:13661 ||| -RRB-
.  ||| S:13661 E:13663 ||| .
The  ||| S:13663 E:13667 ||| DT
trends  ||| S:13667 E:13682 ||| NNS
noted  ||| S:13682 E:13688 ||| VBD
in  ||| S:13688 E:13691 ||| IN
the  ||| S:13691 E:13695 ||| DT
training  ||| S:13695 E:13704 ||| NN
set  ||| S:13704 E:13708 ||| NN
were  ||| S:13708 E:13713 ||| VBD
present  ||| S:13713 E:13721 ||| JJ
in  ||| S:13721 E:13724 ||| IN
the  ||| S:13724 E:13728 ||| DT
entire  ||| S:13728 E:13735 ||| JJ
data  ||| S:13735 E:13748 ||| NNS
set ||| S:13748 E:13751 ||| VBN
,  ||| S:13751 E:13753 ||| ,
although  ||| S:13753 E:13762 ||| IN
with  ||| S:13762 E:13767 ||| IN
increased  ||| S:13767 E:13777 ||| JJ
statistical  ||| S:13777 E:13789 ||| JJ
significance ||| S:13789 E:13801 ||| NN
.  ||| S:13801 E:13803 ||| .
For  ||| S:13803 E:13815 ||| IN
example  ||| S:13815 E:13823 ||| NN
3,591  ||| S:13823 E:13829 ||| NN
of  ||| S:13829 E:13832 ||| IN
the  ||| S:13832 E:13836 ||| DT
15,154  ||| S:13836 E:13843 ||| NNP
M ||| S:13843 E:13844 ||| NNP
/ ||| S:13844 E:13845 ||| NNP
Z  ||| S:13845 E:13847 ||| NNP
values  ||| S:13847 E:13854 ||| NNS
had  ||| S:13854 E:13858 ||| VBD
mean  ||| S:13858 E:13863 ||| JJ
intensities  ||| S:13863 E:13883 ||| NN
that  ||| S:13883 E:13888 ||| WDT
varied  ||| S:13888 E:13895 ||| VBD
between  ||| S:13895 E:13903 ||| IN
cancer  ||| S:13903 E:13910 ||| NN
and  ||| S:13910 E:13914 ||| CC
control  ||| S:13914 E:13922 ||| NN
with  ||| S:13922 E:13927 ||| IN
a  ||| S:13927 E:13929 ||| DT
p-value  ||| S:13929 E:13937 ||| JJ
of  ||| S:13937 E:13940 ||| IN
10  ||| S:13940 E:13951 ||| CD
-6or  ||| S:13951 E:13956 ||| CD
less ||| S:13956 E:13960 ||| JJR
.  ||| S:13960 E:13962 ||| .
In  ||| S:13962 E:13965 ||| IN
a  ||| S:13965 E:13967 ||| DT
sample  ||| S:13967 E:13974 ||| NN
of  ||| S:13974 E:13977 ||| IN
a  ||| S:13977 E:13979 ||| DT
panel  ||| S:13979 E:13985 ||| NN
consisting  ||| S:13985 E:13996 ||| VBG
of  ||| S:13996 E:13999 ||| IN
15,154  ||| S:13999 E:14014 ||| CD
independent  ||| S:14014 E:14026 ||| JJ
random  ||| S:14026 E:14033 ||| JJ
sets  ||| S:14033 E:14038 ||| NNS
of  ||| S:14038 E:14041 ||| IN
measurements  ||| S:14041 E:14054 ||| JJ
split  ||| S:14054 E:14060 ||| NN
between  ||| S:14060 E:14076 ||| IN
cancer  ||| S:14076 E:14083 ||| NN
and  ||| S:14083 E:14087 ||| CC
control ||| S:14087 E:14094 ||| NN
,  ||| S:14094 E:14096 ||| ,
using  ||| S:14096 E:14102 ||| VBG
Wilcoxon  ||| S:14102 E:14111 ||| JJ
test  ||| S:14111 E:14116 ||| NN
15,154  ||| S:14116 E:14123 ||| CD
times  ||| S:14123 E:14129 ||| NNS
with  ||| S:14129 E:14142 ||| IN
an  ||| S:14142 E:14145 ||| DT
individual  ||| S:14145 E:14156 ||| JJ
significance  ||| S:14156 E:14169 ||| NN
level  ||| S:14169 E:14175 ||| NN
of  ||| S:14175 E:14178 ||| IN
10  ||| S:14178 E:14181 ||| CD
-6 ||| S:14181 E:14183 ||| CD
,  ||| S:14183 E:14185 ||| ,
the  ||| S:14185 E:14189 ||| DT
number  ||| S:14189 E:14196 ||| NN
of  ||| S:14196 E:14207 ||| IN
false  ||| S:14207 E:14213 ||| JJ
positives  ||| S:14213 E:14223 ||| NN
is  ||| S:14223 E:14226 ||| VBZ
expected  ||| S:14226 E:14235 ||| VBN
to  ||| S:14235 E:14238 ||| TO
be  ||| S:14238 E:14241 ||| VB
0.015 ||| S:14241 E:14246 ||| CD
.  ||| S:14246 E:14248 ||| .
It  ||| S:14248 E:14251 ||| PRP
is  ||| S:14251 E:14254 ||| VBZ
very  ||| S:14254 E:14259 ||| RB
small ||| S:14259 E:14264 ||| JJ
.  ||| S:14264 E:14274 ||| .
Alternatively ||| S:14274 E:14287 ||| RB
,  ||| S:14287 E:14289 ||| ,
in  ||| S:14289 E:14292 ||| IN
the  ||| S:14292 E:14296 ||| DT
above  ||| S:14296 E:14302 ||| IN
setting  ||| S:14302 E:14310 ||| VBG
the  ||| S:14310 E:14314 ||| DT
chance  ||| S:14314 E:14321 ||| NN
that  ||| S:14321 E:14326 ||| IN
at  ||| S:14326 E:14337 ||| IN
least  ||| S:14337 E:14343 ||| JJS
one  ||| S:14343 E:14347 ||| CD
of  ||| S:14347 E:14350 ||| IN
the  ||| S:14350 E:14354 ||| DT
15,154  ||| S:14354 E:14361 ||| CD
measurements  ||| S:14361 E:14374 ||| NNS
would  ||| S:14374 E:14380 ||| MD
have  ||| S:14380 E:14385 ||| VB
a  ||| S:14385 E:14387 ||| DT
p-value  ||| S:14387 E:14403 ||| JJ
less  ||| S:14403 E:14408 ||| JJR
than  ||| S:14408 E:14413 ||| IN
10  ||| S:14413 E:14416 ||| CD
-6is  ||| S:14416 E:14421 ||| CD
approximately  ||| S:14421 E:14435 ||| CD
1.5 ||| S:14435 E:14438 ||| CD
% ||| S:14438 E:14439 ||| NN
.  ||| S:14439 E:14441 ||| .
Thus  ||| S:14441 E:14446 ||| RB
it  ||| S:14446 E:14449 ||| PRP
is  ||| S:14449 E:14452 ||| VBZ
extremely  ||| S:14452 E:14470 ||| RB
unlikely  ||| S:14470 E:14479 ||| JJ
that  ||| S:14479 E:14484 ||| IN
a  ||| S:14484 E:14486 ||| DT
false  ||| S:14486 E:14492 ||| JJ
positive  ||| S:14492 E:14501 ||| NN
would  ||| S:14501 E:14507 ||| MD
occur  ||| S:14507 E:14513 ||| VB
by  ||| S:14513 E:14516 ||| IN
chance  ||| S:14516 E:14523 ||| NN
alone  ||| S:14523 E:14537 ||| RB
in  ||| S:14537 E:14540 ||| IN
a  ||| S:14540 E:14542 ||| DT
15,154  ||| S:14542 E:14549 ||| JJ
member  ||| S:14549 E:14556 ||| NN
test  ||| S:14556 E:14561 ||| NN
set ||| S:14561 E:14564 ||| NN
.  ||| S:14564 E:14566 ||| .
The  ||| S:14566 E:14570 ||| DT
finding  ||| S:14570 E:14578 ||| NN
of  ||| S:14578 E:14581 ||| IN
significant  ||| S:14581 E:14601 ||| JJ
signals  ||| S:14601 E:14609 ||| NNS
at  ||| S:14609 E:14612 ||| IN
M ||| S:14612 E:14613 ||| NNP
/ ||| S:14613 E:14614 ||| NNP
Z  ||| S:14614 E:14616 ||| NNP
values  ||| S:14616 E:14623 ||| VBZ
less  ||| S:14623 E:14628 ||| JJR
than  ||| S:14628 E:14633 ||| IN
500  ||| S:14633 E:14637 ||| CD
is  ||| S:14637 E:14640 ||| VBZ
consistent  ||| S:14640 E:14651 ||| JJ
with  ||| S:14651 E:14656 ||| IN
two  ||| S:14656 E:14668 ||| CD
of  ||| S:14668 E:14671 ||| IN
the  ||| S:14671 E:14675 ||| DT
seven  ||| S:14675 E:14681 ||| CD
M ||| S:14681 E:14682 ||| NNP
/ ||| S:14682 E:14683 ||| NNP
Z  ||| S:14683 E:14685 ||| NNP
values  ||| S:14685 E:14692 ||| VBZ
used  ||| S:14692 E:14697 ||| VBN
in  ||| S:14697 E:14700 ||| IN
the  ||| S:14700 E:14704 ||| DT
model  ||| S:14704 E:14710 ||| NN
rule  ||| S:14710 E:14715 ||| NN
published  ||| S:14715 E:14725 ||| VBN
at  ||| S:14725 E:14736 ||| IN
the  ||| S:14736 E:14740 ||| DT
Clinical  ||| S:14740 E:14749 ||| NNP
Proteomics  ||| S:14749 E:14760 ||| NNP
Program  ||| S:14760 E:14768 ||| NNP
Databank  ||| S:14768 E:14777 ||| NNP
website  ||| S:14777 E:14785 ||| NN
that  ||| S:14785 E:14790 ||| WDT
was  ||| S:14790 E:14802 ||| VBD
developed  ||| S:14802 E:14812 ||| VBN
on  ||| S:14812 E:14815 ||| IN
the  ||| S:14815 E:14819 ||| DT
same  ||| S:14819 E:14824 ||| JJ
data  ||| S:14824 E:14829 ||| NNS
set  ||| S:14829 E:14833 ||| VBN
( ||| S:14833 E:14834 ||| -LRB-
see  ||| S:14834 E:14838 ||| VB
Table  ||| S:14838 E:14844 ||| NNP
4 ||| S:14844 E:14845 ||| CD
) ||| S:14845 E:14846 ||| -RRB-
,  ||| S:14846 E:14848 ||| ,
specifically  ||| S:14848 E:14869 ||| RB
M ||| S:14869 E:14870 ||| NNP
/ ||| S:14870 E:14871 ||| NNP
Z  ||| S:14871 E:14873 ||| NNP
values  ||| S:14873 E:14880 ||| VBZ
435.46452  ||| S:14880 E:14890 ||| NNP
( ||| S:14890 E:14891 ||| -LRB-
p-value  ||| S:14891 E:14899 ||| NNP
=  ||| S:14899 E:14901 ||| SYM
9.08  ||| S:14901 E:14906 ||| CD
  ||| S:14906 E:14908 ||| CD
10  ||| S:14908 E:14911 ||| CD
-372  ||| S:14911 E:14916 ||| CD
ndmost  ||| S:14916 E:14931 ||| CD
significant  ||| S:14931 E:14943 ||| JJ
of  ||| S:14943 E:14946 ||| IN
9  ||| S:14946 E:14948 ||| CD
values  ||| S:14948 E:14955 ||| NNS
in  ||| S:14955 E:14958 ||| IN
its  ||| S:14958 E:14962 ||| PRP$
bin ||| S:14962 E:14965 ||| NN
)  ||| S:14965 E:14967 ||| -RRB-
and  ||| S:14967 E:14971 ||| CC
465.56916  ||| S:14971 E:14981 ||| NNP
( ||| S:14981 E:14982 ||| -LRB-
p-value  ||| S:14982 E:14998 ||| NNP
=  ||| S:14998 E:15000 ||| SYM
2.50  ||| S:15000 E:15005 ||| CD
  ||| S:15005 E:15007 ||| CD
10  ||| S:15007 E:15010 ||| CD
-286  ||| S:15010 E:15015 ||| CD
thmost  ||| S:15015 E:15022 ||| CD
significant  ||| S:15022 E:15034 ||| JJ
of  ||| S:15034 E:15037 ||| IN
the  ||| S:15037 E:15041 ||| DT
7  ||| S:15041 E:15043 ||| CD
M ||| S:15043 E:15044 ||| NNP
/ ||| S:15044 E:15045 ||| NNP
Z  ||| S:15045 E:15047 ||| NNP
values  ||| S:15047 E:15062 ||| VBZ
found  ||| S:15062 E:15068 ||| VBN
in  ||| S:15068 E:15071 ||| IN
its  ||| S:15071 E:15075 ||| PRP$
bin ||| S:15075 E:15078 ||| NN
)  ||| S:15078 E:15080 ||| -RRB-
[  ||| S:15080 E:15082 ||| -LRB-
7  ||| S:15082 E:15084 ||| CD
]  ||| S:15084 E:15086 ||| -RRB-
.  ||| S:15086 E:15088 ||| .
These  ||| S:15088 E:15094 ||| DT
values  ||| S:15094 E:15101 ||| NNS
correspond  ||| S:15101 E:15112 ||| VBP
to  ||| S:15112 E:15115 ||| TO
M ||| S:15115 E:15116 ||| NNP
/ ||| S:15116 E:15117 ||| NNP
Z  ||| S:15117 E:15127 ||| NNP
values  ||| S:15127 E:15134 ||| NNS
of  ||| S:15134 E:15137 ||| IN
435.0751  ||| S:15137 E:15146 ||| NNP
and  ||| S:15146 E:15150 ||| CC
464.3617  ||| S:15150 E:15159 ||| RB
used  ||| S:15159 E:15164 ||| VBN
in  ||| S:15164 E:15167 ||| IN
Rule  ||| S:15167 E:15172 ||| NNP
1 ||| S:15172 E:15173 ||| CD
.  ||| S:15173 E:15175 ||| .
As  ||| S:15175 E:15178 ||| RB
shown  ||| S:15178 E:15184 ||| VBN
in  ||| S:15184 E:15195 ||| IN
Figure  ||| S:15195 E:15202 ||| NNP
3 ||| S:15202 E:15203 ||| CD
,  ||| S:15203 E:15205 ||| ,
each  ||| S:15205 E:15210 ||| DT
of  ||| S:15210 E:15213 ||| IN
these  ||| S:15213 E:15219 ||| DT
two  ||| S:15219 E:15223 ||| CD
pairs  ||| S:15223 E:15229 ||| NNS
of  ||| S:15229 E:15232 ||| IN
M ||| S:15232 E:15233 ||| NNP
/ ||| S:15233 E:15234 ||| NNP
Z  ||| S:15234 E:15236 ||| NNP
values  ||| S:15236 E:15243 ||| NNS
are  ||| S:15243 E:15255 ||| VBP
surprisingly  ||| S:15255 E:15268 ||| RB
effective  ||| S:15268 E:15278 ||| JJ
at  ||| S:15278 E:15281 ||| IN
separating  ||| S:15281 E:15292 ||| VBG
the  ||| S:15292 E:15296 ||| DT
162  ||| S:15296 E:15300 ||| CD
cancer  ||| S:15300 E:15315 ||| NN
subjects  ||| S:15315 E:15324 ||| NNS
from  ||| S:15324 E:15329 ||| IN
the  ||| S:15329 E:15333 ||| DT
91  ||| S:15333 E:15336 ||| CD
control  ||| S:15336 E:15344 ||| NN
subjects  ||| S:15344 E:15353 ||| NNS
with  ||| S:15353 E:15358 ||| IN
an  ||| S:15358 E:15361 ||| DT
advantage  ||| S:15361 E:15379 ||| NN
noted  ||| S:15379 E:15385 ||| VBD
with  ||| S:15385 E:15390 ||| IN
the  ||| S:15390 E:15394 ||| DT
first  ||| S:15394 E:15400 ||| JJ
pair  ||| S:15400 E:15405 ||| NN
( ||| S:15405 E:15406 ||| -LRB-
compare  ||| S:15406 E:15414 ||| VB
panel  ||| S:15414 E:15420 ||| NN
A  ||| S:15420 E:15422 ||| NN
with  ||| S:15422 E:15427 ||| IN
B ||| S:15427 E:15428 ||| NNP
) ||| S:15428 E:15429 ||| -RRB-
.  ||| S:15429 E:15431 ||| .
Even  ||| S:15431 E:15444 ||| RB
more  ||| S:15444 E:15449 ||| RBR
interesting  ||| S:15449 E:15461 ||| JJ
is  ||| S:15461 E:15464 ||| VBZ
the  ||| S:15464 E:15468 ||| DT
finding  ||| S:15468 E:15476 ||| NN
that  ||| S:15476 E:15481 ||| IN
significant  ||| S:15481 E:15493 ||| JJ
M ||| S:15493 E:15494 ||| NNP
/ ||| S:15494 E:15495 ||| NNP
Z  ||| S:15495 E:15497 ||| NNP
values  ||| S:15497 E:15512 ||| VBZ
found  ||| S:15512 E:15518 ||| VBN
in  ||| S:15518 E:15521 ||| IN
the  ||| S:15521 E:15525 ||| DT
first  ||| S:15525 E:15531 ||| JJ
Rule  ||| S:15531 E:15536 ||| NNP
1  ||| S:15536 E:15538 ||| CD
included  ||| S:15538 E:15547 ||| VBD
the  ||| S:15547 E:15551 ||| DT
M ||| S:15551 E:15552 ||| NNP
/ ||| S:15552 E:15553 ||| NNP
Z  ||| S:15553 E:15555 ||| NNP
values  ||| S:15555 E:15562 ||| NNS
of  ||| S:15562 E:15573 ||| IN
2.7921478  ||| S:15573 E:15583 ||| NNP
and  ||| S:15583 E:15587 ||| CC
245.53704 ||| S:15587 E:15596 ||| NNP
.  ||| S:15596 E:15598 ||| .
As  ||| S:15598 E:15601 ||| RB
shown  ||| S:15601 E:15607 ||| VBN
in  ||| S:15607 E:15610 ||| IN
Figure  ||| S:15610 E:15617 ||| NNP
3 ||| S:15617 E:15618 ||| CD
,  ||| S:15618 E:15620 ||| ,
panel  ||| S:15620 E:15626 ||| NN
C ||| S:15626 E:15627 ||| NNP
,  ||| S:15627 E:15637 ||| ,
these  ||| S:15637 E:15643 ||| DT
two  ||| S:15643 E:15647 ||| CD
values  ||| S:15647 E:15654 ||| NNS
can  ||| S:15654 E:15658 ||| MD
also  ||| S:15658 E:15663 ||| RB
significantly  ||| S:15663 E:15677 ||| RB
separate  ||| S:15677 E:15686 ||| VB
the  ||| S:15686 E:15690 ||| DT
162  ||| S:15690 E:15702 ||| CD
cancer  ||| S:15702 E:15709 ||| NN
subjects  ||| S:15709 E:15718 ||| NNS
from  ||| S:15718 E:15723 ||| IN
the  ||| S:15723 E:15727 ||| DT
91  ||| S:15727 E:15730 ||| CD
control  ||| S:15730 E:15738 ||| NN
subjects ||| S:15738 E:15746 ||| NNS
.  ||| S:15746 E:15748 ||| .
The  ||| S:15748 E:15760 ||| DT
interpretation  ||| S:15760 E:15775 ||| NN
of  ||| S:15775 E:15778 ||| IN
these  ||| S:15778 E:15784 ||| DT
values  ||| S:15784 E:15791 ||| NNS
is  ||| S:15791 E:15794 ||| VBZ
problematic ||| S:15794 E:15805 ||| JJ
,  ||| S:15805 E:15807 ||| ,
given  ||| S:15807 E:15813 ||| VBN
the  ||| S:15813 E:15825 ||| DT
low  ||| S:15825 E:15829 ||| JJ
M ||| S:15829 E:15830 ||| NNP
/ ||| S:15830 E:15831 ||| NNP
Z  ||| S:15831 E:15833 ||| NNP
values  ||| S:15833 E:15840 ||| VBZ
involved ||| S:15840 E:15848 ||| VBN
.  ||| S:15848 E:15850 ||| .
In  ||| S:15850 E:15853 ||| IN
order  ||| S:15853 E:15859 ||| NN
to  ||| S:15859 E:15862 ||| TO
evaluate  ||| S:15862 E:15871 ||| VB
these  ||| S:15871 E:15885 ||| DT
findings ||| S:15885 E:15893 ||| NNS
,  ||| S:15893 E:15895 ||| ,
we  ||| S:15895 E:15898 ||| PRP
first  ||| S:15898 E:15904 ||| RB
investigated  ||| S:15904 E:15917 ||| VBN
whether  ||| S:15917 E:15925 ||| IN
data  ||| S:15925 E:15930 ||| NNS
normalization  ||| S:15930 E:15952 ||| VBP
as  ||| S:15952 E:15955 ||| RB
described  ||| S:15955 E:15965 ||| VBN
at  ||| S:15965 E:15968 ||| IN
the  ||| S:15968 E:15972 ||| DT
Clinical  ||| S:15972 E:15981 ||| NNP
Proteomics  ||| S:15981 E:15992 ||| NNP
Data  ||| S:15992 E:15997 ||| NNP
Bank  ||| S:15997 E:16002 ||| NNP
[  ||| S:16002 E:16004 ||| -LRB-
5  ||| S:16004 E:16006 ||| LS
]  ||| S:16006 E:16016 ||| -RRB-
could  ||| S:16016 E:16022 ||| MD
influence  ||| S:16022 E:16032 ||| VB
the  ||| S:16032 E:16036 ||| DT
Wilcoxon  ||| S:16036 E:16045 ||| JJ
test  ||| S:16045 E:16050 ||| NN
p-values  ||| S:16050 E:16059 ||| NN
found  ||| S:16059 E:16065 ||| VBD
using  ||| S:16065 E:16071 ||| VBG
the  ||| S:16071 E:16083 ||| DT
raw  ||| S:16083 E:16087 ||| JJ
data  ||| S:16087 E:16092 ||| NNS
( ||| S:16092 E:16093 ||| -LRB-
see  ||| S:16093 E:16097 ||| VB
methods ||| S:16097 E:16104 ||| NNS
) ||| S:16104 E:16105 ||| -RRB-
.  ||| S:16105 E:16107 ||| .
Several  ||| S:16107 E:16115 ||| JJ
points  ||| S:16115 E:16122 ||| NNS
were  ||| S:16122 E:16127 ||| VBD
chosen ||| S:16127 E:16133 ||| VBN
,  ||| S:16133 E:16135 ||| ,
and  ||| S:16135 E:16139 ||| CC
no  ||| S:16139 E:16150 ||| DT
effect  ||| S:16150 E:16157 ||| NN
was  ||| S:16157 E:16161 ||| VBD
noted  ||| S:16161 E:16167 ||| VBN
on  ||| S:16167 E:16170 ||| IN
the  ||| S:16170 E:16174 ||| DT
p-values  ||| S:16174 E:16183 ||| JJ
( ||| S:16183 E:16184 ||| -LRB-
see  ||| S:16184 E:16188 ||| VB
Table  ||| S:16188 E:16194 ||| NNP
5 ||| S:16194 E:16195 ||| CD
) ||| S:16195 E:16196 ||| -RRB-
.  ||| S:16196 E:16198 ||| .
We  ||| S:16198 E:16201 ||| PRP
further  ||| S:16201 E:16217 ||| RB
analyzed  ||| S:16217 E:16226 ||| VBD
several  ||| S:16226 E:16234 ||| JJ
selected  ||| S:16234 E:16243 ||| JJ
low  ||| S:16243 E:16247 ||| JJ
M ||| S:16247 E:16248 ||| NNP
/ ||| S:16248 E:16249 ||| NNP
Z  ||| S:16249 E:16251 ||| NNP
values ||| S:16251 E:16257 ||| NNS
,  ||| S:16257 E:16259 ||| ,
less  ||| S:16259 E:16264 ||| JJR
than  ||| S:16264 E:16269 ||| IN
500 ||| S:16269 E:16272 ||| CD
.  ||| S:16272 E:16274 ||| .
In  ||| S:16274 E:16285 ||| IN
this  ||| S:16285 E:16290 ||| DT
process ||| S:16290 E:16297 ||| NN
,  ||| S:16297 E:16299 ||| ,
the  ||| S:16299 E:16303 ||| DT
cancer  ||| S:16303 E:16310 ||| NN
and  ||| S:16310 E:16314 ||| CC
control  ||| S:16314 E:16322 ||| NN
data  ||| S:16322 E:16327 ||| NNS
were  ||| S:16327 E:16332 ||| VBD
pooled ||| S:16332 E:16338 ||| VBN
.  ||| S:16338 E:16340 ||| .
The  ||| S:16340 E:16352 ||| DT
pooled  ||| S:16352 E:16359 ||| JJ
data  ||| S:16359 E:16364 ||| NNS
were  ||| S:16364 E:16369 ||| VBD
randomly  ||| S:16369 E:16378 ||| RB
partitioned  ||| S:16378 E:16390 ||| VBN
between  ||| S:16390 E:16398 ||| IN
a  ||| S:16398 E:16400 ||| DT
set  ||| S:16400 E:16412 ||| VBN
containing  ||| S:16412 E:16423 ||| VBG
91  ||| S:16423 E:16426 ||| CD
members  ||| S:16426 E:16434 ||| NNS
and  ||| S:16434 E:16438 ||| CC
a  ||| S:16438 E:16440 ||| DT
set  ||| S:16440 E:16444 ||| VBN
containing  ||| S:16444 E:16455 ||| VBG
162  ||| S:16455 E:16459 ||| CD
members ||| S:16459 E:16466 ||| NNS
.  ||| S:16466 E:16468 ||| .
The  ||| S:16468 E:16480 ||| DT
Wilcoxon  ||| S:16480 E:16489 ||| JJ
test  ||| S:16489 E:16494 ||| NN
was  ||| S:16494 E:16498 ||| VBD
then  ||| S:16498 E:16503 ||| RB
run  ||| S:16503 E:16507 ||| VBN
on  ||| S:16507 E:16510 ||| IN
the  ||| S:16510 E:16514 ||| DT
randomized  ||| S:16514 E:16525 ||| JJ
set ||| S:16525 E:16528 ||| NN
.  ||| S:16528 E:16530 ||| .
The  ||| S:16530 E:16542 ||| DT
process  ||| S:16542 E:16550 ||| NN
was  ||| S:16550 E:16554 ||| VBD
repeated  ||| S:16554 E:16563 ||| VBN
10,000  ||| S:16563 E:16570 ||| CD
times ||| S:16570 E:16575 ||| NNS
,  ||| S:16575 E:16577 ||| ,
and  ||| S:16577 E:16581 ||| CC
the  ||| S:16581 E:16585 ||| DT
lowest  ||| S:16585 E:16592 ||| JJS
p-values  ||| S:16592 E:16609 ||| NN
were  ||| S:16609 E:16614 ||| VBD
chosen ||| S:16614 E:16620 ||| VBN
.  ||| S:16620 E:16622 ||| .
As  ||| S:16622 E:16625 ||| RB
shown  ||| S:16625 E:16631 ||| VBN
in  ||| S:16631 E:16634 ||| IN
Table  ||| S:16634 E:16640 ||| NNP
5 ||| S:16640 E:16641 ||| CD
,  ||| S:16641 E:16643 ||| ,
the  ||| S:16643 E:16647 ||| DT
lowest  ||| S:16647 E:16654 ||| JJS
p-values  ||| S:16654 E:16671 ||| JJ
generated  ||| S:16671 E:16681 ||| NN
by  ||| S:16681 E:16684 ||| IN
the  ||| S:16684 E:16688 ||| DT
permutation  ||| S:16688 E:16700 ||| JJ
process  ||| S:16700 E:16708 ||| NN
were  ||| S:16708 E:16713 ||| VBD
on  ||| S:16713 E:16716 ||| IN
the  ||| S:16716 E:16720 ||| DT
order  ||| S:16720 E:16726 ||| NN
of  ||| S:16726 E:16737 ||| IN
0.0001 ||| S:16737 E:16743 ||| NNP
,  ||| S:16743 E:16745 ||| ,
as  ||| S:16745 E:16748 ||| RB
expected  ||| S:16748 E:16757 ||| VBN
given  ||| S:16757 E:16763 ||| VBN
the  ||| S:16763 E:16767 ||| DT
number  ||| S:16767 E:16774 ||| NN
of  ||| S:16774 E:16777 ||| IN
permutations  ||| S:16777 E:16798 ||| JJ
tested ||| S:16798 E:16804 ||| NN
.  ||| S:16804 E:16806 ||| .
Thus ||| S:16806 E:16810 ||| RB
,  ||| S:16810 E:16812 ||| ,
it  ||| S:16812 E:16815 ||| PRP
is  ||| S:16815 E:16818 ||| VBZ
highly  ||| S:16818 E:16825 ||| RB
unlikely  ||| S:16825 E:16834 ||| JJ
that  ||| S:16834 E:16839 ||| IN
either  ||| S:16839 E:16846 ||| DT
data  ||| S:16846 E:16859 ||| NN
normalization  ||| S:16859 E:16873 ||| NNS
or  ||| S:16873 E:16876 ||| CC
a  ||| S:16876 E:16878 ||| DT
chance  ||| S:16878 E:16885 ||| NN
distribution  ||| S:16885 E:16898 ||| NN
could  ||| S:16898 E:16904 ||| MD
have  ||| S:16904 E:16909 ||| VB
accounted  ||| S:16909 E:16927 ||| VBN
for  ||| S:16927 E:16931 ||| IN
the  ||| S:16931 E:16935 ||| DT
highly  ||| S:16935 E:16942 ||| RB
significant  ||| S:16942 E:16954 ||| JJ
p-values  ||| S:16954 E:16963 ||| NN
noted  ||| S:16963 E:16969 ||| VBD
in  ||| S:16969 E:16972 ||| IN
the  ||| S:16972 E:16976 ||| DT
M ||| S:16976 E:16977 ||| NNP
/ ||| S:16977 E:16978 ||| NNP
Z  ||| S:16978 E:16980 ||| NNP
region  ||| S:16980 E:16995 ||| NN
less  ||| S:16995 E:17000 ||| RBR
than  ||| S:17000 E:17005 ||| IN
500 ||| S:17005 E:17008 ||| CD
.  ||| S:17008 E:17010 ||| .
Finally ||| S:17010 E:17017 ||| RB
,  ||| S:17017 E:17019 ||| ,
it  ||| S:17019 E:17022 ||| PRP
is  ||| S:17022 E:17025 ||| VBZ
interesting  ||| S:17025 E:17037 ||| JJ
to  ||| S:17037 E:17040 ||| TO
note  ||| S:17040 E:17045 ||| VB
that  ||| S:17045 E:17050 ||| IN
the  ||| S:17050 E:17062 ||| DT
remaining  ||| S:17062 E:17072 ||| JJ
five  ||| S:17072 E:17077 ||| CD
values  ||| S:17077 E:17084 ||| NNS
in  ||| S:17084 E:17087 ||| IN
the  ||| S:17087 E:17091 ||| DT
Clinical  ||| S:17091 E:17100 ||| NNP
Proteomics  ||| S:17100 E:17111 ||| NNP
Program  ||| S:17111 E:17127 ||| NNP
Databank  ||| S:17127 E:17136 ||| NNP
model  ||| S:17136 E:17142 ||| NN
rule  ||| S:17142 E:17147 ||| NN
all  ||| S:17147 E:17151 ||| RB
have  ||| S:17151 E:17156 ||| VB
M ||| S:17156 E:17157 ||| NNP
/ ||| S:17157 E:17158 ||| NNP
Z  ||| S:17158 E:17160 ||| NNP
values  ||| S:17160 E:17167 ||| VBZ
greater  ||| S:17167 E:17175 ||| JJR
than  ||| S:17175 E:17180 ||| IN
2000  ||| S:17180 E:17193 ||| CD
and  ||| S:17193 E:17197 ||| CC
relatively  ||| S:17197 E:17208 ||| RB
high  ||| S:17208 E:17213 ||| JJ
p-values ||| S:17213 E:17221 ||| NN
.  ||| S:17221 E:17223 ||| .
Specifically  ||| S:17223 E:17236 ||| RB
the  ||| S:17236 E:17240 ||| DT
remaining  ||| S:17240 E:17258 ||| JJ
values  ||| S:17258 E:17265 ||| NNS
are  ||| S:17265 E:17269 ||| VBP
( ||| S:17269 E:17270 ||| -LRB-
note  ||| S:17270 E:17275 ||| NN
that  ||| S:17275 E:17280 ||| IN
the  ||| S:17280 E:17284 ||| DT
p-values  ||| S:17284 E:17293 ||| NNS
are  ||| S:17293 E:17297 ||| VBP
calculated  ||| S:17297 E:17308 ||| VBN
from  ||| S:17308 E:17313 ||| IN
the  ||| S:17313 E:17325 ||| DT
entire  ||| S:17325 E:17332 ||| JJ
data  ||| S:17332 E:17337 ||| NNS
set ||| S:17337 E:17340 ||| VBN
) ||| S:17340 E:17341 ||| -RRB-
:  ||| S:17341 E:17351 ||| :
1 ||| S:17351 E:17352 ||| LS
)  ||| S:17352 E:17354 ||| -RRB-
M ||| S:17354 E:17355 ||| NNP
/ ||| S:17355 E:17356 ||| NNP
Z  ||| S:17356 E:17358 ||| NNP
=  ||| S:17358 E:17360 ||| SYM
2760.6685 ||| S:17360 E:17369 ||| CD
,  ||| S:17369 E:17371 ||| ,
p  ||| S:17371 E:17373 ||| VBG
=  ||| S:17373 E:17375 ||| SYM
0.24  ||| S:17375 E:17388 ||| CD
2 ||| S:17388 E:17389 ||| CD
)  ||| S:17389 E:17391 ||| -RRB-
M ||| S:17391 E:17392 ||| NNP
/ ||| S:17392 E:17393 ||| NNP
Z  ||| S:17393 E:17395 ||| NNP
=  ||| S:17395 E:17397 ||| SYM
19643.409 ||| S:17397 E:17406 ||| CD
,  ||| S:17406 E:17408 ||| ,
p  ||| S:17408 E:17410 ||| VBG
=  ||| S:17410 E:17412 ||| SYM
0.52  ||| S:17412 E:17425 ||| CD
3 ||| S:17425 E:17426 ||| CD
)  ||| S:17426 E:17428 ||| -RRB-
M ||| S:17428 E:17429 ||| NNP
/ ||| S:17429 E:17430 ||| NNP
Z  ||| S:17430 E:17432 ||| NNP
=  ||| S:17432 E:17434 ||| SYM
6631.7043 ||| S:17434 E:17443 ||| CD
,  ||| S:17443 E:17445 ||| ,
p  ||| S:17445 E:17447 ||| VBG
=  ||| S:17447 E:17449 ||| SYM
9.0  ||| S:17449 E:17453 ||| CD
  ||| S:17453 E:17455 ||| CD
10  ||| S:17455 E:17458 ||| CD
-4  ||| S:17458 E:17469 ||| CD
4 ||| S:17469 E:17470 ||| CD
)  ||| S:17470 E:17472 ||| -RRB-
M ||| S:17472 E:17473 ||| NNP
/ ||| S:17473 E:17474 ||| NNP
Z  ||| S:17474 E:17476 ||| NNP
=  ||| S:17476 E:17478 ||| SYM
14051.976 ||| S:17478 E:17487 ||| CD
,  ||| S:17487 E:17489 ||| ,
p  ||| S:17489 E:17491 ||| VBG
=  ||| S:17491 E:17493 ||| SYM
1.8  ||| S:17493 E:17497 ||| CD
  ||| S:17497 E:17499 ||| CD
10  ||| S:17499 E:17502 ||| CD
-8  ||| S:17502 E:17513 ||| CD
5 ||| S:17513 E:17514 ||| CD
)  ||| S:17514 E:17516 ||| -RRB-
M ||| S:17516 E:17517 ||| NNP
/ ||| S:17517 E:17518 ||| NNP
Z  ||| S:17518 E:17520 ||| NNP
=  ||| S:17520 E:17522 ||| SYM
3497.5508 ||| S:17522 E:17531 ||| CD
,  ||| S:17531 E:17533 ||| ,
p  ||| S:17533 E:17535 ||| VBG
=  ||| S:17535 E:17537 ||| SYM
1.4  ||| S:17537 E:17541 ||| CD
  ||| S:17541 E:17543 ||| CD
10  ||| S:17543 E:17546 ||| CD
-6  ||| S:17546 E:17557 ||| CD
By  ||| S:17557 E:17560 ||| IN
contrast  ||| S:17560 E:17569 ||| NN
all  ||| S:17569 E:17573 ||| PDT
the  ||| S:17573 E:17577 ||| DT
M ||| S:17577 E:17578 ||| NNP
/ ||| S:17578 E:17579 ||| NNP
Z  ||| S:17579 E:17581 ||| NNP
values  ||| S:17581 E:17588 ||| VBZ
used  ||| S:17588 E:17593 ||| VBN
in  ||| S:17593 E:17596 ||| IN
Rule  ||| S:17596 E:17601 ||| NNP
1  ||| S:17601 E:17603 ||| CD
have  ||| S:17603 E:17616 ||| VBP
p-values  ||| S:17616 E:17625 ||| JJ
less  ||| S:17625 E:17630 ||| JJR
than  ||| S:17630 E:17635 ||| IN
10  ||| S:17635 E:17638 ||| CD
-26 ||| S:17638 E:17641 ||| CD
( ||| S:17641 E:17642 ||| -LRB-
compare  ||| S:17642 E:17650 ||| VB
Table  ||| S:17650 E:17656 ||| NNP
1with  ||| S:17656 E:17662 ||| NNP
Table  ||| S:17662 E:17668 ||| NNP
4 ||| S:17668 E:17669 ||| CD
) ||| S:17669 E:17670 ||| -RRB-
.  ||| S:17670 E:17680 ||| .
There  ||| S:17680 E:17686 ||| EX
are  ||| S:17686 E:17690 ||| VBP
several  ||| S:17690 E:17698 ||| JJ
non-exclusive  ||| S:17698 E:17712 ||| JJ
explanations  ||| S:17712 E:17725 ||| NNS
for  ||| S:17725 E:17729 ||| IN
the  ||| S:17729 E:17741 ||| DT
presence  ||| S:17741 E:17750 ||| NN
of  ||| S:17750 E:17753 ||| IN
significant  ||| S:17753 E:17765 ||| JJ
P-values  ||| S:17765 E:17774 ||| NN
in  ||| S:17774 E:17777 ||| IN
M ||| S:17777 E:17778 ||| NNP
/ ||| S:17778 E:17779 ||| NNP
Z  ||| S:17779 E:17781 ||| NNP
region  ||| S:17781 E:17788 ||| NN
less  ||| S:17788 E:17793 ||| RBR
than  ||| S:17793 E:17806 ||| IN
500 ||| S:17806 E:17809 ||| CD
.  ||| S:17809 E:17811 ||| .
First ||| S:17811 E:17816 ||| NNP
,  ||| S:17816 E:17818 ||| ,
these  ||| S:17818 E:17824 ||| DT
may  ||| S:17824 E:17828 ||| MD
actually  ||| S:17828 E:17837 ||| RB
represent  ||| S:17837 E:17847 ||| VB
biomarkers  ||| S:17847 E:17858 ||| VBN
that  ||| S:17858 E:17871 ||| IN
correlate  ||| S:17871 E:17881 ||| NN
with  ||| S:17881 E:17886 ||| IN
ovarian  ||| S:17886 E:17894 ||| JJ
cancer ||| S:17894 E:17900 ||| NN
.  ||| S:17900 E:17902 ||| .
The  ||| S:17902 E:17906 ||| DT
disease  ||| S:17906 E:17914 ||| NN
process  ||| S:17914 E:17922 ||| NN
may  ||| S:17922 E:17934 ||| MD
influence  ||| S:17934 E:17944 ||| VB
the  ||| S:17944 E:17948 ||| DT
serum  ||| S:17948 E:17954 ||| JJ
concentration  ||| S:17954 E:17968 ||| NN
of  ||| S:17968 E:17971 ||| IN
lipids ||| S:17971 E:17977 ||| NN
,  ||| S:17977 E:17979 ||| ,
or  ||| S:17979 E:17982 ||| CC
other  ||| S:17982 E:17988 ||| JJ
small  ||| S:17988 E:18002 ||| JJ
molecules  ||| S:18002 E:18012 ||| NNS
that  ||| S:18012 E:18017 ||| IN
either  ||| S:18017 E:18024 ||| DT
bind  ||| S:18024 E:18029 ||| NN
to  ||| S:18029 E:18032 ||| TO
the  ||| S:18032 E:18036 ||| DT
chip  ||| S:18036 E:18041 ||| NN
directly  ||| S:18041 E:18050 ||| RB
or  ||| S:18050 E:18053 ||| CC
through  ||| S:18053 E:18069 ||| IN
a  ||| S:18069 E:18071 ||| DT
complex  ||| S:18071 E:18079 ||| JJ
formation  ||| S:18079 E:18089 ||| NN
with  ||| S:18089 E:18094 ||| IN
other  ||| S:18094 E:18100 ||| JJ
macromolecules  ||| S:18100 E:18115 ||| NNS
( ||| S:18115 E:18116 ||| -LRB-
e.g. ||| S:18116 E:18120 ||| NNP
,  ||| S:18120 E:18130 ||| ,
binding  ||| S:18130 E:18138 ||| VBG
to  ||| S:18138 E:18141 ||| TO
a  ||| S:18141 E:18143 ||| DT
receptor ||| S:18143 E:18151 ||| NN
) ||| S:18151 E:18152 ||| -RRB-
.  ||| S:18152 E:18154 ||| .
For  ||| S:18154 E:18158 ||| IN
example ||| S:18158 E:18165 ||| NN
,  ||| S:18165 E:18167 ||| ,
the  ||| S:18167 E:18171 ||| DT
lysophospholipids  ||| S:18171 E:18197 ||| NNS
represent  ||| S:18197 E:18207 ||| VBP
a  ||| S:18207 E:18209 ||| DT
class  ||| S:18209 E:18215 ||| NN
of  ||| S:18215 E:18218 ||| IN
compounds  ||| S:18218 E:18228 ||| NNS
that  ||| S:18228 E:18233 ||| WDT
have  ||| S:18233 E:18238 ||| VBP
an  ||| S:18238 E:18241 ||| DT
important  ||| S:18241 E:18251 ||| JJ
role  ||| S:18251 E:18264 ||| NN
in  ||| S:18264 E:18267 ||| IN
extracellular  ||| S:18267 E:18281 ||| JJ
signaling ||| S:18281 E:18290 ||| NN
.  ||| S:18290 E:18292 ||| .
Lysophophatidic  ||| S:18292 E:18308 ||| NNP
Acid  ||| S:18308 E:18313 ||| NNP
( ||| S:18313 E:18314 ||| -LRB-
LPA ||| S:18314 E:18317 ||| NNP
)  ||| S:18317 E:18319 ||| -RRB-
is  ||| S:18319 E:18322 ||| VBZ
a  ||| S:18322 E:18332 ||| DT
member  ||| S:18332 E:18339 ||| NN
of  ||| S:18339 E:18342 ||| IN
this  ||| S:18342 E:18347 ||| DT
class  ||| S:18347 E:18353 ||| NN
of  ||| S:18353 E:18356 ||| IN
compounds ||| S:18356 E:18365 ||| NN
,  ||| S:18365 E:18367 ||| ,
and  ||| S:18367 E:18371 ||| CC
its  ||| S:18371 E:18375 ||| PRP$
plasma  ||| S:18375 E:18382 ||| JJ
levels  ||| S:18382 E:18397 ||| NNS
have  ||| S:18397 E:18402 ||| VBP
been  ||| S:18402 E:18407 ||| VBN
proposed  ||| S:18407 E:18416 ||| VBN
as  ||| S:18416 E:18419 ||| IN
a  ||| S:18419 E:18421 ||| DT
potential  ||| S:18421 E:18431 ||| JJ
biomarker  ||| S:18431 E:18441 ||| NN
for  ||| S:18441 E:18445 ||| IN
ovarian  ||| S:18445 E:18461 ||| JJ
cancer  ||| S:18461 E:18468 ||| NN
[  ||| S:18468 E:18470 ||| -LRB-
16  ||| S:18470 E:18473 ||| CD
17  ||| S:18473 E:18476 ||| CD
]  ||| S:18476 E:18478 ||| -RRB-
.  ||| S:18478 E:18480 ||| .
LPA  ||| S:18480 E:18484 ||| NNP
is  ||| S:18484 E:18487 ||| VBZ
a  ||| S:18487 E:18489 ||| DT
family  ||| S:18489 E:18496 ||| NN
of  ||| S:18496 E:18499 ||| IN
related  ||| S:18499 E:18507 ||| JJ
molecules  ||| S:18507 E:18525 ||| NNS
with  ||| S:18525 E:18530 ||| IN
molecular  ||| S:18530 E:18540 ||| JJ
weights  ||| S:18540 E:18548 ||| NNS
in  ||| S:18548 E:18551 ||| IN
the  ||| S:18551 E:18555 ||| DT
vicinity  ||| S:18555 E:18564 ||| NN
of  ||| S:18564 E:18567 ||| IN
400  ||| S:18567 E:18571 ||| CD
to  ||| S:18571 E:18574 ||| TO
600  ||| S:18574 E:18586 ||| CD
Daltons ||| S:18586 E:18593 ||| NNP
,  ||| S:18593 E:18595 ||| ,
and  ||| S:18595 E:18599 ||| CC
a  ||| S:18599 E:18601 ||| DT
variety  ||| S:18601 E:18609 ||| NN
of  ||| S:18609 E:18612 ||| IN
LPA  ||| S:18612 E:18616 ||| NNP
species  ||| S:18616 E:18624 ||| NN
has  ||| S:18624 E:18628 ||| VBZ
been  ||| S:18628 E:18633 ||| VBN
reported  ||| S:18633 E:18642 ||| VBN
to  ||| S:18642 E:18653 ||| TO
be  ||| S:18653 E:18656 ||| VB
increased  ||| S:18656 E:18666 ||| VBN
in  ||| S:18666 E:18669 ||| IN
malignant  ||| S:18669 E:18679 ||| JJ
ascites  ||| S:18679 E:18687 ||| NN
from  ||| S:18687 E:18692 ||| IN
patients  ||| S:18692 E:18701 ||| NNS
with  ||| S:18701 E:18714 ||| IN
ovarian  ||| S:18714 E:18722 ||| JJ
cancer  ||| S:18722 E:18729 ||| NN
as  ||| S:18729 E:18732 ||| IN
detected  ||| S:18732 E:18741 ||| VBN
by  ||| S:18741 E:18744 ||| IN
electrospray  ||| S:18744 E:18757 ||| FW
ionization  ||| S:18757 E:18768 ||| FW
mass  ||| S:18768 E:18781 ||| FW
spectrometry  ||| S:18781 E:18794 ||| FW
( ||| S:18794 E:18795 ||| -LRB-
ESI-MS ||| S:18795 E:18801 ||| NNP
)  ||| S:18801 E:18803 ||| -RRB-
[  ||| S:18803 E:18805 ||| -LRB-
18  ||| S:18805 E:18808 ||| CD
]  ||| S:18808 E:18810 ||| -RRB-
.  ||| S:18810 E:18812 ||| .
LPA  ||| S:18812 E:18816 ||| NNP
related  ||| S:18816 E:18824 ||| JJ
species  ||| S:18824 E:18832 ||| NNS
have  ||| S:18832 E:18845 ||| VBP
also  ||| S:18845 E:18850 ||| RB
been  ||| S:18850 E:18855 ||| VBN
reported  ||| S:18855 E:18864 ||| VBN
to  ||| S:18864 E:18867 ||| TO
be  ||| S:18867 E:18870 ||| VB
increased  ||| S:18870 E:18880 ||| VBN
in  ||| S:18880 E:18883 ||| IN
plasma  ||| S:18883 E:18890 ||| JJ
samples  ||| S:18890 E:18898 ||| NNS
from  ||| S:18898 E:18911 ||| IN
patients  ||| S:18911 E:18920 ||| NNS
with  ||| S:18920 E:18925 ||| IN
ovarian  ||| S:18925 E:18933 ||| JJ
cancer  ||| S:18933 E:18940 ||| NN
using  ||| S:18940 E:18946 ||| VBG
a  ||| S:18946 E:18948 ||| DT
combination  ||| S:18948 E:18960 ||| NN
of  ||| S:18960 E:18963 ||| IN
thin  ||| S:18963 E:18976 ||| JJ
layer  ||| S:18976 E:18982 ||| NN
chromatography  ||| S:18982 E:18997 ||| NNS
( ||| S:18997 E:18998 ||| -LRB-
to  ||| S:18998 E:19001 ||| TO
isolate  ||| S:19001 E:19009 ||| VB
an  ||| S:19009 E:19012 ||| DT
"LPA  ||| S:19012 E:19017 ||| JJ
band ||| S:19017 E:19021 ||| NN
"  ||| S:19021 E:19023 ||| ''
from  ||| S:19023 E:19028 ||| IN
patient  ||| S:19028 E:19044 ||| JJ
plasma ||| S:19044 E:19050 ||| NN
)  ||| S:19050 E:19052 ||| -RRB-
followed  ||| S:19052 E:19061 ||| VBD
by  ||| S:19061 E:19064 ||| IN
ESI-MS ||| S:19064 E:19070 ||| JJ
.  ||| S:19070 E:19072 ||| .
This  ||| S:19072 E:19077 ||| DT
study  ||| S:19077 E:19083 ||| NN
reported  ||| S:19083 E:19092 ||| VBD
significant  ||| S:19092 E:19112 ||| JJ
LPA  ||| S:19112 E:19116 ||| NN
increases  ||| S:19116 E:19126 ||| NNS
in  ||| S:19126 E:19129 ||| IN
cancer  ||| S:19129 E:19136 ||| NN
samples  ||| S:19136 E:19144 ||| NNS
with  ||| S:19144 E:19149 ||| IN
increased  ||| S:19149 E:19159 ||| JJ
intensities  ||| S:19159 E:19179 ||| NN
noted  ||| S:19179 E:19185 ||| VBD
at  ||| S:19185 E:19188 ||| IN
M ||| S:19188 E:19189 ||| NNP
/ ||| S:19189 E:19190 ||| NNP
Z  ||| S:19190 E:19192 ||| NNP
values  ||| S:19192 E:19199 ||| NNS
of  ||| S:19199 E:19202 ||| IN
409 ||| S:19202 E:19205 ||| CD
,  ||| S:19205 E:19207 ||| ,
433-437 ||| S:19207 E:19214 ||| NNP
,  ||| S:19214 E:19216 ||| ,
457 ||| S:19216 E:19219 ||| CD
,  ||| S:19219 E:19221 ||| ,
481-482 ||| S:19221 E:19228 ||| NNP
,  ||| S:19228 E:19230 ||| ,
571 ||| S:19230 E:19233 ||| CD
,  ||| S:19233 E:19243 ||| ,
599 ||| S:19243 E:19246 ||| CD
,  ||| S:19246 E:19248 ||| ,
and  ||| S:19248 E:19252 ||| CC
619 ||| S:19252 E:19255 ||| CD
.  ||| S:19255 E:19257 ||| .
This  ||| S:19257 E:19262 ||| DT
report  ||| S:19262 E:19269 ||| NN
also  ||| S:19269 E:19274 ||| RB
reviews  ||| S:19274 E:19282 ||| VBZ
the  ||| S:19282 E:19286 ||| DT
evidence  ||| S:19286 E:19295 ||| NN
that  ||| S:19295 E:19308 ||| IN
these  ||| S:19308 E:19314 ||| DT
M ||| S:19314 E:19315 ||| NNP
/ ||| S:19315 E:19316 ||| NNP
Z  ||| S:19316 E:19318 ||| NNP
values  ||| S:19318 E:19325 ||| NNS
are  ||| S:19325 E:19329 ||| VBP
consistent  ||| S:19329 E:19340 ||| JJ
with  ||| S:19340 E:19345 ||| IN
LPA  ||| S:19345 E:19349 ||| NNP
family  ||| S:19349 E:19356 ||| NN
members  ||| S:19356 E:19364 ||| NNS
[  ||| S:19364 E:19374 ||| -LRB-
19  ||| S:19374 E:19377 ||| CD
]  ||| S:19377 E:19379 ||| -RRB-
.  ||| S:19379 E:19381 ||| .
Figure  ||| S:19381 E:19388 ||| NN
4shows  ||| S:19388 E:19395 ||| VBZ
the  ||| S:19395 E:19399 ||| DT
average  ||| S:19399 E:19407 ||| JJ
intensities  ||| S:19407 E:19419 ||| NN
and  ||| S:19419 E:19423 ||| CC
p-values  ||| S:19423 E:19440 ||| JJ
for  ||| S:19440 E:19444 ||| IN
both  ||| S:19444 E:19449 ||| PDT
the  ||| S:19449 E:19453 ||| DT
cancer  ||| S:19453 E:19460 ||| NN
and  ||| S:19460 E:19464 ||| CC
control  ||| S:19464 E:19472 ||| NN
groups  ||| S:19472 E:19479 ||| NNS
in  ||| S:19479 E:19482 ||| IN
the  ||| S:19482 E:19486 ||| DT
region  ||| S:19486 E:19501 ||| NN
between  ||| S:19501 E:19509 ||| IN
M ||| S:19509 E:19510 ||| NNP
/ ||| S:19510 E:19511 ||| NNP
Z  ||| S:19511 E:19513 ||| NNP
values  ||| S:19513 E:19520 ||| NNS
of  ||| S:19520 E:19523 ||| IN
410  ||| S:19523 E:19527 ||| CD
to  ||| S:19527 E:19530 ||| TO
470 ||| S:19530 E:19533 ||| CD
.  ||| S:19533 E:19535 ||| .
Among  ||| S:19535 E:19541 ||| IN
other  ||| S:19541 E:19547 ||| JJ
features ||| S:19547 E:19555 ||| NNS
,  ||| S:19555 E:19557 ||| ,
an  ||| S:19557 E:19568 ||| DT
increase  ||| S:19568 E:19577 ||| NN
in  ||| S:19577 E:19580 ||| IN
the  ||| S:19580 E:19584 ||| DT
mean  ||| S:19584 E:19589 ||| JJ
intensity  ||| S:19589 E:19599 ||| NN
for  ||| S:19599 E:19603 ||| IN
cancers  ||| S:19603 E:19611 ||| NNS
at  ||| S:19611 E:19614 ||| IN
a  ||| S:19614 E:19616 ||| DT
peak  ||| S:19616 E:19629 ||| NN
centered  ||| S:19629 E:19638 ||| VBN
at  ||| S:19638 E:19641 ||| IN
an  ||| S:19641 E:19644 ||| DT
M ||| S:19644 E:19645 ||| NNP
/ ||| S:19645 E:19646 ||| NNP
Z  ||| S:19646 E:19648 ||| NNP
of  ||| S:19648 E:19651 ||| IN
459  ||| S:19651 E:19655 ||| CD
is  ||| S:19655 E:19658 ||| VBZ
noted ||| S:19658 E:19663 ||| VBN
.  ||| S:19663 E:19665 ||| .
However ||| S:19665 E:19672 ||| RB
,  ||| S:19672 E:19674 ||| ,
also  ||| S:19674 E:19679 ||| RB
of  ||| S:19679 E:19682 ||| IN
note  ||| S:19682 E:19695 ||| NN
in  ||| S:19695 E:19698 ||| IN
this  ||| S:19698 E:19703 ||| DT
region  ||| S:19703 E:19710 ||| NN
are ||| S:19710 E:19713 ||| VBP
:  ||| S:19713 E:19723 ||| :
1 ||| S:19723 E:19724 ||| LS
)  ||| S:19724 E:19726 ||| -RRB-
M ||| S:19726 E:19727 ||| NNP
/ ||| S:19727 E:19728 ||| NNP
Z  ||| S:19728 E:19730 ||| NNP
=  ||| S:19730 E:19732 ||| SYM
464.3617  ||| S:19732 E:19741 ||| CD
with  ||| S:19741 E:19746 ||| IN
a  ||| S:19746 E:19748 ||| DT
p-value  ||| S:19748 E:19756 ||| JJ
less  ||| S:19756 E:19761 ||| JJR
than  ||| S:19761 E:19766 ||| IN
6.8  ||| S:19766 E:19770 ||| CD
  ||| S:19770 E:19772 ||| CD
10  ||| S:19772 E:19775 ||| CD
-35 ||| S:19775 E:19778 ||| CD
,  ||| S:19778 E:19788 ||| ,
that  ||| S:19788 E:19793 ||| WDT
correlates  ||| S:19793 E:19804 ||| VBZ
with  ||| S:19804 E:19809 ||| IN
a  ||| S:19809 E:19811 ||| DT
shoulder  ||| S:19811 E:19820 ||| NN
in  ||| S:19820 E:19823 ||| IN
a  ||| S:19823 E:19825 ||| DT
secondary  ||| S:19825 E:19835 ||| JJ
peak  ||| S:19835 E:19840 ||| NN
at  ||| S:19840 E:19851 ||| IN
about  ||| S:19851 E:19857 ||| IN
463 ||| S:19857 E:19860 ||| CD
,  ||| S:19860 E:19862 ||| ,
that  ||| S:19862 E:19867 ||| WDT
is  ||| S:19867 E:19870 ||| VBZ
decreased  ||| S:19870 E:19880 ||| VBN
in  ||| S:19880 E:19883 ||| IN
cancer  ||| S:19883 E:19890 ||| NN
patients  ||| S:19890 E:19899 ||| NNS
( ||| S:19899 E:19900 ||| -LRB-
average  ||| S:19900 E:19916 ||| JJ
intensity  ||| S:19916 E:19926 ||| NN
17.5  ||| S:19926 E:19931 ||| CD
for  ||| S:19931 E:19935 ||| IN
cancer  ||| S:19935 E:19942 ||| NN
versus  ||| S:19942 E:19949 ||| IN
23.6  ||| S:19949 E:19954 ||| CD
for  ||| S:19954 E:19958 ||| IN
controls ||| S:19958 E:19966 ||| NNS
) ||| S:19966 E:19967 ||| -RRB-
.  ||| S:19967 E:19977 ||| .
2 ||| S:19977 E:19978 ||| LS
)  ||| S:19978 E:19980 ||| -RRB-
M ||| S:19980 E:19981 ||| NNP
/ ||| S:19981 E:19982 ||| NNP
Z  ||| S:19982 E:19984 ||| NNP
=  ||| S:19984 E:19986 ||| SYM
435.0751  ||| S:19986 E:19995 ||| CD
with  ||| S:19995 E:20000 ||| IN
a  ||| S:20000 E:20002 ||| DT
p-value  ||| S:20002 E:20010 ||| JJ
of  ||| S:20010 E:20013 ||| IN
less  ||| S:20013 E:20018 ||| JJR
than  ||| S:20018 E:20023 ||| IN
3.9  ||| S:20023 E:20027 ||| CD
  ||| S:20027 E:20029 ||| CD
10  ||| S:20029 E:20040 ||| CD
-37 ||| S:20040 E:20043 ||| CD
,  ||| S:20043 E:20045 ||| ,
that  ||| S:20045 E:20050 ||| WDT
corresponds  ||| S:20050 E:20062 ||| VBZ
to  ||| S:20062 E:20065 ||| TO
a  ||| S:20065 E:20067 ||| DT
peak  ||| S:20067 E:20072 ||| NN
with  ||| S:20072 E:20077 ||| IN
increased  ||| S:20077 E:20087 ||| JJ
intensity  ||| S:20087 E:20097 ||| NN
in  ||| S:20097 E:20108 ||| IN
cancer  ||| S:20108 E:20115 ||| NN
( ||| S:20115 E:20116 ||| -LRB-
average  ||| S:20116 E:20124 ||| JJ
intensity  ||| S:20124 E:20134 ||| NN
33  ||| S:20134 E:20137 ||| CD
for  ||| S:20137 E:20141 ||| IN
cancer  ||| S:20141 E:20148 ||| NN
versus  ||| S:20148 E:20155 ||| IN
25.5  ||| S:20155 E:20160 ||| CD
for  ||| S:20160 E:20172 ||| IN
controls ||| S:20172 E:20180 ||| NNS
) ||| S:20180 E:20181 ||| -RRB-
.  ||| S:20181 E:20191 ||| .
3 ||| S:20191 E:20192 ||| LS
)  ||| S:20192 E:20194 ||| -RRB-
M ||| S:20194 E:20195 ||| NNP
/ ||| S:20195 E:20196 ||| NNP
Z  ||| S:20196 E:20198 ||| NNP
=  ||| S:20198 E:20200 ||| SYM
417.73207  ||| S:20200 E:20210 ||| CD
with  ||| S:20210 E:20215 ||| IN
a  ||| S:20215 E:20217 ||| DT
p-value  ||| S:20217 E:20225 ||| JJ
less  ||| S:20225 E:20230 ||| JJR
than  ||| S:20230 E:20235 ||| IN
6.2  ||| S:20235 E:20239 ||| CD
  ||| S:20239 E:20241 ||| CD
10  ||| S:20241 E:20252 ||| CD
-35 ||| S:20252 E:20255 ||| CD
,  ||| S:20255 E:20257 ||| ,
that  ||| S:20257 E:20262 ||| WDT
corresponds  ||| S:20262 E:20274 ||| VBZ
to  ||| S:20274 E:20277 ||| TO
a  ||| S:20277 E:20279 ||| DT
peak  ||| S:20279 E:20284 ||| NN
that  ||| S:20284 E:20289 ||| WDT
is  ||| S:20289 E:20292 ||| VBZ
decreased  ||| S:20292 E:20302 ||| VBN
in  ||| S:20302 E:20305 ||| IN
cancer  ||| S:20305 E:20320 ||| NN
( ||| S:20320 E:20321 ||| -LRB-
average  ||| S:20321 E:20329 ||| JJ
intensity  ||| S:20329 E:20339 ||| NN
39.5  ||| S:20339 E:20344 ||| CD
for  ||| S:20344 E:20348 ||| IN
cancer  ||| S:20348 E:20355 ||| NN
versus  ||| S:20355 E:20362 ||| IN
47.4  ||| S:20362 E:20367 ||| CD
for  ||| S:20367 E:20379 ||| IN
controls ||| S:20379 E:20387 ||| NNS
)  ||| S:20387 E:20397 ||| -RRB-
The  ||| S:20397 E:20401 ||| DT
identity  ||| S:20401 E:20410 ||| NN
of  ||| S:20410 E:20413 ||| IN
the  ||| S:20413 E:20417 ||| DT
molecules  ||| S:20417 E:20427 ||| JJ
responsible  ||| S:20427 E:20439 ||| JJ
for  ||| S:20439 E:20443 ||| IN
these  ||| S:20443 E:20457 ||| DT
differences  ||| S:20457 E:20469 ||| NNS
cannot  ||| S:20469 E:20476 ||| RB
be  ||| S:20476 E:20479 ||| VB
determined  ||| S:20479 E:20490 ||| VBN
from  ||| S:20490 E:20495 ||| IN
this  ||| S:20495 E:20500 ||| DT
data ||| S:20500 E:20504 ||| NNS
.  ||| S:20504 E:20506 ||| .
However ||| S:20506 E:20513 ||| RB
,  ||| S:20513 E:20523 ||| ,
it  ||| S:20523 E:20526 ||| PRP
is  ||| S:20526 E:20529 ||| VBZ
possible  ||| S:20529 E:20538 ||| JJ
that  ||| S:20538 E:20543 ||| IN
in  ||| S:20543 E:20546 ||| IN
some  ||| S:20546 E:20551 ||| DT
cases  ||| S:20551 E:20557 ||| NNS
they  ||| S:20557 E:20562 ||| PRP
may  ||| S:20562 E:20566 ||| MD
relate  ||| S:20566 E:20573 ||| VB
to  ||| S:20573 E:20576 ||| TO
the  ||| S:20576 E:20588 ||| DT
LPA  ||| S:20588 E:20592 ||| NNP
family  ||| S:20592 E:20599 ||| NN
of  ||| S:20599 E:20602 ||| IN
molecules ||| S:20602 E:20611 ||| NNS
,  ||| S:20611 E:20613 ||| ,
or  ||| S:20613 E:20616 ||| CC
to  ||| S:20616 E:20619 ||| TO
alterations  ||| S:20619 E:20631 ||| VB
in  ||| S:20631 E:20634 ||| IN
proteins  ||| S:20634 E:20643 ||| NNS
that  ||| S:20643 E:20656 ||| IN
bind  ||| S:20656 E:20661 ||| JJ
LPA  ||| S:20661 E:20665 ||| NNP
family  ||| S:20665 E:20672 ||| NN
members ||| S:20672 E:20679 ||| NNS
.  ||| S:20679 E:20689 ||| .
Other  ||| S:20689 E:20695 ||| JJ
explanations  ||| S:20695 E:20708 ||| NNS
for  ||| S:20708 E:20712 ||| IN
the  ||| S:20712 E:20716 ||| DT
presence  ||| S:20716 E:20725 ||| NN
of  ||| S:20725 E:20728 ||| IN
statistically  ||| S:20728 E:20750 ||| JJ
significant  ||| S:20750 E:20762 ||| JJ
bands  ||| S:20762 E:20768 ||| NNS
of  ||| S:20768 E:20771 ||| IN
low  ||| S:20771 E:20775 ||| JJ
M ||| S:20775 E:20776 ||| NNP
/ ||| S:20776 E:20777 ||| NNP
Z  ||| S:20777 E:20779 ||| NNP
include  ||| S:20779 E:20787 ||| VBP
degradation  ||| S:20787 E:20799 ||| JJ
products  ||| S:20799 E:20816 ||| NNS
of  ||| S:20816 E:20819 ||| IN
higher  ||| S:20819 E:20826 ||| JJR
molecular  ||| S:20826 E:20836 ||| JJ
weight  ||| S:20836 E:20843 ||| NN
macromolecules  ||| S:20843 E:20858 ||| NNS
or  ||| S:20858 E:20861 ||| CC
a  ||| S:20861 E:20863 ||| DT
matrix  ||| S:20863 E:20878 ||| JJ
effect ||| S:20878 E:20884 ||| NN
.  ||| S:20884 E:20886 ||| .
For  ||| S:20886 E:20890 ||| IN
example ||| S:20890 E:20897 ||| NN
,  ||| S:20897 E:20899 ||| ,
if  ||| S:20899 E:20902 ||| IN
a  ||| S:20902 E:20904 ||| DT
set  ||| S:20904 E:20908 ||| NN
of  ||| S:20908 E:20911 ||| IN
proteins  ||| S:20911 E:20920 ||| NNS
exist  ||| S:20920 E:20926 ||| VBP
that  ||| S:20926 E:20931 ||| WDT
are  ||| S:20931 E:20943 ||| VBP
expressed  ||| S:20943 E:20953 ||| VBN
at  ||| S:20953 E:20956 ||| IN
different  ||| S:20956 E:20966 ||| JJ
levels  ||| S:20966 E:20973 ||| NNS
between  ||| S:20973 E:20981 ||| IN
cancer  ||| S:20981 E:20988 ||| NN
and  ||| S:20988 E:20992 ||| CC
control  ||| S:20992 E:21008 ||| NN
subjects  ||| S:21008 E:21017 ||| NNS
but  ||| S:21017 E:21021 ||| CC
have  ||| S:21021 E:21026 ||| VB
a  ||| S:21026 E:21028 ||| DT
common  ||| S:21028 E:21035 ||| JJ
domain ||| S:21035 E:21041 ||| NN
,  ||| S:21041 E:21043 ||| ,
then  ||| S:21043 E:21048 ||| RB
a  ||| S:21048 E:21050 ||| DT
common  ||| S:21050 E:21057 ||| JJ
product  ||| S:21057 E:21073 ||| NN
ion  ||| S:21073 E:21077 ||| NN
of  ||| S:21077 E:21080 ||| IN
lower  ||| S:21080 E:21086 ||| JJR
M ||| S:21086 E:21087 ||| NNP
/ ||| S:21087 E:21088 ||| NNP
Z  ||| S:21088 E:21090 ||| NNP
may  ||| S:21090 E:21094 ||| MD
be  ||| S:21094 E:21097 ||| VB
generated  ||| S:21097 E:21107 ||| VBN
that  ||| S:21107 E:21112 ||| WDT
would  ||| S:21112 E:21118 ||| MD
represent  ||| S:21118 E:21128 ||| VB
a  ||| S:21128 E:21138 ||| DT
summation  ||| S:21138 E:21148 ||| NN
of  ||| S:21148 E:21151 ||| IN
all  ||| S:21151 E:21155 ||| PDT
the  ||| S:21155 E:21159 ||| DT
changes  ||| S:21159 E:21167 ||| NNS
in  ||| S:21167 E:21170 ||| IN
expression  ||| S:21170 E:21181 ||| NN
of  ||| S:21181 E:21184 ||| IN
the  ||| S:21184 E:21188 ||| DT
group  ||| S:21188 E:21194 ||| NN
of  ||| S:21194 E:21205 ||| IN
proteins ||| S:21205 E:21213 ||| NNS
,  ||| S:21213 E:21215 ||| ,
and  ||| S:21215 E:21219 ||| CC
might  ||| S:21219 E:21225 ||| MD
thus  ||| S:21225 E:21230 ||| RB
have  ||| S:21230 E:21235 ||| VB
greater  ||| S:21235 E:21243 ||| JJR
statistical  ||| S:21243 E:21263 ||| JJ
significance  ||| S:21263 E:21276 ||| NN
than  ||| S:21276 E:21281 ||| IN
the  ||| S:21281 E:21285 ||| DT
changes  ||| S:21285 E:21293 ||| NNS
associated  ||| S:21293 E:21304 ||| VBN
with  ||| S:21304 E:21309 ||| IN
any  ||| S:21309 E:21313 ||| DT
single  ||| S:21313 E:21328 ||| JJ
high  ||| S:21328 E:21333 ||| JJ
M ||| S:21333 E:21334 ||| NNP
/ ||| S:21334 E:21335 ||| NNP
Z  ||| S:21335 E:21337 ||| NNP
value ||| S:21337 E:21342 ||| NN
.  ||| S:21342 E:21344 ||| .
Similarly ||| S:21344 E:21353 ||| RB
,  ||| S:21353 E:21355 ||| ,
a  ||| S:21355 E:21357 ||| DT
set  ||| S:21357 E:21361 ||| NN
of  ||| S:21361 E:21364 ||| IN
low  ||| S:21364 E:21368 ||| JJ
M ||| S:21368 E:21369 ||| NNP
/ ||| S:21369 E:21370 ||| NNP
Z  ||| S:21370 E:21372 ||| NNP
molecules  ||| S:21372 E:21390 ||| NNS
( ||| S:21390 E:21391 ||| -LRB-
e.g. ||| S:21391 E:21395 ||| NNP
,  ||| S:21395 E:21397 ||| ,
energy-absorbing  ||| S:21397 E:21414 ||| JJ
molecule  ||| S:21414 E:21423 ||| NN
or  ||| S:21423 E:21426 ||| CC
matrix ||| S:21426 E:21432 ||| CD
)  ||| S:21432 E:21434 ||| -RRB-
that  ||| S:21434 E:21439 ||| WDT
interacts  ||| S:21439 E:21457 ||| VBP
differently  ||| S:21457 E:21469 ||| RB
in  ||| S:21469 E:21472 ||| IN
a  ||| S:21472 E:21474 ||| DT
protein  ||| S:21474 E:21482 ||| NN
environment  ||| S:21482 E:21494 ||| NN
that  ||| S:21494 E:21499 ||| WDT
differs  ||| S:21499 E:21507 ||| VBZ
markedly  ||| S:21507 E:21524 ||| RB
between  ||| S:21524 E:21532 ||| IN
cancer  ||| S:21532 E:21539 ||| NN
and  ||| S:21539 E:21543 ||| CC
control  ||| S:21543 E:21551 ||| NN
could  ||| S:21551 E:21557 ||| MD
hypothetically  ||| S:21557 E:21572 ||| RB
generate  ||| S:21572 E:21581 ||| VB
a  ||| S:21581 E:21591 ||| DT
similar  ||| S:21591 E:21599 ||| JJ
phenomenon ||| S:21599 E:21609 ||| NN
.  ||| S:21609 E:21611 ||| .
However ||| S:21611 E:21618 ||| RB
,  ||| S:21618 E:21620 ||| ,
it  ||| S:21620 E:21623 ||| PRP
is  ||| S:21623 E:21626 ||| VBZ
difficult  ||| S:21626 E:21636 ||| JJ
to  ||| S:21636 E:21639 ||| TO
apply  ||| S:21639 E:21645 ||| VB
any  ||| S:21645 E:21657 ||| DT
of  ||| S:21657 E:21660 ||| IN
the  ||| S:21660 E:21664 ||| DT
above  ||| S:21664 E:21670 ||| JJ
explanations  ||| S:21670 E:21683 ||| NNS
to  ||| S:21683 E:21686 ||| TO
the  ||| S:21686 E:21690 ||| DT
very  ||| S:21690 E:21695 ||| RB
low  ||| S:21695 E:21699 ||| JJ
M ||| S:21699 E:21700 ||| NNP
/ ||| S:21700 E:21701 ||| NNP
Z  ||| S:21701 E:21703 ||| NNP
values  ||| S:21703 E:21710 ||| VBZ
such  ||| S:21710 E:21723 ||| JJ
as  ||| S:21723 E:21726 ||| IN
2.7921478  ||| S:21726 E:21736 ||| NNP
and  ||| S:21736 E:21740 ||| CC
245.53704 ||| S:21740 E:21749 ||| NNP
,  ||| S:21749 E:21751 ||| ,
although  ||| S:21751 E:21760 ||| IN
in  ||| S:21760 E:21763 ||| IN
the  ||| S:21763 E:21767 ||| DT
last  ||| S:21767 E:21772 ||| JJ
case  ||| S:21772 E:21777 ||| NN
an  ||| S:21777 E:21788 ||| DT
extremely  ||| S:21788 E:21798 ||| RB
small  ||| S:21798 E:21804 ||| JJ
organic  ||| S:21804 E:21812 ||| JJ
molecule  ||| S:21812 E:21821 ||| NN
is  ||| S:21821 E:21824 ||| VBZ
possible ||| S:21824 E:21832 ||| JJ
.  ||| S:21832 E:21842 ||| .
Alternatively ||| S:21842 E:21855 ||| RB
,  ||| S:21855 E:21857 ||| ,
there  ||| S:21857 E:21863 ||| EX
maybe  ||| S:21863 E:21869 ||| RB
some  ||| S:21869 E:21874 ||| DT
unexpected  ||| S:21874 E:21885 ||| JJ
experimental  ||| S:21885 E:21906 ||| JJ
bias  ||| S:21906 E:21911 ||| NN
or  ||| S:21911 E:21914 ||| CC
systematic  ||| S:21914 E:21925 ||| JJ
error  ||| S:21925 E:21931 ||| NN
that  ||| S:21931 E:21936 ||| IN
accounts  ||| S:21936 E:21945 ||| NNS
for  ||| S:21945 E:21949 ||| IN
low  ||| S:21949 E:21953 ||| JJ
M ||| S:21953 E:21954 ||| NNP
/ ||| S:21954 E:21955 ||| NNP
Z  ||| S:21955 E:21965 ||| NNP
discrimination ||| S:21965 E:21979 ||| NN
.  ||| S:21979 E:21981 ||| .
This  ||| S:21981 E:21986 ||| DT
could  ||| S:21986 E:21992 ||| MD
occur  ||| S:21992 E:21998 ||| VB
at  ||| S:21998 E:22001 ||| IN
any  ||| S:22001 E:22005 ||| DT
experimental  ||| S:22005 E:22018 ||| JJ
step ||| S:22018 E:22022 ||| NN
,  ||| S:22022 E:22032 ||| ,
and  ||| S:22032 E:22036 ||| CC
might  ||| S:22036 E:22042 ||| MD
include  ||| S:22042 E:22050 ||| VB
medication  ||| S:22050 E:22061 ||| NN
or  ||| S:22061 E:22064 ||| CC
lifestyle  ||| S:22064 E:22074 ||| JJ
change  ||| S:22074 E:22081 ||| NN
that  ||| S:22081 E:22094 ||| WDT
occurs  ||| S:22094 E:22101 ||| VBZ
in  ||| S:22101 E:22104 ||| IN
patients  ||| S:22104 E:22113 ||| NNS
who  ||| S:22113 E:22117 ||| WP
learn  ||| S:22117 E:22123 ||| VBP
they  ||| S:22123 E:22128 ||| PRP
have  ||| S:22128 E:22133 ||| VBP
a  ||| S:22133 E:22135 ||| DT
cancer  ||| S:22135 E:22142 ||| NN
diagnosis ||| S:22142 E:22151 ||| NN
,  ||| S:22151 E:22161 ||| ,
variation  ||| S:22161 E:22171 ||| NN
in  ||| S:22171 E:22174 ||| IN
sample  ||| S:22174 E:22181 ||| NN
collection ||| S:22181 E:22191 ||| NN
,  ||| S:22191 E:22193 ||| ,
processing  ||| S:22193 E:22204 ||| NN
and  ||| S:22204 E:22216 ||| CC
preservation ||| S:22216 E:22228 ||| NN
,  ||| S:22228 E:22230 ||| ,
as  ||| S:22230 E:22233 ||| RB
well  ||| S:22233 E:22238 ||| RB
as  ||| S:22238 E:22241 ||| IN
bias  ||| S:22241 E:22246 ||| NN
introduced  ||| S:22246 E:22257 ||| VBN
at  ||| S:22257 E:22260 ||| IN
the  ||| S:22260 E:22264 ||| DT
time  ||| S:22264 E:22269 ||| NN
of  ||| S:22269 E:22280 ||| IN
analysis ||| S:22280 E:22288 ||| NN
.  ||| S:22288 E:22290 ||| .
In  ||| S:22290 E:22293 ||| IN
the  ||| S:22293 E:22297 ||| DT
case  ||| S:22297 E:22302 ||| NN
of  ||| S:22302 E:22305 ||| IN
LPA ||| S:22305 E:22308 ||| NNP
,  ||| S:22308 E:22310 ||| ,
increased  ||| S:22310 E:22320 ||| VBD
plasma  ||| S:22320 E:22327 ||| JJ
levels  ||| S:22327 E:22334 ||| NNS
may  ||| S:22334 E:22346 ||| MD
be  ||| S:22346 E:22349 ||| VB
associated  ||| S:22349 E:22360 ||| VBN
with  ||| S:22360 E:22365 ||| IN
platelet  ||| S:22365 E:22374 ||| JJ
activation ||| S:22374 E:22384 ||| NN
.  ||| S:22384 E:22386 ||| .
Another  ||| S:22386 E:22394 ||| DT
group  ||| S:22394 E:22408 ||| NN
trying  ||| S:22408 E:22415 ||| VBG
to  ||| S:22415 E:22418 ||| TO
repeat  ||| S:22418 E:22425 ||| VB
the  ||| S:22425 E:22429 ||| DT
observations  ||| S:22429 E:22442 ||| NNS
of  ||| S:22442 E:22445 ||| IN
increased  ||| S:22445 E:22455 ||| JJ
levels  ||| S:22455 E:22462 ||| NNS
of  ||| S:22462 E:22473 ||| IN
LPA  ||| S:22473 E:22477 ||| NNP
associated  ||| S:22477 E:22488 ||| VBN
with  ||| S:22488 E:22493 ||| IN
ovarian  ||| S:22493 E:22501 ||| JJ
cancer  ||| S:22501 E:22508 ||| NN
concluded  ||| S:22508 E:22518 ||| VBD
that  ||| S:22518 E:22523 ||| IN
there  ||| S:22523 E:22529 ||| EX
was  ||| S:22529 E:22541 ||| VBD
no  ||| S:22541 E:22544 ||| DT
diagnostic  ||| S:22544 E:22555 ||| JJ
value  ||| S:22555 E:22561 ||| NN
in  ||| S:22561 E:22564 ||| IN
the  ||| S:22564 E:22568 ||| DT
assay ||| S:22568 E:22573 ||| NN
,  ||| S:22573 E:22575 ||| ,
and  ||| S:22575 E:22579 ||| CC
attributed  ||| S:22579 E:22590 ||| VBD
the  ||| S:22590 E:22602 ||| DT
discrepant  ||| S:22602 E:22613 ||| JJ
findings  ||| S:22613 E:22622 ||| NNS
as  ||| S:22622 E:22625 ||| IN
possibly  ||| S:22625 E:22634 ||| RB
related  ||| S:22634 E:22642 ||| VBN
to  ||| S:22642 E:22645 ||| TO
different  ||| S:22645 E:22655 ||| JJ
sample  ||| S:22655 E:22670 ||| NN
centrifugation  ||| S:22670 E:22685 ||| NNS
protocols  ||| S:22685 E:22695 ||| VBP
used  ||| S:22695 E:22700 ||| VBN
by  ||| S:22700 E:22703 ||| IN
the  ||| S:22703 E:22707 ||| DT
two  ||| S:22707 E:22711 ||| CD
groups  ||| S:22711 E:22718 ||| NNS
to  ||| S:22718 E:22721 ||| TO
remove  ||| S:22721 E:22736 ||| VB
platelets  ||| S:22736 E:22746 ||| VBN
from  ||| S:22746 E:22751 ||| IN
the  ||| S:22751 E:22755 ||| DT
samples  ||| S:22755 E:22763 ||| NNS
prior  ||| S:22763 E:22769 ||| RB
to  ||| S:22769 E:22772 ||| TO
analysis  ||| S:22772 E:22781 ||| NN
[  ||| S:22781 E:22783 ||| -LRB-
20  ||| S:22783 E:22786 ||| CD
]  ||| S:22786 E:22788 ||| -RRB-
.  ||| S:22788 E:22798 ||| .
However ||| S:22798 E:22805 ||| RB
,  ||| S:22805 E:22807 ||| ,
LPA  ||| S:22807 E:22811 ||| NNP
continues  ||| S:22811 E:22821 ||| VBZ
to  ||| S:22821 E:22824 ||| TO
be  ||| S:22824 E:22827 ||| VB
actively  ||| S:22827 E:22836 ||| RB
evaluated  ||| S:22836 E:22846 ||| VBN
for  ||| S:22846 E:22850 ||| IN
its  ||| S:22850 E:22862 ||| PRP$
clinical  ||| S:22862 E:22871 ||| JJ
utility  ||| S:22871 E:22879 ||| NN
[  ||| S:22879 E:22881 ||| -LRB-
21  ||| S:22881 E:22884 ||| CD
]  ||| S:22884 E:22886 ||| -RRB-
.  ||| S:22886 E:22910 ||| .
Conclusions  ||| S:22910 E:22930 ||| FW
Serum  ||| S:22930 E:22936 ||| FW
proteomic  ||| S:22936 E:22946 ||| FW
profiling  ||| S:22946 E:22956 ||| FW
is  ||| S:22956 E:22959 ||| VBZ
a  ||| S:22959 E:22961 ||| DT
new  ||| S:22961 E:22965 ||| JJ
approach  ||| S:22965 E:22974 ||| NN
to  ||| S:22974 E:22977 ||| TO
cancer  ||| S:22977 E:22992 ||| NN
diagnosis ||| S:22992 E:23001 ||| NN
.  ||| S:23001 E:23003 ||| .
However  ||| S:23003 E:23011 ||| RB
it  ||| S:23011 E:23014 ||| PRP
confronts  ||| S:23014 E:23024 ||| VBZ
a  ||| S:23024 E:23026 ||| DT
challenging  ||| S:23026 E:23038 ||| JJ
environment ||| S:23038 E:23049 ||| NN
,  ||| S:23049 E:23059 ||| ,
as  ||| S:23059 E:23062 ||| IN
it  ||| S:23062 E:23065 ||| PRP
combines  ||| S:23065 E:23074 ||| VBZ
measurement  ||| S:23074 E:23086 ||| JJ
technologies  ||| S:23086 E:23099 ||| NNS
that  ||| S:23099 E:23104 ||| WDT
are  ||| S:23104 E:23108 ||| VBP
new  ||| S:23108 E:23112 ||| JJ
in  ||| S:23112 E:23115 ||| IN
the  ||| S:23115 E:23127 ||| DT
clinical  ||| S:23127 E:23136 ||| JJ
setting  ||| S:23136 E:23144 ||| NN
with  ||| S:23144 E:23149 ||| IN
novel  ||| S:23149 E:23155 ||| NN
approaches  ||| S:23155 E:23166 ||| NNS
to  ||| S:23166 E:23169 ||| TO
processing  ||| S:23169 E:23180 ||| NN
and  ||| S:23180 E:23192 ||| CC
interpreting  ||| S:23192 E:23205 ||| VBG
high  ||| S:23205 E:23210 ||| JJ
dimensional  ||| S:23210 E:23222 ||| JJ
data ||| S:23222 E:23226 ||| NNS
.  ||| S:23226 E:23228 ||| .
Further ||| S:23228 E:23235 ||| RB
,  ||| S:23235 E:23237 ||| ,
controlling  ||| S:23237 E:23257 ||| VBG
large  ||| S:23257 E:23263 ||| JJ
clinical  ||| S:23263 E:23272 ||| JJ
studies  ||| S:23272 E:23280 ||| NNS
can  ||| S:23280 E:23284 ||| MD
be  ||| S:23284 E:23287 ||| VB
challenging  ||| S:23287 E:23299 ||| VBG
even  ||| S:23299 E:23304 ||| RB
in  ||| S:23304 E:23307 ||| IN
more  ||| S:23307 E:23320 ||| RBR
established  ||| S:23320 E:23332 ||| JJ
settings ||| S:23332 E:23340 ||| NNS
.  ||| S:23340 E:23342 ||| .
Nevertheless ||| S:23342 E:23354 ||| RB
,  ||| S:23354 E:23356 ||| ,
it  ||| S:23356 E:23359 ||| PRP
represents  ||| S:23359 E:23370 ||| VBZ
an  ||| S:23370 E:23381 ||| DT
advance  ||| S:23381 E:23389 ||| NN
in  ||| S:23389 E:23392 ||| IN
the  ||| S:23392 E:23396 ||| DT
ability  ||| S:23396 E:23404 ||| NN
to  ||| S:23404 E:23407 ||| TO
diagnose  ||| S:23407 E:23416 ||| VB
and  ||| S:23416 E:23420 ||| CC
understand  ||| S:23420 E:23431 ||| VB
illness ||| S:23431 E:23438 ||| NN
.  ||| S:23438 E:23448 ||| .
The  ||| S:23448 E:23452 ||| DT
results  ||| S:23452 E:23460 ||| NNS
presented  ||| S:23460 E:23470 ||| VBN
in  ||| S:23470 E:23473 ||| IN
this  ||| S:23473 E:23478 ||| DT
study  ||| S:23478 E:23484 ||| NN
are  ||| S:23484 E:23488 ||| VBP
useful  ||| S:23488 E:23495 ||| JJ
for  ||| S:23495 E:23499 ||| IN
several  ||| S:23499 E:23515 ||| JJ
reasons ||| S:23515 E:23522 ||| NNS
.  ||| S:23522 E:23524 ||| .
First ||| S:23524 E:23529 ||| NNP
,  ||| S:23529 E:23531 ||| ,
in  ||| S:23531 E:23534 ||| IN
regard  ||| S:23534 E:23541 ||| NN
to  ||| S:23541 E:23544 ||| TO
disease  ||| S:23544 E:23552 ||| NN
classification ||| S:23552 E:23566 ||| NN
,  ||| S:23566 E:23576 ||| ,
advanced  ||| S:23576 E:23585 ||| JJ
data  ||| S:23585 E:23590 ||| NN
mining  ||| S:23590 E:23597 ||| NN
techniques  ||| S:23597 E:23608 ||| NNS
should  ||| S:23608 E:23615 ||| MD
be  ||| S:23615 E:23618 ||| VB
benchmarked  ||| S:23618 E:23638 ||| VBN
against  ||| S:23638 E:23646 ||| IN
traditional  ||| S:23646 E:23658 ||| JJ
methods  ||| S:23658 E:23666 ||| NNS
when  ||| S:23666 E:23671 ||| WRB
possible ||| S:23671 E:23679 ||| JJ
.  ||| S:23679 E:23681 ||| .
Further  ||| S:23681 E:23697 ||| RBR
identical  ||| S:23697 E:23707 ||| JJ
training  ||| S:23707 E:23716 ||| NN
sets  ||| S:23716 E:23721 ||| NNS
should  ||| S:23721 E:23728 ||| MD
be  ||| S:23728 E:23731 ||| VB
defined  ||| S:23731 E:23739 ||| VBN
for  ||| S:23739 E:23743 ||| IN
such  ||| S:23743 E:23748 ||| PDT
a  ||| S:23748 E:23758 ||| DT
comparison  ||| S:23758 E:23769 ||| NN
as  ||| S:23769 E:23772 ||| IN
results  ||| S:23772 E:23780 ||| NNS
may  ||| S:23780 E:23784 ||| MD
very  ||| S:23784 E:23789 ||| RB
depending  ||| S:23789 E:23799 ||| VBG
on  ||| S:23799 E:23802 ||| IN
the  ||| S:23802 E:23806 ||| DT
samples  ||| S:23806 E:23822 ||| NNS
chosen  ||| S:23822 E:23829 ||| VBN
for  ||| S:23829 E:23833 ||| IN
inclusion  ||| S:23833 E:23843 ||| NN
in  ||| S:23843 E:23846 ||| IN
the  ||| S:23846 E:23850 ||| DT
training  ||| S:23850 E:23859 ||| NN
set ||| S:23859 E:23862 ||| NN
.  ||| S:23862 E:23864 ||| .
The  ||| S:23864 E:23868 ||| DT
development  ||| S:23868 E:23888 ||| NN
of  ||| S:23888 E:23891 ||| IN
disease  ||| S:23891 E:23899 ||| NN
classifiers  ||| S:23899 E:23911 ||| VBZ
using  ||| S:23911 E:23917 ||| VBG
routine  ||| S:23917 E:23925 ||| JJ
analysis  ||| S:23925 E:23934 ||| NN
proved  ||| S:23934 E:23941 ||| VBD
to  ||| S:23941 E:23944 ||| TO
be  ||| S:23944 E:23955 ||| VB
straightforward ||| S:23955 E:23970 ||| JJ
,  ||| S:23970 E:23972 ||| ,
and  ||| S:23972 E:23976 ||| CC
resulted  ||| S:23976 E:23985 ||| VBD
in  ||| S:23985 E:23988 ||| IN
excellent  ||| S:23988 E:23998 ||| JJ
performance  ||| S:23998 E:24010 ||| NN
in  ||| S:24010 E:24021 ||| IN
both  ||| S:24021 E:24026 ||| PDT
the  ||| S:24026 E:24030 ||| DT
test  ||| S:24030 E:24035 ||| NN
and  ||| S:24035 E:24039 ||| CC
training  ||| S:24039 E:24048 ||| NN
sets  ||| S:24048 E:24053 ||| NNS
( ||| S:24053 E:24054 ||| -LRB-
e.g.  ||| S:24054 E:24059 ||| CD
100 ||| S:24059 E:24062 ||| CD
%  ||| S:24062 E:24064 ||| NN
sensitivity  ||| S:24064 E:24076 ||| NN
and  ||| S:24076 E:24088 ||| CC
specificity  ||| S:24088 E:24100 ||| NN
for  ||| S:24100 E:24104 ||| IN
Rules  ||| S:24104 E:24110 ||| NNP
1  ||| S:24110 E:24112 ||| CD
and  ||| S:24112 E:24116 ||| CC
3  ||| S:24116 E:24118 ||| CD
in  ||| S:24118 E:24121 ||| IN
the  ||| S:24121 E:24125 ||| DT
first  ||| S:24125 E:24131 ||| JJ
training  ||| S:24131 E:24140 ||| NN
set ||| S:24140 E:24143 ||| NN
) ||| S:24143 E:24144 ||| -RRB-
.  ||| S:24144 E:24154 ||| .
In  ||| S:24154 E:24157 ||| IN
particular  ||| S:24157 E:24168 ||| JJ
these  ||| S:24168 E:24174 ||| DT
preliminary  ||| S:24174 E:24186 ||| JJ
data  ||| S:24186 E:24191 ||| NNS
suggest  ||| S:24191 E:24199 ||| VBP
that  ||| S:24199 E:24204 ||| IN
these  ||| S:24204 E:24210 ||| DT
two  ||| S:24210 E:24222 ||| CD
rules  ||| S:24222 E:24228 ||| NNS
may  ||| S:24228 E:24232 ||| MD
be  ||| S:24232 E:24235 ||| VB
specific  ||| S:24235 E:24244 ||| JJ
enough  ||| S:24244 E:24251 ||| JJ
to  ||| S:24251 E:24254 ||| TO
scale  ||| S:24254 E:24260 ||| VB
to  ||| S:24260 E:24263 ||| TO
larger  ||| S:24263 E:24270 ||| JJR
population  ||| S:24270 E:24289 ||| NN
trials  ||| S:24289 E:24296 ||| NNS
without  ||| S:24296 E:24304 ||| IN
generating  ||| S:24304 E:24315 ||| VBG
an  ||| S:24315 E:24318 ||| DT
unacceptably  ||| S:24318 E:24331 ||| JJ
high  ||| S:24331 E:24336 ||| JJ
false  ||| S:24336 E:24350 ||| JJ
positive  ||| S:24350 E:24359 ||| JJ
rate ||| S:24359 E:24363 ||| NN
.  ||| S:24363 E:24365 ||| .
This  ||| S:24365 E:24370 ||| DT
study  ||| S:24370 E:24376 ||| NN
also  ||| S:24376 E:24381 ||| RB
confirms  ||| S:24381 E:24390 ||| VBZ
that  ||| S:24390 E:24395 ||| IN
a  ||| S:24395 E:24397 ||| DT
classifier  ||| S:24397 E:24416 ||| NN
could  ||| S:24416 E:24422 ||| MD
be  ||| S:24422 E:24425 ||| VB
developed  ||| S:24425 E:24435 ||| VBN
with  ||| S:24435 E:24440 ||| IN
M ||| S:24440 E:24441 ||| NNP
/ ||| S:24441 E:24442 ||| NNP
Z  ||| S:24442 E:24444 ||| NNP
values  ||| S:24444 E:24451 ||| VBZ
greater  ||| S:24451 E:24459 ||| JJR
than  ||| S:24459 E:24464 ||| IN
2000 ||| S:24464 E:24468 ||| CD
.  ||| S:24468 E:24470 ||| .
This  ||| S:24470 E:24483 ||| DT
indicates  ||| S:24483 E:24493 ||| VBZ
that  ||| S:24493 E:24498 ||| DT
information  ||| S:24498 E:24510 ||| NN
regarding  ||| S:24510 E:24520 ||| VBG
the  ||| S:24520 E:24524 ||| DT
difference  ||| S:24524 E:24535 ||| NN
between  ||| S:24535 E:24551 ||| IN
cancer  ||| S:24551 E:24558 ||| NN
and  ||| S:24558 E:24562 ||| CC
control  ||| S:24562 E:24570 ||| NN
is  ||| S:24570 E:24573 ||| VBZ
present  ||| S:24573 E:24581 ||| JJ
throughout  ||| S:24581 E:24592 ||| IN
the  ||| S:24592 E:24596 ||| DT
entire  ||| S:24596 E:24603 ||| JJ
M ||| S:24603 E:24604 ||| NNP
/ ||| S:24604 E:24605 ||| NNP
Z  ||| S:24605 E:24615 ||| NNP
region  ||| S:24615 E:24622 ||| NN
studied ||| S:24622 E:24629 ||| VBD
,  ||| S:24629 E:24631 ||| ,
a  ||| S:24631 E:24633 ||| DT
result  ||| S:24633 E:24640 ||| NN
entirely  ||| S:24640 E:24649 ||| RB
consistent  ||| S:24649 E:24660 ||| JJ
with  ||| S:24660 E:24665 ||| IN
the  ||| S:24665 E:24677 ||| DT
observed  ||| S:24677 E:24686 ||| JJ
Wilcoxon  ||| S:24686 E:24695 ||| JJ
test  ||| S:24695 E:24700 ||| NN
p-values ||| S:24700 E:24708 ||| NN
.  ||| S:24708 E:24710 ||| .
Secondly ||| S:24710 E:24718 ||| RB
,  ||| S:24718 E:24720 ||| ,
routine  ||| S:24720 E:24728 ||| JJ
analysis  ||| S:24728 E:24745 ||| NN
allows  ||| S:24745 E:24752 ||| VBZ
investigators  ||| S:24752 E:24766 ||| NNS
to  ||| S:24766 E:24769 ||| TO
rapidly  ||| S:24769 E:24777 ||| RB
review  ||| S:24777 E:24784 ||| VB
the  ||| S:24784 E:24788 ||| DT
data  ||| S:24788 E:24793 ||| NNS
for  ||| S:24793 E:24797 ||| IN
their  ||| S:24797 E:24811 ||| PRP$
general  ||| S:24811 E:24819 ||| JJ
trends ||| S:24819 E:24825 ||| NNS
,  ||| S:24825 E:24827 ||| ,
and  ||| S:24827 E:24831 ||| CC
correlate  ||| S:24831 E:24841 ||| VBG
the  ||| S:24841 E:24845 ||| DT
findings  ||| S:24845 E:24854 ||| NNS
with  ||| S:24854 E:24859 ||| IN
other  ||| S:24859 E:24873 ||| JJ
information ||| S:24873 E:24884 ||| NN
.  ||| S:24884 E:24886 ||| .
The  ||| S:24886 E:24890 ||| DT
findings  ||| S:24890 E:24899 ||| NNS
of  ||| S:24899 E:24902 ||| IN
significant  ||| S:24902 E:24914 ||| JJ
discrimination  ||| S:24914 E:24937 ||| NN
between  ||| S:24937 E:24945 ||| IN
cancer  ||| S:24945 E:24952 ||| NN
and  ||| S:24952 E:24956 ||| CC
control  ||| S:24956 E:24964 ||| NN
groups  ||| S:24964 E:24971 ||| NNS
at  ||| S:24971 E:24974 ||| IN
low  ||| S:24974 E:24978 ||| JJ
M ||| S:24978 E:24979 ||| NNP
/ ||| S:24979 E:24980 ||| NNP
Z  ||| S:24980 E:24982 ||| NNP
values  ||| S:24982 E:24997 ||| NNS
indicates  ||| S:24997 E:25007 ||| VBZ
that  ||| S:25007 E:25012 ||| DT
attention  ||| S:25012 E:25022 ||| NN
should  ||| S:25022 E:25029 ||| MD
be  ||| S:25029 E:25032 ||| VB
focused  ||| S:25032 E:25040 ||| VBN
in  ||| S:25040 E:25043 ||| IN
this  ||| S:25043 E:25048 ||| DT
region ||| S:25048 E:25054 ||| NN
.  ||| S:25054 E:25064 ||| .
In  ||| S:25064 E:25067 ||| IN
particular ||| S:25067 E:25077 ||| JJ
,  ||| S:25077 E:25079 ||| ,
if  ||| S:25079 E:25082 ||| IN
experimental  ||| S:25082 E:25095 ||| JJ
bias  ||| S:25095 E:25100 ||| NN
and  ||| S:25100 E:25104 ||| CC
noise  ||| S:25104 E:25110 ||| NN
effects  ||| S:25110 E:25118 ||| NNS
can  ||| S:25118 E:25130 ||| MD
be  ||| S:25130 E:25133 ||| VB
excluded ||| S:25133 E:25141 ||| VBN
,  ||| S:25141 E:25143 ||| ,
this  ||| S:25143 E:25148 ||| DT
region  ||| S:25148 E:25155 ||| NN
may  ||| S:25155 E:25159 ||| MD
prove  ||| S:25159 E:25165 ||| VB
to  ||| S:25165 E:25168 ||| TO
offer  ||| S:25168 E:25174 ||| VB
the  ||| S:25174 E:25178 ||| DT
optimum  ||| S:25178 E:25186 ||| NN
for  ||| S:25186 E:25198 ||| IN
ovarian  ||| S:25198 E:25206 ||| JJ
cancer  ||| S:25206 E:25213 ||| NN
diagnostic  ||| S:25213 E:25224 ||| JJ
test  ||| S:25224 E:25229 ||| NN
development ||| S:25229 E:25240 ||| NN
.  ||| S:25240 E:25242 ||| .
On  ||| S:25242 E:25245 ||| IN
the  ||| S:25245 E:25249 ||| DT
other  ||| S:25249 E:25263 ||| JJ
hand ||| S:25263 E:25267 ||| NN
,  ||| S:25267 E:25269 ||| ,
if  ||| S:25269 E:25272 ||| IN
bias  ||| S:25272 E:25277 ||| NN
cannot  ||| S:25277 E:25284 ||| RB
be  ||| S:25284 E:25287 ||| VB
excluded ||| S:25287 E:25295 ||| VBN
,  ||| S:25295 E:25297 ||| ,
the  ||| S:25297 E:25301 ||| DT
possibility  ||| S:25301 E:25313 ||| NN
must  ||| S:25313 E:25318 ||| MD
be  ||| S:25318 E:25329 ||| VB
entertained  ||| S:25329 E:25341 ||| VBN
that  ||| S:25341 E:25346 ||| IN
higher  ||| S:25346 E:25353 ||| JJR
M ||| S:25353 E:25354 ||| NNP
/ ||| S:25354 E:25355 ||| NNP
Z  ||| S:25355 E:25357 ||| NNP
values  ||| S:25357 E:25364 ||| NNS
may  ||| S:25364 E:25368 ||| MD
also  ||| S:25368 E:25373 ||| RB
have  ||| S:25373 E:25378 ||| VBP
been  ||| S:25378 E:25391 ||| VBN
similarly  ||| S:25391 E:25401 ||| RB
affected ||| S:25401 E:25409 ||| VBN
.  ||| S:25409 E:25411 ||| .
In  ||| S:25411 E:25414 ||| IN
order  ||| S:25414 E:25420 ||| NN
to  ||| S:25420 E:25423 ||| TO
address  ||| S:25423 E:25431 ||| VB
these  ||| S:25431 E:25437 ||| DT
issues ||| S:25437 E:25443 ||| NNS
,  ||| S:25443 E:25453 ||| ,
consideration  ||| S:25453 E:25467 ||| NN
may  ||| S:25467 E:25471 ||| MD
be  ||| S:25471 E:25474 ||| VB
given  ||| S:25474 E:25480 ||| VBN
to  ||| S:25480 E:25483 ||| TO
using  ||| S:25483 E:25489 ||| VBG
mass  ||| S:25489 E:25494 ||| JJ
spectrometry  ||| S:25494 E:25515 ||| JJ
methods  ||| S:25515 E:25523 ||| NNS
with  ||| S:25523 E:25528 ||| IN
increased  ||| S:25528 E:25538 ||| JJ
sensitivity  ||| S:25538 E:25550 ||| NN
in  ||| S:25550 E:25553 ||| IN
the  ||| S:25553 E:25557 ||| DT
low  ||| S:25557 E:25561 ||| JJ
M ||| S:25561 E:25562 ||| NNP
/ ||| S:25562 E:25563 ||| NNP
Z  ||| S:25563 E:25565 ||| NNP
region ||| S:25565 E:25571 ||| NN
.  ||| S:25571 E:25581 ||| .
The  ||| S:25581 E:25585 ||| DT
experimental  ||| S:25585 E:25598 ||| JJ
conditions  ||| S:25598 E:25609 ||| NNS
used  ||| S:25609 E:25614 ||| VBN
to  ||| S:25614 E:25617 ||| TO
physically  ||| S:25617 E:25628 ||| VB
bind  ||| S:25628 E:25633 ||| VBN
the  ||| S:25633 E:25645 ||| DT
serum  ||| S:25645 E:25651 ||| JJ
samples  ||| S:25651 E:25659 ||| NNS
to  ||| S:25659 E:25662 ||| TO
the  ||| S:25662 E:25666 ||| DT
chip  ||| S:25666 E:25671 ||| NN
prior  ||| S:25671 E:25677 ||| RB
to  ||| S:25677 E:25680 ||| TO
analysis  ||| S:25680 E:25689 ||| NN
may  ||| S:25689 E:25693 ||| MD
also  ||| S:25693 E:25698 ||| RB
prove  ||| S:25698 E:25712 ||| VB
critical ||| S:25712 E:25720 ||| JJ
,  ||| S:25720 E:25722 ||| ,
and  ||| S:25722 E:25726 ||| CC
should  ||| S:25726 E:25733 ||| MD
be  ||| S:25733 E:25736 ||| VB
consistent  ||| S:25736 E:25747 ||| JJ
with  ||| S:25747 E:25752 ||| IN
those  ||| S:25752 E:25758 ||| DT
used  ||| S:25758 E:25763 ||| VBN
in  ||| S:25763 E:25774 ||| IN
collecting  ||| S:25774 E:25785 ||| VBG
the  ||| S:25785 E:25789 ||| DT
current  ||| S:25789 E:25797 ||| JJ
data  ||| S:25797 E:25802 ||| NNS
set ||| S:25802 E:25805 ||| VBN
.  ||| S:25805 E:25807 ||| .
Also ||| S:25807 E:25811 ||| RB
,  ||| S:25811 E:25813 ||| ,
the  ||| S:25813 E:25817 ||| DT
possibility  ||| S:25817 E:25829 ||| NN
that  ||| S:25829 E:25842 ||| IN
the  ||| S:25842 E:25846 ||| DT
changes  ||| S:25846 E:25854 ||| NNS
in  ||| S:25854 E:25857 ||| IN
the  ||| S:25857 E:25861 ||| DT
low  ||| S:25861 E:25865 ||| JJ
M ||| S:25865 E:25866 ||| NNP
/ ||| S:25866 E:25867 ||| NNP
Z  ||| S:25867 E:25869 ||| NNP
region  ||| S:25869 E:25876 ||| NN
may  ||| S:25876 E:25880 ||| MD
represent  ||| S:25880 E:25890 ||| VB
an  ||| S:25890 E:25893 ||| DT
additive  ||| S:25893 E:25910 ||| JJ
effect  ||| S:25910 E:25917 ||| NN
caused  ||| S:25917 E:25924 ||| VBN
by  ||| S:25924 E:25927 ||| IN
differing  ||| S:25927 E:25937 ||| VBG
protein  ||| S:25937 E:25945 ||| NN
environments  ||| S:25945 E:25958 ||| NNS
between  ||| S:25958 E:25974 ||| IN
cancer  ||| S:25974 E:25981 ||| NN
and  ||| S:25981 E:25985 ||| CC
normal  ||| S:25985 E:25992 ||| JJ
may  ||| S:25992 E:25996 ||| MD
be  ||| S:25996 E:25999 ||| VB
approached  ||| S:25999 E:26010 ||| VBN
by  ||| S:26010 E:26013 ||| IN
intentionally  ||| S:26013 E:26035 ||| RB
spiking  ||| S:26035 E:26043 ||| JJ
samples  ||| S:26043 E:26051 ||| NNS
with  ||| S:26051 E:26056 ||| IN
panels  ||| S:26056 E:26063 ||| NNS
of  ||| S:26063 E:26066 ||| IN
known  ||| S:26066 E:26072 ||| JJ
proteins ||| S:26072 E:26080 ||| NNS
,  ||| S:26080 E:26082 ||| ,
and  ||| S:26082 E:26094 ||| CC
determining  ||| S:26094 E:26106 ||| VBG
if  ||| S:26106 E:26109 ||| IN
there  ||| S:26109 E:26115 ||| EX
is  ||| S:26115 E:26118 ||| VBZ
an  ||| S:26118 E:26121 ||| DT
effect  ||| S:26121 E:26128 ||| NN
on  ||| S:26128 E:26131 ||| IN
the  ||| S:26131 E:26135 ||| DT
spectra  ||| S:26135 E:26143 ||| NN
in  ||| S:26143 E:26146 ||| IN
the  ||| S:26146 E:26150 ||| DT
low  ||| S:26150 E:26162 ||| JJ
M ||| S:26162 E:26163 ||| NNP
/ ||| S:26163 E:26164 ||| NNP
Z  ||| S:26164 E:26166 ||| NNP
region ||| S:26166 E:26172 ||| NN
.  ||| S:26172 E:26174 ||| .
The  ||| S:26174 E:26178 ||| DT
use  ||| S:26178 E:26182 ||| NN
of  ||| S:26182 E:26185 ||| IN
internal  ||| S:26185 E:26194 ||| JJ
standards  ||| S:26194 E:26204 ||| NNS
to  ||| S:26204 E:26207 ||| TO
normalize  ||| S:26207 E:26217 ||| VB
this  ||| S:26217 E:26230 ||| DT
type  ||| S:26230 E:26235 ||| NN
of  ||| S:26235 E:26238 ||| IN
experimental  ||| S:26238 E:26251 ||| JJ
system  ||| S:26251 E:26258 ||| NN
in  ||| S:26258 E:26261 ||| IN
general  ||| S:26261 E:26269 ||| NN
may  ||| S:26269 E:26273 ||| MD
also  ||| S:26273 E:26278 ||| RB
be  ||| S:26278 E:26289 ||| VB
considered ||| S:26289 E:26299 ||| VBN
.  ||| S:26299 E:26301 ||| .
As  ||| S:26301 E:26304 ||| RB
with  ||| S:26304 E:26309 ||| IN
all  ||| S:26309 E:26313 ||| DT
clinical  ||| S:26313 E:26322 ||| JJ
test  ||| S:26322 E:26327 ||| NN
development ||| S:26327 E:26338 ||| NN
,  ||| S:26338 E:26348 ||| ,
confirmation  ||| S:26348 E:26361 ||| NN
of  ||| S:26361 E:26364 ||| IN
results  ||| S:26364 E:26372 ||| NNS
in  ||| S:26372 E:26375 ||| IN
independent  ||| S:26375 E:26387 ||| JJ
laboratories  ||| S:26387 E:26400 ||| NNS
running  ||| S:26400 E:26416 ||| VBG
blinded  ||| S:26416 E:26424 ||| JJ
samples  ||| S:26424 E:26432 ||| NNS
will  ||| S:26432 E:26437 ||| MD
remain  ||| S:26437 E:26444 ||| VB
the  ||| S:26444 E:26448 ||| DT
gold  ||| S:26448 E:26453 ||| NN
standard  ||| S:26453 E:26462 ||| NN
in  ||| S:26462 E:26465 ||| IN
ruling  ||| S:26465 E:26472 ||| VBG
out  ||| S:26472 E:26484 ||| RP
the  ||| S:26484 E:26488 ||| DT
possible  ||| S:26488 E:26497 ||| JJ
effects  ||| S:26497 E:26505 ||| NNS
of  ||| S:26505 E:26508 ||| IN
bias ||| S:26508 E:26512 ||| NN
,  ||| S:26512 E:26514 ||| ,
unless  ||| S:26514 E:26521 ||| IN
the  ||| S:26521 E:26525 ||| DT
sample  ||| S:26525 E:26532 ||| NN
set  ||| S:26532 E:26536 ||| VBD
itself  ||| S:26536 E:26551 ||| PRP
contains  ||| S:26551 E:26560 ||| VBZ
the  ||| S:26560 E:26564 ||| DT
bias ||| S:26564 E:26568 ||| NN
.  ||| S:26568 E:26570 ||| .
Particular  ||| S:26570 E:26581 ||| JJ
attention  ||| S:26581 E:26591 ||| NN
should  ||| S:26591 E:26598 ||| MD
be  ||| S:26598 E:26601 ||| VB
paid  ||| S:26601 E:26606 ||| VBN
to  ||| S:26606 E:26617 ||| TO
pre-analytic  ||| S:26617 E:26630 ||| JJ
causes  ||| S:26630 E:26637 ||| NNS
of  ||| S:26637 E:26640 ||| IN
bias  ||| S:26640 E:26645 ||| NN
that  ||| S:26645 E:26650 ||| WDT
may  ||| S:26650 E:26654 ||| MD
influence  ||| S:26654 E:26664 ||| VB
the  ||| S:26664 E:26668 ||| DT
serum  ||| S:26668 E:26682 ||| JJ
proteome ||| S:26682 E:26690 ||| NN
.  ||| S:26690 E:26692 ||| .
In  ||| S:26692 E:26695 ||| IN
particular  ||| S:26695 E:26706 ||| JJ
the  ||| S:26706 E:26710 ||| DT
coagulation  ||| S:26710 E:26722 ||| NN
and  ||| S:26722 E:26726 ||| CC
complement  ||| S:26726 E:26745 ||| JJ
systems  ||| S:26745 E:26753 ||| NNS
should  ||| S:26753 E:26760 ||| MD
be  ||| S:26760 E:26763 ||| VB
considered  ||| S:26763 E:26774 ||| VBN
as  ||| S:26774 E:26777 ||| IN
potential  ||| S:26777 E:26787 ||| JJ
sources  ||| S:26787 E:26795 ||| NNS
of  ||| S:26795 E:26798 ||| IN
noise  ||| S:26798 E:26812 ||| NN
in  ||| S:26812 E:26815 ||| IN
this  ||| S:26815 E:26820 ||| DT
context ||| S:26820 E:26827 ||| NN
,  ||| S:26827 E:26829 ||| ,
as  ||| S:26829 E:26832 ||| IN
both  ||| S:26832 E:26837 ||| DT
are  ||| S:26837 E:26841 ||| VBP
activated  ||| S:26841 E:26851 ||| VBN
during  ||| S:26851 E:26858 ||| IN
serum  ||| S:26858 E:26864 ||| JJ
sample  ||| S:26864 E:26879 ||| NN
collection  ||| S:26879 E:26890 ||| NN
and  ||| S:26890 E:26894 ||| CC
generate  ||| S:26894 E:26903 ||| VB
low  ||| S:26903 E:26907 ||| JJ
molecular  ||| S:26907 E:26917 ||| JJ
weight  ||| S:26917 E:26924 ||| NN
products ||| S:26924 E:26932 ||| NNS
.  ||| S:26932 E:26942 ||| .
These  ||| S:26942 E:26948 ||| DT
products  ||| S:26948 E:26957 ||| NNS
are  ||| S:26957 E:26961 ||| VBP
undesirable  ||| S:26961 E:26973 ||| VBN
for  ||| S:26973 E:26977 ||| IN
two  ||| S:26977 E:26981 ||| CD
reasons ||| S:26981 E:26988 ||| NNS
.  ||| S:26988 E:26990 ||| .
First ||| S:26990 E:26995 ||| NNP
,  ||| S:26995 E:26997 ||| ,
if  ||| S:26997 E:27000 ||| IN
a  ||| S:27000 E:27010 ||| DT
putative  ||| S:27010 E:27019 ||| JJ
tumor  ||| S:27019 E:27025 ||| NN
biomarker  ||| S:27025 E:27035 ||| NNS
( ||| S:27035 E:27036 ||| -LRB-
e.g.  ||| S:27036 E:27041 ||| NNP
LPA ||| S:27041 E:27044 ||| NNP
)  ||| S:27044 E:27046 ||| -RRB-
is  ||| S:27046 E:27049 ||| VBZ
a  ||| S:27049 E:27051 ||| DT
member  ||| S:27051 E:27058 ||| NN
of  ||| S:27058 E:27061 ||| IN
a  ||| S:27061 E:27071 ||| DT
pathway  ||| S:27071 E:27079 ||| NN
altered  ||| S:27079 E:27087 ||| VBN
during  ||| S:27087 E:27094 ||| IN
serum  ||| S:27094 E:27100 ||| JJ
sample  ||| S:27100 E:27107 ||| NN
collection ||| S:27107 E:27117 ||| NN
,  ||| S:27117 E:27119 ||| ,
changes  ||| S:27119 E:27135 ||| NNS
between  ||| S:27135 E:27143 ||| IN
plasma  ||| S:27143 E:27150 ||| JJ
levels  ||| S:27150 E:27157 ||| NNS
of  ||| S:27157 E:27160 ||| IN
cancer  ||| S:27160 E:27167 ||| NN
and  ||| S:27167 E:27171 ||| CC
control  ||| S:27171 E:27179 ||| NN
subjects  ||| S:27179 E:27188 ||| NNS
may  ||| S:27188 E:27192 ||| MD
be  ||| S:27192 E:27203 ||| VB
obscured ||| S:27203 E:27211 ||| NNS
.  ||| S:27211 E:27213 ||| .
Secondly ||| S:27213 E:27221 ||| RB
,  ||| S:27221 E:27223 ||| ,
the  ||| S:27223 E:27227 ||| DT
generation  ||| S:27227 E:27238 ||| NN
of  ||| S:27238 E:27241 ||| IN
activation  ||| S:27241 E:27252 ||| JJ
products  ||| S:27252 E:27269 ||| NNS
may  ||| S:27269 E:27273 ||| MD
simply  ||| S:27273 E:27280 ||| RB
complicate  ||| S:27280 E:27291 ||| VB
the  ||| S:27291 E:27295 ||| DT
spectrum ||| S:27295 E:27303 ||| NN
.  ||| S:27303 E:27305 ||| .
Also ||| S:27305 E:27309 ||| RB
,  ||| S:27309 E:27311 ||| ,
sample  ||| S:27311 E:27318 ||| NN
collection  ||| S:27318 E:27337 ||| NN
practices  ||| S:27337 E:27347 ||| NNS
should  ||| S:27347 E:27354 ||| MD
be  ||| S:27354 E:27357 ||| VB
rigorously  ||| S:27357 E:27368 ||| RB
defined ||| S:27368 E:27375 ||| VBN
,  ||| S:27375 E:27377 ||| ,
and  ||| S:27377 E:27381 ||| CC
include  ||| S:27381 E:27397 ||| VBP
submitting  ||| S:27397 E:27408 ||| VBG
matched  ||| S:27408 E:27416 ||| VBN
control  ||| S:27416 E:27424 ||| NN
and  ||| S:27424 E:27428 ||| CC
cancer  ||| S:27428 E:27435 ||| NN
samples  ||| S:27435 E:27443 ||| NNS
from  ||| S:27443 E:27448 ||| IN
all  ||| S:27448 E:27460 ||| DT
centers  ||| S:27460 E:27468 ||| NNS
participating  ||| S:27468 E:27482 ||| VBG
in  ||| S:27482 E:27485 ||| IN
the  ||| S:27485 E:27489 ||| DT
study ||| S:27489 E:27494 ||| NN
.  ||| S:27494 E:27496 ||| .
Matching  ||| S:27496 E:27505 ||| VBG
for  ||| S:27505 E:27509 ||| IN
age  ||| S:27509 E:27513 ||| NN
and  ||| S:27513 E:27525 ||| CC
menopausal  ||| S:27525 E:27536 ||| JJ
status  ||| S:27536 E:27543 ||| NN
should  ||| S:27543 E:27550 ||| MD
be  ||| S:27550 E:27553 ||| VB
considered ||| S:27553 E:27563 ||| VBN
.  ||| S:27563 E:27565 ||| .
For  ||| S:27565 E:27569 ||| IN
example ||| S:27569 E:27576 ||| NN
,  ||| S:27576 E:27578 ||| ,
in  ||| S:27578 E:27581 ||| IN
the  ||| S:27581 E:27593 ||| DT
data  ||| S:27593 E:27598 ||| NNS
set  ||| S:27598 E:27602 ||| VBD
used  ||| S:27602 E:27607 ||| VBN
in  ||| S:27607 E:27610 ||| IN
this  ||| S:27610 E:27615 ||| DT
study ||| S:27615 E:27620 ||| NN
,  ||| S:27620 E:27622 ||| ,
the  ||| S:27622 E:27626 ||| DT
mean  ||| S:27626 E:27631 ||| JJ
age  ||| S:27631 E:27635 ||| NN
of  ||| S:27635 E:27638 ||| IN
the  ||| S:27638 E:27642 ||| DT
control  ||| S:27642 E:27658 ||| NN
group  ||| S:27658 E:27664 ||| NN
was  ||| S:27664 E:27668 ||| VBD
47  ||| S:27668 E:27671 ||| CD
years  ||| S:27671 E:27677 ||| NNS
and  ||| S:27677 E:27681 ||| CC
the  ||| S:27681 E:27685 ||| DT
cancer  ||| S:27685 E:27692 ||| NN
group  ||| S:27692 E:27698 ||| NN
60  ||| S:27698 E:27701 ||| CD
years ||| S:27701 E:27706 ||| NNS
.  ||| S:27706 E:27708 ||| .
It  ||| S:27708 E:27711 ||| PRP
is  ||| S:27711 E:27722 ||| VBZ
noteworthy  ||| S:27722 E:27733 ||| VBN
that  ||| S:27733 E:27738 ||| IN
the  ||| S:27738 E:27742 ||| DT
average  ||| S:27742 E:27750 ||| JJ
age  ||| S:27750 E:27754 ||| NN
of  ||| S:27754 E:27757 ||| IN
menopause  ||| S:27757 E:27767 ||| NN
is  ||| S:27767 E:27778 ||| VBZ
approximately  ||| S:27778 E:27792 ||| RB
51  ||| S:27792 E:27795 ||| CD
years  ||| S:27795 E:27801 ||| NNS
[  ||| S:27801 E:27803 ||| -LRB-
22  ||| S:27803 E:27806 ||| CD
]  ||| S:27806 E:27808 ||| -RRB-
.  ||| S:27808 E:27810 ||| .
This  ||| S:27810 E:27815 ||| DT
may  ||| S:27815 E:27819 ||| MD
introduce  ||| S:27819 E:27829 ||| VB
a  ||| S:27829 E:27831 ||| DT
bias  ||| S:27831 E:27844 ||| NN
in  ||| S:27844 E:27847 ||| IN
the  ||| S:27847 E:27851 ||| DT
results  ||| S:27851 E:27859 ||| NNS
reported  ||| S:27859 E:27868 ||| VBD
in  ||| S:27868 E:27871 ||| IN
this  ||| S:27871 E:27876 ||| DT
study  ||| S:27876 E:27882 ||| NN
as  ||| S:27882 E:27885 ||| IN
well  ||| S:27885 E:27890 ||| RB
as  ||| S:27890 E:27893 ||| IN
all  ||| S:27893 E:27897 ||| DT
others  ||| S:27897 E:27912 ||| NNS
derived  ||| S:27912 E:27920 ||| VBN
from  ||| S:27920 E:27925 ||| IN
this  ||| S:27925 E:27930 ||| DT
dataset ||| S:27930 E:27937 ||| NN
.  ||| S:27937 E:27939 ||| .
Finally ||| S:27939 E:27946 ||| RB
,  ||| S:27946 E:27948 ||| ,
the  ||| S:27948 E:27952 ||| DT
steps  ||| S:27952 E:27958 ||| NNS
associated  ||| S:27958 E:27977 ||| VBN
with  ||| S:27977 E:27982 ||| IN
sample  ||| S:27982 E:27989 ||| NN
collection ||| S:27989 E:27999 ||| NN
,  ||| S:27999 E:28001 ||| ,
processing ||| S:28001 E:28011 ||| NN
,  ||| S:28011 E:28013 ||| ,
and  ||| S:28013 E:28017 ||| CC
binding  ||| S:28017 E:28025 ||| VBG
to  ||| S:28025 E:28028 ||| TO
the  ||| S:28028 E:28032 ||| DT
chip  ||| S:28032 E:28045 ||| NN
may  ||| S:28045 E:28049 ||| MD
represent  ||| S:28049 E:28059 ||| VB
a  ||| S:28059 E:28061 ||| DT
particularly  ||| S:28061 E:28074 ||| RB
fertile  ||| S:28074 E:28082 ||| JJ
area  ||| S:28082 E:28087 ||| NN
for  ||| S:28087 E:28091 ||| IN
research ||| S:28091 E:28099 ||| NN
.  ||| S:28099 E:28101 ||| .
Any  ||| S:28101 E:28113 ||| DT
combination  ||| S:28113 E:28125 ||| NN
of  ||| S:28125 E:28128 ||| IN
such  ||| S:28128 E:28133 ||| JJ
steps  ||| S:28133 E:28139 ||| NNS
may  ||| S:28139 E:28143 ||| MD
significantly  ||| S:28143 E:28157 ||| RB
alter  ||| S:28157 E:28163 ||| VB
the  ||| S:28163 E:28175 ||| DT
molecular  ||| S:28175 E:28185 ||| JJ
subset  ||| S:28185 E:28192 ||| NN
of  ||| S:28192 E:28195 ||| IN
the  ||| S:28195 E:28199 ||| DT
sample  ||| S:28199 E:28206 ||| NN
that  ||| S:28206 E:28211 ||| WDT
can  ||| S:28211 E:28215 ||| MD
be  ||| S:28215 E:28218 ||| VB
successfully  ||| S:28218 E:28239 ||| RB
analyzed ||| S:28239 E:28247 ||| VBD
.  ||| S:28247 E:28257 ||| .
However ||| S:28257 E:28264 ||| RB
,  ||| S:28264 E:28266 ||| ,
the  ||| S:28266 E:28270 ||| DT
ability  ||| S:28270 E:28278 ||| NN
to  ||| S:28278 E:28281 ||| TO
discriminate  ||| S:28281 E:28294 ||| VB
between  ||| S:28294 E:28302 ||| IN
cancer  ||| S:28302 E:28309 ||| NN
and  ||| S:28309 E:28321 ||| CC
control  ||| S:28321 E:28329 ||| VB
based  ||| S:28329 E:28335 ||| VBN
on  ||| S:28335 E:28338 ||| IN
the  ||| S:28338 E:28342 ||| DT
M ||| S:28342 E:28343 ||| NNP
/ ||| S:28343 E:28344 ||| NNP
Z  ||| S:28344 E:28346 ||| NNP
values  ||| S:28346 E:28353 ||| NNS
of  ||| S:28353 E:28356 ||| IN
2.79  ||| S:28356 E:28361 ||| CD
and  ||| S:28361 E:28365 ||| CC
245.5  ||| S:28365 E:28371 ||| NNP
reveals  ||| S:28371 E:28387 ||| VBZ
the  ||| S:28387 E:28391 ||| DT
presence  ||| S:28391 E:28400 ||| NN
of  ||| S:28400 E:28403 ||| IN
a  ||| S:28403 E:28405 ||| DT
significant  ||| S:28405 E:28417 ||| JJ
experimental  ||| S:28417 E:28430 ||| JJ
bias  ||| S:28430 E:28435 ||| NN
not  ||| S:28435 E:28439 ||| RB
related  ||| S:28439 E:28455 ||| VBN
to  ||| S:28455 E:28458 ||| TO
disease  ||| S:28458 E:28466 ||| NN
pathology ||| S:28466 E:28475 ||| NN
,  ||| S:28475 E:28477 ||| ,
that  ||| S:28477 E:28482 ||| WDT
likely  ||| S:28482 E:28489 ||| RB
involves  ||| S:28489 E:28498 ||| VBZ
machine  ||| S:28498 E:28506 ||| NN
noise  ||| S:28506 E:28520 ||| NN
and  ||| S:28520 E:28524 ||| CC
matrix  ||| S:28524 E:28531 ||| JJ
effects ||| S:28531 E:28538 ||| NNS
.  ||| S:28538 E:28540 ||| .
This  ||| S:28540 E:28545 ||| DT
is  ||| S:28545 E:28548 ||| VBZ
particularly  ||| S:28548 E:28561 ||| RB
true  ||| S:28561 E:28566 ||| JJ
of  ||| S:28566 E:28569 ||| IN
the  ||| S:28569 E:28573 ||| DT
M ||| S:28573 E:28574 ||| NNP
/ ||| S:28574 E:28575 ||| NNP
Z  ||| S:28575 E:28585 ||| NNP
value  ||| S:28585 E:28591 ||| NN
at  ||| S:28591 E:28594 ||| IN
2.79  ||| S:28594 E:28599 ||| CD
which  ||| S:28599 E:28605 ||| WDT
represents  ||| S:28605 E:28616 ||| VBZ
a  ||| S:28616 E:28618 ||| DT
bias  ||| S:28618 E:28623 ||| NN
of  ||| S:28623 E:28626 ||| IN
the  ||| S:28626 E:28630 ||| DT
mass  ||| S:28630 E:28643 ||| JJ
spectrometer  ||| S:28643 E:28656 ||| JJ
instrument  ||| S:28656 E:28667 ||| NN
itself ||| S:28667 E:28673 ||| PRP
.  ||| S:28673 E:28675 ||| .
If  ||| S:28675 E:28678 ||| IN
this  ||| S:28678 E:28683 ||| DT
is  ||| S:28683 E:28686 ||| VBZ
the  ||| S:28686 E:28690 ||| DT
case  ||| S:28690 E:28695 ||| NN
the  ||| S:28695 E:28707 ||| DT
higher  ||| S:28707 E:28714 ||| JJR
M ||| S:28714 E:28715 ||| NNP
/ ||| S:28715 E:28716 ||| NNP
Z  ||| S:28716 E:28718 ||| NNP
regions  ||| S:28718 E:28726 ||| NNS
may  ||| S:28726 E:28730 ||| MD
also  ||| S:28730 E:28735 ||| RB
be  ||| S:28735 E:28738 ||| VB
affected ||| S:28738 E:28746 ||| VBN
.  ||| S:28746 E:28748 ||| .
These  ||| S:28748 E:28754 ||| DT
findings  ||| S:28754 E:28771 ||| NNS
indicate  ||| S:28771 E:28780 ||| VBP
that  ||| S:28780 E:28785 ||| IN
any  ||| S:28785 E:28789 ||| DT
rule  ||| S:28789 E:28794 ||| NN
derived  ||| S:28794 E:28802 ||| VBN
from  ||| S:28802 E:28807 ||| IN
this  ||| S:28807 E:28812 ||| DT
data  ||| S:28812 E:28817 ||| NNS
set ||| S:28817 E:28820 ||| VBN
,  ||| S:28820 E:28830 ||| ,
including  ||| S:28830 E:28840 ||| VBG
the  ||| S:28840 E:28844 ||| DT
ones  ||| S:28844 E:28849 ||| NNS
presented  ||| S:28849 E:28859 ||| VBN
in  ||| S:28859 E:28862 ||| IN
this  ||| S:28862 E:28867 ||| DT
paper ||| S:28867 E:28872 ||| NN
,  ||| S:28872 E:28874 ||| ,
may  ||| S:28874 E:28878 ||| MD
be  ||| S:28878 E:28889 ||| VB
detecting  ||| S:28889 E:28899 ||| JJ
differences  ||| S:28899 E:28911 ||| NNS
in  ||| S:28911 E:28914 ||| IN
experimental  ||| S:28914 E:28927 ||| JJ
bias  ||| S:28927 E:28932 ||| NN
and  ||| S:28932 E:28936 ||| CC
not  ||| S:28936 E:28940 ||| RB
disease  ||| S:28940 E:28956 ||| JJ
pathology ||| S:28956 E:28965 ||| NN
.  ||| S:28965 E:28967 ||| .
Investigators  ||| S:28967 E:28981 ||| NNS
in  ||| S:28981 E:28984 ||| IN
this  ||| S:28984 E:28989 ||| DT
field  ||| S:28989 E:28995 ||| NN
may  ||| S:28995 E:28999 ||| MD
minimize  ||| S:28999 E:29008 ||| VB
their  ||| S:29008 E:29022 ||| PRP$
chances  ||| S:29022 E:29030 ||| NNS
of  ||| S:29030 E:29033 ||| IN
false  ||| S:29033 E:29039 ||| JJ
discovery  ||| S:29039 E:29049 ||| NN
by  ||| S:29049 E:29052 ||| IN
careful  ||| S:29052 E:29060 ||| JJ
experimental  ||| S:29060 E:29073 ||| JJ
design  ||| S:29073 E:29088 ||| NN
and  ||| S:29088 E:29092 ||| CC
by  ||| S:29092 E:29095 ||| IN
using  ||| S:29095 E:29101 ||| VBG
routine  ||| S:29101 E:29109 ||| JJ
statistical  ||| S:29109 E:29121 ||| JJ
methods  ||| S:29121 E:29129 ||| NNS
to  ||| S:29129 E:29132 ||| TO
both  ||| S:29132 E:29137 ||| DT
overview  ||| S:29137 E:29154 ||| NN
the  ||| S:29154 E:29158 ||| DT
data  ||| S:29158 E:29163 ||| NNS
( ||| S:29163 E:29164 ||| -LRB-
in  ||| S:29164 E:29167 ||| IN
an  ||| S:29167 E:29170 ||| DT
intentional  ||| S:29170 E:29182 ||| JJ
search  ||| S:29182 E:29189 ||| NN
for  ||| S:29189 E:29193 ||| IN
bias ||| S:29193 E:29197 ||| NN
)  ||| S:29197 E:29199 ||| -RRB-
as  ||| S:29199 E:29202 ||| IN
well  ||| S:29202 E:29207 ||| RB
as  ||| S:29207 E:29210 ||| IN
a  ||| S:29210 E:29220 ||| DT
benchmark  ||| S:29220 E:29230 ||| NN
for  ||| S:29230 E:29234 ||| IN
comparison  ||| S:29234 E:29245 ||| NN
with  ||| S:29245 E:29250 ||| IN
other  ||| S:29250 E:29256 ||| JJ
data  ||| S:29256 E:29261 ||| NN
mining  ||| S:29261 E:29276 ||| NN
algorithms ||| S:29276 E:29286 ||| NN
.  ||| S:29286 E:29310 ||| .
Methods  ||| S:29310 E:29326 ||| NNS
A  ||| S:29326 E:29328 ||| DT
training  ||| S:29328 E:29337 ||| NN
set  ||| S:29337 E:29341 ||| NN
was  ||| S:29341 E:29345 ||| VBD
formed  ||| S:29345 E:29352 ||| VBN
by  ||| S:29352 E:29355 ||| IN
randomly  ||| S:29355 E:29364 ||| RB
sampling  ||| S:29364 E:29373 ||| CD
45  ||| S:29373 E:29384 ||| CD
spectra  ||| S:29384 E:29392 ||| NNS
out  ||| S:29392 E:29396 ||| RP
of  ||| S:29396 E:29399 ||| IN
the  ||| S:29399 E:29403 ||| DT
91  ||| S:29403 E:29406 ||| CD
controls  ||| S:29406 E:29415 ||| NNS
and  ||| S:29415 E:29419 ||| CC
80  ||| S:29419 E:29422 ||| CD
spectra  ||| S:29422 E:29430 ||| NNS
out  ||| S:29430 E:29434 ||| RP
of  ||| S:29434 E:29437 ||| IN
the  ||| S:29437 E:29449 ||| DT
162  ||| S:29449 E:29453 ||| CD
cancer  ||| S:29453 E:29460 ||| NN
cases  ||| S:29460 E:29466 ||| NNS
( ||| S:29466 E:29467 ||| -LRB-
see  ||| S:29467 E:29471 ||| VB
Figure  ||| S:29471 E:29478 ||| NNP
1 ||| S:29478 E:29479 ||| CD
) ||| S:29479 E:29480 ||| -RRB-
.  ||| S:29480 E:29482 ||| .
Those  ||| S:29482 E:29488 ||| DT
spectra  ||| S:29488 E:29496 ||| NN
that  ||| S:29496 E:29501 ||| WDT
were  ||| S:29501 E:29506 ||| VBD
in  ||| S:29506 E:29517 ||| IN
the  ||| S:29517 E:29521 ||| DT
original  ||| S:29521 E:29530 ||| JJ
data  ||| S:29530 E:29535 ||| NNS
set  ||| S:29535 E:29539 ||| VBN
but  ||| S:29539 E:29543 ||| CC
not  ||| S:29543 E:29547 ||| RB
in  ||| S:29547 E:29550 ||| IN
the  ||| S:29550 E:29554 ||| DT
training  ||| S:29554 E:29563 ||| NN
set  ||| S:29563 E:29567 ||| NN
were  ||| S:29567 E:29580 ||| VBD
considered  ||| S:29580 E:29591 ||| VBN
in  ||| S:29591 E:29594 ||| IN
a  ||| S:29594 E:29596 ||| DT
' ||| S:29596 E:29597 ||| POS
test ||| S:29597 E:29601 ||| NN
'  ||| S:29601 E:29603 ||| POS
set ||| S:29603 E:29606 ||| NN
.  ||| S:29606 E:29608 ||| .
Two-sided  ||| S:29608 E:29618 ||| NNP
Wilcoxon  ||| S:29618 E:29627 ||| NNP
test  ||| S:29627 E:29632 ||| NN
was  ||| S:29632 E:29644 ||| VBD
used  ||| S:29644 E:29649 ||| VBN
to  ||| S:29649 E:29652 ||| TO
compare  ||| S:29652 E:29660 ||| VB
the  ||| S:29660 E:29664 ||| DT
intensity  ||| S:29664 E:29674 ||| NN
between  ||| S:29674 E:29682 ||| IN
the  ||| S:29682 E:29686 ||| DT
controls  ||| S:29686 E:29695 ||| NNS
and  ||| S:29695 E:29707 ||| CC
cancers  ||| S:29707 E:29715 ||| NNS
in  ||| S:29715 E:29718 ||| IN
the  ||| S:29718 E:29722 ||| DT
training  ||| S:29722 E:29731 ||| NN
set  ||| S:29731 E:29735 ||| VBN
at  ||| S:29735 E:29738 ||| IN
each  ||| S:29738 E:29743 ||| DT
of  ||| S:29743 E:29746 ||| IN
the  ||| S:29746 E:29750 ||| DT
15,154  ||| S:29750 E:29757 ||| NNP
M ||| S:29757 E:29758 ||| NNP
/ ||| S:29758 E:29759 ||| NNP
Z  ||| S:29759 E:29769 ||| NNP
values ||| S:29769 E:29775 ||| NNS
.  ||| S:29775 E:29777 ||| .
We  ||| S:29777 E:29780 ||| PRP
then  ||| S:29780 E:29785 ||| RB
selected  ||| S:29785 E:29794 ||| VBN
a  ||| S:29794 E:29796 ||| DT
subset  ||| S:29796 E:29803 ||| NN
of  ||| S:29803 E:29806 ||| IN
the  ||| S:29806 E:29810 ||| DT
M ||| S:29810 E:29811 ||| NNP
/ ||| S:29811 E:29812 ||| NNP
Z  ||| S:29812 E:29814 ||| NNP
values  ||| S:29814 E:29821 ||| NNS
with  ||| S:29821 E:29834 ||| IN
the  ||| S:29834 E:29838 ||| DT
lowest  ||| S:29838 E:29845 ||| JJS
Wilcoxon  ||| S:29845 E:29854 ||| JJ
test  ||| S:29854 E:29859 ||| NN
p-values  ||| S:29859 E:29868 ||| NNS
( ||| S:29868 E:29869 ||| -LRB-
see  ||| S:29869 E:29873 ||| VB
the  ||| S:29873 E:29877 ||| DT
Results  ||| S:29877 E:29885 ||| NNS
section  ||| S:29885 E:29901 ||| NN
for  ||| S:29901 E:29905 ||| IN
details ||| S:29905 E:29912 ||| NNS
) ||| S:29912 E:29913 ||| -RRB-
.  ||| S:29913 E:29915 ||| .
We  ||| S:29915 E:29918 ||| PRP
sorted  ||| S:29918 E:29925 ||| VBD
on  ||| S:29925 E:29928 ||| IN
consecutive  ||| S:29928 E:29940 ||| JJ
M ||| S:29940 E:29941 ||| NNP
/ ||| S:29941 E:29942 ||| NNP
Z  ||| S:29942 E:29944 ||| NNP
values  ||| S:29944 E:29951 ||| VBZ
to  ||| S:29951 E:29954 ||| TO
get  ||| S:29954 E:29966 ||| VB
bins ||| S:29966 E:29970 ||| NNS
.  ||| S:29970 E:29972 ||| .
A  ||| S:29972 E:29974 ||| DT
separation  ||| S:29974 E:29985 ||| NN
of  ||| S:29985 E:29988 ||| IN
at  ||| S:29988 E:29991 ||| IN
least  ||| S:29991 E:29997 ||| JJS
one  ||| S:29997 E:30001 ||| CD
M ||| S:30001 E:30002 ||| NNP
/ ||| S:30002 E:30003 ||| NNP
Z  ||| S:30003 E:30005 ||| NNP
value  ||| S:30005 E:30011 ||| NN
was  ||| S:30011 E:30015 ||| VBD
required  ||| S:30015 E:30032 ||| VBN
to  ||| S:30032 E:30035 ||| TO
start  ||| S:30035 E:30041 ||| VB
the  ||| S:30041 E:30045 ||| DT
next  ||| S:30045 E:30050 ||| JJ
bin ||| S:30050 E:30053 ||| NN
.  ||| S:30053 E:30055 ||| .
The  ||| S:30055 E:30059 ||| DT
lowest  ||| S:30059 E:30066 ||| JJS
p-value  ||| S:30066 E:30074 ||| JJ
in  ||| S:30074 E:30077 ||| IN
each  ||| S:30077 E:30082 ||| DT
bin  ||| S:30082 E:30086 ||| NN
was  ||| S:30086 E:30098 ||| VBD
selected  ||| S:30098 E:30107 ||| VBN
and  ||| S:30107 E:30111 ||| CC
the  ||| S:30111 E:30115 ||| DT
corresponding  ||| S:30115 E:30129 ||| JJ
M ||| S:30129 E:30130 ||| NNP
/ ||| S:30130 E:30131 ||| NNP
Z  ||| S:30131 E:30133 ||| NNP
value  ||| S:30133 E:30139 ||| NN
was  ||| S:30139 E:30143 ||| VBD
used  ||| S:30143 E:30148 ||| VBN
in  ||| S:30148 E:30159 ||| IN
stepwise  ||| S:30159 E:30168 ||| JJ
discriminant  ||| S:30168 E:30181 ||| JJ
analysis  ||| S:30181 E:30190 ||| NN
to  ||| S:30190 E:30193 ||| TO
determine  ||| S:30193 E:30203 ||| VB
the  ||| S:30203 E:30207 ||| DT
subset  ||| S:30207 E:30214 ||| NN
of  ||| S:30214 E:30225 ||| IN
M ||| S:30225 E:30226 ||| NNP
/ ||| S:30226 E:30227 ||| NNP
Z  ||| S:30227 E:30229 ||| NNP
values  ||| S:30229 E:30236 ||| NNS
that  ||| S:30236 E:30241 ||| IN
best  ||| S:30241 E:30246 ||| JJS
discriminated  ||| S:30246 E:30260 ||| JJ
cancer  ||| S:30260 E:30267 ||| NN
from  ||| S:30267 E:30272 ||| IN
control  ||| S:30272 E:30280 ||| NN
in  ||| S:30280 E:30291 ||| IN
the  ||| S:30291 E:30295 ||| DT
training  ||| S:30295 E:30304 ||| NN
set ||| S:30304 E:30307 ||| NN
.  ||| S:30307 E:30309 ||| .
The  ||| S:30309 E:30313 ||| DT
criteria  ||| S:30313 E:30322 ||| NNS
were  ||| S:30322 E:30327 ||| VBD
applied  ||| S:30327 E:30335 ||| VBN
to  ||| S:30335 E:30338 ||| TO
the  ||| S:30338 E:30342 ||| DT
test  ||| S:30342 E:30355 ||| NN
data  ||| S:30355 E:30360 ||| NNS
set ||| S:30360 E:30363 ||| VBN
,  ||| S:30363 E:30365 ||| ,
and  ||| S:30365 E:30369 ||| CC
sensitivity  ||| S:30369 E:30381 ||| NN
and  ||| S:30381 E:30385 ||| CC
specificity  ||| S:30385 E:30397 ||| NN
were  ||| S:30397 E:30402 ||| VBD
computed ||| S:30402 E:30410 ||| VBN
.  ||| S:30410 E:30420 ||| .
All  ||| S:30420 E:30424 ||| PDT
the  ||| S:30424 E:30428 ||| DT
analyses  ||| S:30428 E:30437 ||| NNS
were  ||| S:30437 E:30442 ||| VBD
performed  ||| S:30442 E:30452 ||| VBN
in  ||| S:30452 E:30455 ||| IN
SAS  ||| S:30455 E:30459 ||| NNP
Version  ||| S:30459 E:30467 ||| NNP
8.2  ||| S:30467 E:30471 ||| CD
( ||| S:30471 E:30472 ||| -LRB-
A  ||| S:30472 E:30482 ||| DT
statistical  ||| S:30482 E:30494 ||| JJ
package  ||| S:30494 E:30502 ||| NN
from  ||| S:30502 E:30507 ||| IN
SAS  ||| S:30507 E:30511 ||| NNP
Institute  ||| S:30511 E:30521 ||| NNP
Inc. ||| S:30521 E:30525 ||| NNP
,  ||| S:30525 E:30527 ||| ,
Cary ||| S:30527 E:30531 ||| NNP
,  ||| S:30531 E:30533 ||| ,
NC ||| S:30533 E:30535 ||| NNP
,  ||| S:30535 E:30537 ||| ,
USA ||| S:30537 E:30540 ||| NNP
)  ||| S:30540 E:30550 ||| -RRB-
on  ||| S:30550 E:30553 ||| IN
a  ||| S:30553 E:30555 ||| DT
personal  ||| S:30555 E:30564 ||| JJ
computer ||| S:30564 E:30572 ||| NN
.  ||| S:30572 E:30574 ||| .
Wilcoxon  ||| S:30574 E:30583 ||| JJ
test  ||| S:30583 E:30588 ||| NN
was  ||| S:30588 E:30592 ||| VBD
performed  ||| S:30592 E:30602 ||| VBN
using  ||| S:30602 E:30616 ||| VBG
NPAR1WAY  ||| S:30616 E:30625 ||| CD
procedure  ||| S:30625 E:30635 ||| NN
in  ||| S:30635 E:30638 ||| IN
SAS ||| S:30638 E:30641 ||| NNP
,  ||| S:30641 E:30643 ||| ,
stepwise  ||| S:30643 E:30652 ||| JJ
discriminant  ||| S:30652 E:30665 ||| JJ
analysis  ||| S:30665 E:30682 ||| NN
was  ||| S:30682 E:30686 ||| VBD
performed  ||| S:30686 E:30696 ||| VBN
using  ||| S:30696 E:30702 ||| VBG
STEPDISC  ||| S:30702 E:30711 ||| NNP
procedure  ||| S:30711 E:30721 ||| NN
in  ||| S:30721 E:30724 ||| IN
SAS ||| S:30724 E:30727 ||| NNP
,  ||| S:30727 E:30729 ||| ,
and  ||| S:30729 E:30741 ||| CC
discriminant  ||| S:30741 E:30754 ||| JJ
analysis  ||| S:30754 E:30763 ||| NN
was  ||| S:30763 E:30767 ||| VBD
performed  ||| S:30767 E:30777 ||| VBN
using  ||| S:30777 E:30783 ||| VBG
DISCRIM  ||| S:30783 E:30791 ||| NNP
procedure  ||| S:30791 E:30809 ||| NN
in  ||| S:30809 E:30812 ||| IN
SAS  ||| S:30812 E:30816 ||| NNP
[  ||| S:30816 E:30818 ||| -LRB-
23  ||| S:30818 E:30821 ||| CD
]  ||| S:30821 E:30823 ||| -RRB-
.  ||| S:30823 E:30833 ||| .
To  ||| S:30833 E:30836 ||| TO
normalize  ||| S:30836 E:30846 ||| VB
the  ||| S:30846 E:30850 ||| DT
data ||| S:30850 E:30854 ||| NNS
,  ||| S:30854 E:30856 ||| ,
the  ||| S:30856 E:30860 ||| DT
procedure  ||| S:30860 E:30870 ||| NN
outlined  ||| S:30870 E:30879 ||| VBN
by  ||| S:30879 E:30882 ||| IN
the  ||| S:30882 E:30894 ||| DT
Clinical  ||| S:30894 E:30903 ||| NNP
Proteomics  ||| S:30903 E:30914 ||| NNP
Program  ||| S:30914 E:30922 ||| NNP
Databank  ||| S:30922 E:30931 ||| NNP
was  ||| S:30931 E:30935 ||| VBD
used  ||| S:30935 E:30940 ||| VBN
[  ||| S:30940 E:30942 ||| -LRB-
24  ||| S:30942 E:30945 ||| CD
]  ||| S:30945 E:30947 ||| -RRB-
.  ||| S:30947 E:30949 ||| .
The  ||| S:30949 E:30961 ||| DT
cancer  ||| S:30961 E:30968 ||| NN
and  ||| S:30968 E:30972 ||| CC
control  ||| S:30972 E:30980 ||| NN
values  ||| S:30980 E:30987 ||| NNS
for  ||| S:30987 E:30991 ||| IN
each  ||| S:30991 E:30996 ||| DT
M ||| S:30996 E:30997 ||| NNP
/ ||| S:30997 E:30998 ||| NNP
Z  ||| S:30998 E:31000 ||| NNP
were  ||| S:31000 E:31005 ||| VBD
given  ||| S:31005 E:31019 ||| VBN
respective  ||| S:31019 E:31030 ||| JJ
labels ||| S:31030 E:31036 ||| NNS
,  ||| S:31036 E:31038 ||| ,
and  ||| S:31038 E:31042 ||| CC
the  ||| S:31042 E:31046 ||| DT
data  ||| S:31046 E:31051 ||| NNS
were  ||| S:31051 E:31056 ||| VBD
then  ||| S:31056 E:31061 ||| RB
pooled  ||| S:31061 E:31068 ||| VBN
and  ||| S:31068 E:31080 ||| CC
normalized  ||| S:31080 E:31091 ||| VBP
using  ||| S:31091 E:31097 ||| VBG
the  ||| S:31097 E:31101 ||| DT
formula  ||| S:31101 E:31109 ||| NN
NV  ||| S:31109 E:31112 ||| NNP
=  ||| S:31112 E:31114 ||| NNP
( ||| S:31114 E:31115 ||| -LRB-
V-Min ||| S:31115 E:31120 ||| NNP
) ||| S:31120 E:31121 ||| -RRB-
/ ||| S:31121 E:31122 ||| NNP
( ||| S:31122 E:31123 ||| -LRB-
Max  ||| S:31123 E:31127 ||| NNP
-  ||| S:31127 E:31129 ||| :
Min ||| S:31129 E:31132 ||| LS
) ||| S:31132 E:31133 ||| -RRB-
.  ||| S:31133 E:31135 ||| .
In  ||| S:31135 E:31146 ||| IN
this  ||| S:31146 E:31151 ||| DT
expression ||| S:31151 E:31161 ||| NN
,  ||| S:31161 E:31163 ||| ,
Min  ||| S:31163 E:31167 ||| NNP
is  ||| S:31167 E:31170 ||| VBZ
the  ||| S:31170 E:31174 ||| DT
minimum  ||| S:31174 E:31182 ||| JJ
intensity  ||| S:31182 E:31192 ||| NN
of  ||| S:31192 E:31195 ||| IN
the  ||| S:31195 E:31199 ||| DT
pooled  ||| S:31199 E:31214 ||| JJ
samples ||| S:31214 E:31221 ||| NNS
,  ||| S:31221 E:31223 ||| ,
Max  ||| S:31223 E:31227 ||| NNP
represents  ||| S:31227 E:31238 ||| VBZ
the  ||| S:31238 E:31242 ||| DT
maximum  ||| S:31242 E:31250 ||| JJ
intensity  ||| S:31250 E:31260 ||| NN
found  ||| S:31260 E:31266 ||| VBD
in  ||| S:31266 E:31269 ||| IN
the  ||| S:31269 E:31281 ||| DT
pooled  ||| S:31281 E:31288 ||| JJ
samples ||| S:31288 E:31295 ||| NNS
,  ||| S:31295 E:31297 ||| ,
and  ||| S:31297 E:31301 ||| CC
NV  ||| S:31301 E:31304 ||| NNP
represents  ||| S:31304 E:31315 ||| VBZ
the  ||| S:31315 E:31319 ||| DT
normalized  ||| S:31319 E:31330 ||| JJ
value ||| S:31330 E:31335 ||| NN
.  ||| S:31335 E:31345 ||| .
Using  ||| S:31345 E:31351 ||| VBG
this  ||| S:31351 E:31356 ||| DT
procedure ||| S:31356 E:31365 ||| NN
,  ||| S:31365 E:31367 ||| ,
the  ||| S:31367 E:31371 ||| DT
data  ||| S:31371 E:31376 ||| NN
intensities  ||| S:31376 E:31388 ||| NNS
will  ||| S:31388 E:31393 ||| MD
all  ||| S:31393 E:31397 ||| RB
fall  ||| S:31397 E:31410 ||| VB
between  ||| S:31410 E:31418 ||| IN
0  ||| S:31418 E:31420 ||| CD
and  ||| S:31420 E:31424 ||| CC
1 ||| S:31424 E:31425 ||| CD
.  ||| S:31425 E:31427 ||| .
The  ||| S:31427 E:31431 ||| DT
data  ||| S:31431 E:31436 ||| NN
points  ||| S:31436 E:31443 ||| NNS
were  ||| S:31443 E:31448 ||| VBD
sorted  ||| S:31448 E:31455 ||| VBN
into  ||| S:31455 E:31460 ||| IN
cancer  ||| S:31460 E:31475 ||| NN
and  ||| S:31475 E:31479 ||| CC
controls ||| S:31479 E:31487 ||| NNS
,  ||| S:31487 E:31489 ||| ,
and  ||| S:31489 E:31493 ||| CC
the  ||| S:31493 E:31497 ||| DT
p-values  ||| S:31497 E:31506 ||| NN
were  ||| S:31506 E:31511 ||| VBD
calculated ||| S:31511 E:31521 ||| VBN
.  ||| S:31521 E:31545 ||| .
Authors ||| S:31545 E:31552 ||| NNP
'  ||| S:31552 E:31554 ||| POS
contributions  ||| S:31554 E:31576 ||| NNS
JMS  ||| S:31576 E:31580 ||| VBP
conceived  ||| S:31580 E:31590 ||| VBN
of  ||| S:31590 E:31593 ||| IN
the  ||| S:31593 E:31597 ||| DT
studies  ||| S:31597 E:31605 ||| NNS
and  ||| S:31605 E:31609 ||| CC
developed  ||| S:31609 E:31619 ||| VBD
the  ||| S:31619 E:31623 ||| DT
initial  ||| S:31623 E:31639 ||| JJ
process  ||| S:31639 E:31647 ||| NN
for  ||| S:31647 E:31651 ||| IN
selecting  ||| S:31651 E:31661 ||| VBG
diagnostic  ||| S:31661 E:31672 ||| JJ
rules ||| S:31672 E:31677 ||| NNS
.  ||| S:31677 E:31679 ||| .
MZ  ||| S:31679 E:31682 ||| NNP
performed  ||| S:31682 E:31692 ||| VBD
the  ||| S:31692 E:31704 ||| DT
statistical  ||| S:31704 E:31716 ||| JJ
analysis  ||| S:31716 E:31725 ||| NN
and  ||| S:31725 E:31729 ||| CC
further  ||| S:31729 E:31737 ||| RB
refined  ||| S:31737 E:31745 ||| VBN
the  ||| S:31745 E:31749 ||| DT
rules  ||| S:31749 E:31755 ||| NNS
with  ||| S:31755 E:31768 ||| IN
stepwise  ||| S:31768 E:31777 ||| JJ
discrminant  ||| S:31777 E:31789 ||| JJ
analysis ||| S:31789 E:31797 ||| NN
.  ||| S:31797 E:31799 ||| .
All  ||| S:31799 E:31803 ||| DT
authors  ||| S:31803 E:31811 ||| NNS
read  ||| S:31811 E:31816 ||| VBP
and  ||| S:31816 E:31820 ||| CC
agreed  ||| S:31820 E:31835 ||| VBD
with  ||| S:31835 E:31840 ||| IN
the  ||| S:31840 E:31844 ||| DT
final  ||| S:31844 E:31850 ||| JJ
manuscript ||| S:31850 E:31860 ||| NN
.  ||| S:31860 E:31877 ||| .
